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Abstract 
 
WNT lipoglycoproteins (WNTs) modulate a plethora of cellular functions through 
the activation of the family of frizzled receptors (FZDs). Deregulation in 
components of the WNT signalling pathways is often observed in human 
cancers and associated with uncontrolled proliferation and metastasis. Frizzled 
receptor 6 (Fzd6), one of the ten human FZDs, is frequently overexpressed in 
cancer, but its role in tumorigenesis is still unclear. 
In this study we investigated the role Fzd6 in breast cancer. We found that 
expression of Fzd6 predicts distant relapse in patients with localised breast 
cancers, particularly in those bearing the triple negative subtype.  Using a loss 
of function approach, we demonstrated that Fzd6 is important to regulate 
motility and invasion of breast cancer cells in vitro and in vivo. Indeed, Fzd6 
regulates the tropism of breast cancer cells the bone, liver and heart of mice. 
Mechanistically, we found that Fzd6 signalling activates the small GTPase Rho 
and is important in the organisation of the fibronectin matrix. Both Rho and 
fibronectin have been previously implicated in the development of metastasis in 
different systems. 
All together, these results demonstrate that Fzd6 is an important driver of 
metastatic spread and a predictive marker of metastatic relapse in breast 
cancer patients. Fzd6 could therefore be used as a biomarker and target in 
metastatic breast cancer.  
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CHAPTER I 
 
Introduction 
 
1.1 Breast cancer 
 
According to Cancer Research UK 
(http://publications.cancerresearchuk.org/downloads/Product/CS_KF_BREAST.
pdf), breast cancer is the most common malignancy in the United Kingdom and 
the second most common cause of death from cancer in women after lung 
cancer.  In 2012, about 11600 women died of breast cancer. The mortality rate 
per 100000 population was 24 % for females and 0.2 % for males. In women, 
the five-year net survival estimated between 2010 and 2011 was 86.6%, while 
the ten-year net survival was 78.4%. In Europe, an average of 464,000 new 
cases of breast cancer was diagnosed in 2012. Breast cancer affects also men 
but with a much lower rate (1 in 100000). Worldwide, less than 1% of all the 
breast cancer patients are male (Sasco, Lowenfels and Pasker-De Jong, 1993).  
Women from western and developed countries are more likely to develop the 
disease (Ferlay et al., 2010). Life style factors might explain why women of 
developed countries have an increased risk to develop breast cancer. These 
include having less children, giving birth at an older age and avoiding 
breastfeeding, all factors that have been reported to increase the risk of breast 
cancer (Porter, 2008; Parkin and Fernández, 2006; Hortobagyi et al., 2005). 
Breast cancer survival rates strongly depend on the disease stage at the time of 
diagnosis, but the majority of patients are alive after 5 years from the diagnosis. 
When breast cancer is diagnosed at early stages the outcome it is usually 
positive, but survival rates are low in metastatic breast cancer (Baade, Youlden 
and Chambers, 2011; Soerjomataram et al., 2008). For this reason population 
screening and mammography are essential tools for the reduction of breast 
cancer mortality (Elmore et al., 2005; Smith, 2003). 
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1.1.1 Breast cancer symptoms and diagnosis 
 
According to the Merk Manual of Diagnosis and Therapy (Beers, 2006), the 
most common first symptom of breast cancer is a painless lump which is usually 
recognized by the patient. In the early stages the lump might be movable 
underneath the skin. In later stages, the lump adheres to the chest wall or to the 
skin over it. In very advanced stages, swollen bumps or festering sores may 
occur. Sometimes the skin over the lump can look dimpled, with a pattern 
similar to the orange skin, and lumps can become painful. A subtype of breast 
cancer called inflammatory breast cancer is characterized by a warm, red and 
swollen breast, which could occur with or without skin ridges or 
inhomogeneities. There might be nipple inversion or nipple discharge. Often in 
this kind of breast cancer there are no lumps (Beers, 2006). When symptoms of 
breast cancer are detected, the patient is referred to designated breast clinics 
where the diagnosis is made by “triple assessment”. This consists of a 
combination of mammography and ultrasound imaging. If a suspicious mass is 
found, core biopsy and/or fine needle aspiration cytology is performed (National 
Institute for Health and Care Excellence guidelines, https://www.nice.org.uk/). 
Magnetic resonance imaging (MRI) of the breast might also be used for further 
investigations in patients with confirmed breast cancer (Willett, Michell and Lee, 
2010). In invasive breast cancer the axillary lymph nodes are usually the first 
sites of metastatic spread (Giuliano et al., 1994). Therefore, ultrasound imaging 
of the axilla is also carried out in all patients when a malignancy is suspected.  If 
lymph nodes are found to have an altered morphology on ultrasound, a biopsy 
is also taken. Following the triple assessment, a definitive diagnosis is made in 
most patients (Willett, Michell and Lee, 2010). 
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1.1.2 Breast cancer staging and grading 
 
In United Kingdom, breast cancer is diagnosed following the TNM staging 
system (http://www.cancerresearchuk.org/about-cancer/type/breast-
cancer/treatment/tnm-breast-cancer-staging#fit). TNM stands for Tumour, 
Node, Metastasis, and takes into account the size of the tumour (T), the 
presence of cancer cells in the lymph node (N) and the presence of metastasis 
(M). An overview of different breast cancer stages is summarized in table 1.1. 
TNM is the most widely used system to classify the anatomic spread of a 
neoplasia (Sobin and Fleming, 1997). This staging system was developed by 
the American Joint Committee on Cancer (AJCC) and the Union for 
International Cancer Control (UICC). The TNM classification system is a tool for 
clinicians to describe the severity of cancer using standardized criteria 
(https://cancerstaging.org/references-tools/Pages/What-is-Cancer-
Staging.aspx). To complete the diagnosis of breast cancer, biopsies are 
analysed by pathologists to assess tumour grade and tumour subtype. The 
grade of a tumour is evaluated depending on the appearance of cancer cells 
under a microscope, using the “Nottingham grading system”. Tissue 
morphology, mitotic index and cells nuclear shape are evaluated according to 
standardized criteria to give a final score between 1 and 3 (source: NHS, 
http://www.cancerscreening.nhs.uk/breastscreen/publications/nhsbsp58-
poster.pdf). Grade 1 or low-grade is attributed when cancer cells look similar to 
normal cells (i.e. are well differentiated) and usually grow slowly. In this case 
cancer cells are less likely to spread. Grade 2 or moderate-grade is attributed 
when cancer cells look more abnormal and grow slightly faster than grade 1 
cells. Grade 3 or high-grade is attributed when the cancer cells look very 
different from normal cells (are poorly differentiated) and may grow quicker than 
grade 1 or 2 cells (source: 
http://www.macmillan.org.uk/Cancerinformation/Cancertypes/Breast/Symptoms
diagnosSy/Stagingandgrading.aspx). 
Biopsies are also analysed to assess the receptor status, i.e. if cancer cells 
express the oestrogen receptor (ER), progesterone receptor (PR) and Human 
epidermal growth factor receptor 2 (HER2). This is required to predict the 
response to certain therapies: Breast cancers that are oestrogen receptor 
positive are more likely to respond to hormone therapies, and HER2 positive 
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tumours can be treated with monoclonal antibodies (Trastuzumab) (source: 
http://www.cancerresearchuk.org/about-cancer/type/breast-
cancer/diagnosis/further-tests-for-breast-cancer#hormone). 
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Table 1.1: TMN staging of breast cancer (Source: Cancer Research UK) 
T STAGES 
Stage Description 
TX The tumour size cannot be assessed 
T1 The tumour is 2 cm across or less. T1 
tumours are further classified in: 
T1mi – the tumour is 0.1cm across or less 
T1a – the tumour is more than 0.1 cm but not 
more than 0.5 cm 
T1b – the tumour is more than 0.5 cm but not 
more than 1 cm 
T1c – the tumour is more than 1 cm but not 
more than 2 cm 
T2 The tumour is more than 2 centimetres, but 
no more than 5 centimetres across 
T3  The tumour is bigger than 5 centimetres 
across 
T4 T4 tumours are further classified in: 
 
T4a – The tumour has spread into the chest 
wall 
T4b – The tumour has spread into the skin 
and the breast may be swollen 
T4c – The tumour has spread to both the skin 
and the chest wall 
T4d – Inflammatory carcinoma – this is a 
cancer in which the overlying skin is red, 
swollen and painful to the touch 
 
N STAGES 
Stage Description 
NX The lymph nodes cannot be assessed (for 
example, if they were previously removed) 
N0  No cancer cells found in any nearby nodes 
ITCs (Isolated tumour cells) When small clusters of 
cancer cells, less than 0.2 mm across, or a 
single tumour cell, or a cluster of fewer than 
200 cells are found in one area of a lymph 
node. Lymph nodes containing only isolated 
tumour cells are not counted as positive 
lymph nodes 
N1  Cancer cells are in the lymph nodes in the 
armpit but the nodes are not stuck to 
surrounding tissues 
pN1mi  One or more lymph nodes contain 
micrometastases that are larger than 0.2mm 
or contain more than 200 cancer cells, but are 
less than 2mm 
N2  
 
N2 is divided into 2 groups: 
 
N2a – there are cancer cells in the lymph 
nodes in the armpit, which are stuck to each 
other and to other structures 
N2b – there are cancer cells in the lymph 
nodes behind the breast bone (the internal 
mammary nodes), which have either been 
seen on a scan or felt by the doctor. There is 
no evidence of cancer in lymph nodes in the 
armpit 
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Table 1.1 continued 
 
1.1.3 Breast carcinogenesis 
 
The most accredited theory to explain the onset of cancer is based on the clonal 
expansion of a population of cells carrying driver mutations that confer a 
selective growth advantage; certain mutations are observed with a high 
frequency in tumours, therefore are believed to be the initial events in the 
process of tumorigenesis (Stephens et al., 2012). During the clonal expansion 
of cancer cells, more mutations, defined as “passenger mutations”, can be 
acquired, conferring a further growth advantage and/or a metastatic phenotype 
(Greaves and Maley, 2012; Bozic et al., 2010). A plethora of somatic and 
germline mutations in oncogenes and tumour suppressor genes have been 
linked to the onset and development of breast cancer. According to the 
Catalogue of  Somatic Mutations in Cancer (COSMIC) (Forbes et al., 2008), the 
most common somatic mutations occurring in breast cancer are affecting, in 
order of decreasing frequency, the following genes: PIK3CA (encoding the 
phosphatidylinositol-4,5-bisphosphate 3-kinase-catalytic alpha subunit), TP53 
(encoding the protein p53), CDH1 (encoding for E-Cadherin), MLL3 (Gene 
encoding the Histone-lysine N-methyltransferase), GATA3 (encoding for Trans-
acting T-cell-specific transcription factor) and PTEN (encoding for the 
Phosphatase and Tensin homolog protein). These mutations are therefore likely 
drivers responsible for the aetiology of breast cancer (Stephens et al., 2012). 
N3 N3 is further divided in 
N3a – there are cancer cells in lymph nodes 
below the collarbone 
N3b – there are cancer cells in lymph nodes 
in the armpit and behind the breast bone 
N3c – there are cancer cells in lymph nodes 
above the collarbone 
M STAGES 
M0 There is no sign of cancer spread to distant 
organs 
cMo(i+) Means there is no sign of the cancer on 
physical examination, scans or X-rays but 
cancer cells are present in blood, bone 
marrow, or lymph nodes far away from the 
breast cancer as detected by  laboratory tests 
M1  means the cancer has spread to another part 
of the body 
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PI3KCA encodes the p110α catalytic subunit of the class IA phosphatidylinositol 
3-kinases (PI3Ks). PI3Ks catalyses the phosphorylation of a class of inositol-
containing lipids called phosphatidylinositols (PIs), giving rise to several 
signalling molecules involved in the control of a broad range of cell functions 
(Vanhaesebroeck and Waterfield, 1999). Particularly, the phosphatidyl-inositol-
3,4,5-triphosphate (PIP3) can activate the AKT serine/threonine kinase which 
regulates cell proliferation, survival, and motility. The tumour suppressor gene 
PTEN, also often mutated in breast cancer, inhibits the PI3K pathway by 
dephosphorylating PIP3 (Samuels et al., 2005; Sun et al., 1999; Li et al., 1997). 
Deregulation of the PI3K/AKT/PTEN pathway is a common event in cancer and 
considered a frequent driver event in the development of breast tumours (Wood 
et al., 2007; Samuels et al., 2005). 
The tumour suppressor gene p53 is commonly defined as the “guardian of the 
genome” (Lane, 1992). This definition originates from the propriety of p53 to 
control proteins involved in the cell cycle, DNA repair or apoptosis, in case of 
DNA damage; the regulation of these processes by p53 prevents the 
propagation of potentially toxic mutations during cell division and, therefore, 
defines p53 as an essential tumour suppressor gene (Sengupta and Harris, 
2005; Kastan, Canman and Leonard, 1995; Lowe et al., 1993). Not surprisingly, 
mutations of p53 are the most common in human cancers and very frequent in 
breast tumours (Pharoah, Day and Caldas, 1999; Levine, Momand and Finlay, 
1991). 
E-cadherin is part of the cadherins family, a group of transmembrane proteins 
involved in cell-cell junctions (Angst, Marcozzi and Magee, 2001). E-cadherin is 
often downregulated in breast cancer. This is associated with an unfavourable 
prognosis and aggressive phenotypes (Siitonen et al., 1996; Pierceall et al., 
1995; Oka et al., 1993). E-cadherin can suppress cell proliferation by 
dephosphorylating the retinoblastoma protein (Rb), reducing Cyclin D1 and 
elevating p27 levels (St Croix et al., 1998). Moreover, E-cadherin can inhibit 
tumour growth by reducing the transcriptional activity of β-catenin and 
interacting with members of the Hippo pathway (Kim et al., 2011; Stockinger et 
al., 2001). Therefore, mutations of CDH1 can be driver events of breast cancer 
tumorigenesis by enhancing uncontrolled cell proliferation (Berx and Van Roy, 
2001).  
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MML3 encodes the Histone 3-lysine-4 -methyltransferase and is commonly 
mutated in breast cancer, although is function in this tumour is still poorly 
characterized (Stephens et al., 2012). Studies on mice suggest that MML3 
interacts with p53 in the response to DNA damage, and since its removal 
results in urinary tumours, MML3 is a putative tumour suppressor gene (Wang 
et al., 2011; Lee et al., 2009). 
GATA3 (Trans-acting T-cell-specific transcription factor 3) belongs to the family 
of GATA transcription factors and is important to regulate the differentiation of 
luminal cells in the mammary gland (Kouros-Mehr et al., 2006). Array-based 
studies have linked high expression of GATA3 with lower tumour grade and 
reduced proliferation index in breast tumours. Moreover, lower expression of 
GATA3 was associated with poor outcome and lower survival in breast cancer 
patients (Yoon et al., 2010; Mehra et al., 2005; Usary et al., 2004). 
Mechanistically, mutations in GATA3 might result in the failure to maintain a 
differentiated low proliferative phenotype of the luminal cells of the breast, 
promoting tumorigenesis through the epithelial mesenchymal transition (EMT) 
(Yan et al., 2010; Usary et al., 2004).  
In addition to point mutations, gene copy number variations (CNV) are known to 
give a major contribution to the genetic landscape of tumours (Pollack et al., 
2002). Particularly, vast areas of the chromosome 1,8 and 17 are often 
subjected to extensive CNV in breast cancer (fig.1.1) (Forbes et al., 2008; 
Fridlyand et al., 2006; Pollack et al., 2002; Kallioniemi et al., 1994). For 
example, the copy number gain of HER2 was associated with a worse outcome 
and tumour relapse before the introduction of Trastuzumab in the therapy of 
HER2 positive tumours (Slamon et al., 1987). 
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Figure 1.1: Circos image displaying CNV in breast cancer: the height of the bar is 
the total number of samples which had a CNV event in that region, with blue representing loss 
and pink representing gain (Source: COSMIC, (Forbes et al., 2008). 
 
Other genes commonly subjected to CNV in breast cancer are MYC and the 
fibroblast growth factor receptor 1 (FGFR1), both in the chromosome 8 
(Stephens et al., 2012). Amplification of FGFR1 has been associated with poor 
prognosis and resistance to hormone therapy in breast cancer (Turner et al., 
2010). MYC or (c-MYC) is a transcription factor which is thought to regulate 
about 15 % of all the human genes (Gearhart, Pashos and Prasad, 2007). MYC 
regulates cell proliferation and growth, and is often overexpressed in human 
cancers (Dang, 2012). In breast tumours, the amplification of c-MYC strongly 
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reduces the survival end increases the risk of tumour relapse (Sotiriou et al., 
2003; Deming et al., 2000; Berns et al., 1992).  
Several other transcription factors are often found overexpressed in breast 
cancer and could participate to the early stages of the disease. The forkhead 
box proteins (Fox) are a class of transcription factors which are often 
deregulated in human cancers (Myatt and Lam, 2007). FOXM1, a member of 
the Fox family, is frequently overexpressed in numerous malignancies (Koo, 
Muir and Lam, 2012). In the COSMIC database, 15.17 % of the breast cancer 
samples overexpress FOXM1 (Forbes et al. 2014). FOXM1 was shown to 
regulate the expression of the oestrogen receptor α, which plays a major role in 
the proliferation of breast cancer cells (Millour and Lam, 2010). Indeed, RNA 
interference of FOXM1 inhibits cell growth and invasion of breast cancer cell 
lines (Ahmad et al., 2010). 
Another transcription factor which is commonly deregulated in breast cancer is 
the Hypoxia-inducible factor 1 (HIF-1), which controls the expression of genes 
involved in cancer metabolism and tumour vascularization, required for the 
survival and propagation of cancer cells (Semenza, 2003). HIF-1α, a functional 
subunit of HIF-1, is often overexpressed in breast tumours and its upregulation 
is associated with unfavourable prognosis in patients (Dales et al., 2005; 
Schindl et al., 2002; Zhong et al., 1999). 
 Epigenetic modifications, i.e. DNA methylations and histones modifications 
could also contribute to the breast cancer landscape influencing the expression 
of oncogenes and tumour suppressor genes. For example, the 
hypermethytlation of tumour suppressor genes such as BRCA1 or MLH1 is a 
common events in breast cancer which strongly enhances cancer progression 
(Veeck et al. 2010).  
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1.1.4 Breast cancer aetiology 
 
There are several factors that are known to increase the risk of breast cancer 
and these can be grouped in the following categories: genetic/familial, 
reproductive/hormonal, lifestyle related, and environmental (Salehi et al., 2008). 
Genetic predisposition influences up to 10% of all breast cancers (McPherson, 
Steel and Dixon, 2000). Germline mutations have been involved in breast 
cancer, but two in particular, BRCA1 and BRCA2, have been largely studied 
and considered as the principal cause of familiar breast cancer (Ford et al., 
1998). The functions of BRCA1 and BRCA2 have not been fully elucidated yet, 
but it is clear that they are implicated in the processes of DNA repair and cell 
cycle control. Mutations in these genes can therefore facilitate the onset of 
driver mutations in breast cancer (Venkitaraman, 2002; Moynahan et al., 1999; 
Patel et al., 1998). Taken together, germline mutations of BRCA1 and BRCA2 
encounter for 80–90% of all the familial breast cancer cases (Duncan, Reeves 
and Cooke, 1998). Germline mutations of the tumour suppressor gene p53 are 
less common (Li-Fraumeni syndrome) and can cause early onset of breast 
cancer (Malkin et al. 1990). 
Age is one of the main risk factors. The risk of breast cancer doubles about 
every 10 years until the menopause, when the risk drops dramatically 
(McPherson, Steel and Dixon, 2000).  
The altered homeostasis of ovarian hormones is another factor known to 
increase breast cancer incidence. In normal tissue, oestrogens and 
progesterone are finely regulated to modulate proliferation and differentiation of 
breast cells (Pike et al., 1993). Reproductive factors that enhance oestrogens 
levels (such as early age at menarche, nulliparity and late onset of menopause) 
are known to enhance the risk of breast cancer. Conversely, reproductive 
factors associated with a reduced exposure to oestrogens, such as low number 
of ovulatory cycles, have been shown to be protective against breast cancer 
(Martin and Weber, 2000). Mechanistically, the increase in cell proliferation 
caused by oestrogens also increases the chances that genetic errors occur 
during cell replication; if the mutations occur in tumour suppressor genes or 
oncogenes, this could give rise to breast cancer (Preston-Martin et al., 1990). 
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Progesterone levels might also influence breast cancer occurrence. 
Progesterone is crucial for normal breast tissue regulation, particularly lobular-
alveolar development (Ismail et al., 2003). Its role in breast cancer is still 
controversial, but it is probably associated with the different progesterone 
receptors isoforms subtypes expressed in the tumour tissue and is probably 
exercised indirectly through the regulation of oestrogens levels (Salehi et al., 
2008).  
Lifestyle is another key factor in breast cancer incidence. Obesity has been 
shown to increase two fold the risk of developing the disease. Other habits such 
as alcohol consumption and smoking have been suggested as potential risk 
factors, although other investigators have reported a minimal or null increase of 
the risk (Romieu et al., 2015; Ali et al., 2014; Dossus et al., 2014; McPherson, 
Steel and Dixon, 2000).  
 
1.2 Breast cancer subtypes  
 
Breast tumours can be categorized into different subtypes depending on the 
origin of the cells and molecular features. 90% of all breast cancers derive from 
epithelial cells of the milk ducts, therefore are called ductal carcinomas. Breast 
tumours originating from the milk producing glands (lobules) are called lobular 
carcinomas (figure 1.2). A third rare subtype, breast sarcoma, originates from 
the fatty or connective tissue (Beers 2006). 
If breast cancer cells are confined where the lesion first occurred, the tumour is 
defined as “in situ” carcinoma. Ductal carcinomas in situ accounts for 20 to 30% 
of all breast cancers (Beers 2006). Nearly all women diagnosed at this early 
stage can be cured (Source: American Cancer Society website, 
http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-breast-
cancer-types). Lobular carcinomas in situ accounts for 1 to 2 % of all breast 
cancers (Beers 2006).  
Invasive ductal carcinomas are characterized by the tumour cells capability to 
pass through the walls of the ducts, invading the surrounding tissue. This type 
can generate metastases. It accounts for 65 to 85% of all breast cancers and it 
is the most common subtype (Beers 2006). Invasive lobular carcinomas are 
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more likely to occur in both breasts and they account for 10 to 15% of all breast 
cancers (Beers, 2006).  
In about 20 % of the women diagnosed with early breast cancer, the tumour can 
spread to secondary organs and develop metastases. Currently, there is no 
cure for metastatic breast cancer and therapies are aimed to prolong as much 
as possible the survival of these patients (Stevanovic, Lee and Wilcken, 2006). 
 
 
Figure 1.2: Schematic representation of the mammary gland: The mammary gland 
is constituted of milk secreting cells organized in lobules and ducts that convoy the milk towards 
the nipple. The milk duct is composed of two different cell types: the luminal cells which 
constitute the inner part of the duct and form the duct lumen, and the basal/myoepithelial cells 
which constitute a more external layer of cells. The basal lamina separates the duct from the 
surrounding stroma.  
 
The most aggressive type is inflammatory breast cancer. This is characterized 
by skin erythema, peau d’orange and poor prognosis. Molecular profiling and 
histopathology might vary, but it always implicates invasion of tumour cells into 
the surrounding lymph nodes (Cariati et al., 2005).  
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A very rare form of breast cancer is the Paget’s disease of the nipple. It is 
caused by the infiltration of carcinoma cells with glandular features in the 
epidermal layer of the nipple and areola. It accounts for 1% of all breast cancers 
(Lohsiriwat et al., 2012; Beers, 2006). 
Breast cancer biopsies are required to identify the molecular changes relevant 
for the establishment of appropriate therapeutic protocols. According to the St. 
Gallen International Expert Consensus, breast cancer cases can be categorized 
in 4 intrinsic subtypes: Luminal A, Luminal B, HER2 positive and Basal-like 
(Goldhirsch et al., 2013). Recently, gene expression studies identified a claudin-
low subtype, similar to the basal subtype but distinctive for the overexpression 
of 40 genes involved in the immune response. However, at present there are no 
standardized procedures for the identification of this subtype in the clinical 
practice (Eroles et al., 2012).  
 
1.2.1 Luminal breast cancer 
 
Luminal breast tumour cells have features similar to the epithelial cells 
constituting the milk ducts lumen and express similar proteins. These tumours 
are ER positive and express the transcription factors downstream the 
oestrogens pathway (Rakha and Ellis, 2009; Sims et al., 2007). Moreover, 
luminal tumours express cytokeratins 8 and 18 (Eroles et al., 2012). Luminal 
breast cancer can be further categorized in two subgroups: Luminal A and 
Luminal B. 
Luminal A. This subtype accounts for about 50-60% of all the breast cancers 
and is the most common subtype. Luminal A tumours usually have good 
prognosis, with lower probability of relapse and the highest rate of survival 
(Eroles et al., 2012). The Luminal A subtype can be identified by 
immunohistochemistry: these tumours are positive for the Oestrogen Receptor 
(ER) and Progesterone Receptor (PGR), negative for HER2, and < 14% of the 
cells are positive for the proliferative marker Ki-67 (although this cut point might 
vary between laboratories) (Goldhirsch et al., 2013).  
Luminal B. This subtype accounts for about 10-20 % of all breast cancers. It 
has a worse prognosis, a more aggressive phenotype and a higher histological 
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grade compared to the Luminal A subtype (Eroles et al., 2012; Cheang et al., 
2009). This subtype can be further divided into HER2 positive or HER2 
negative. The Luminal B HER2 positive tumours can have any grade of Ki-67 or 
PGR to be defined as luminal B, whereas Luminal B HER2 negative tumours 
must have in addition high levels of Ki-67 (≥ 20 % of the cells positive for Ki-67) 
or low or absent PGR (Goldhirsch et al., 2013). 
 
1.2.2 HER2 amplified breast cancer 
 
ERBB2 gene encodes the protein HER2 which belongs to the family of the 
epidermal growth factor receptors. These receptors have intrinsic tyrosine 
kinase activity and mediate the response to extracellular cues by regulating 
complex cellular functions such as proliferation, survival and migration 
(Wieduwilt and Moasser, 2008). HER2 function seems to be exerted by the 
dimerization with other receptors of the same family, rather than direct 
activation by specific ligands (Olayioye, 2001). 15-20% of all breast cancers 
show overexpression of HER2. This is correlated with higher tumour size, 
increased invasiveness and high histological grade (Yarden and Sliwkowski, 
2001). HER2 activation enhances the cell proliferation rate and reduces 
apoptosis by activating signalling pathways involving PI3K, AKT, PLC and PKC 
(Roy and Perez, 2009). In the COSMIC repository, about 12% of the breast 
cancer samples present a gene copy number gain of ERBB2 (Forbes et al. 
2014). A direct correlation betweenERBB2 copy number gain and HER2 
overexpression has been observed in breast cancer cell lines (Szollosi et al., 
1995). 
HER2 overexpressing tumours had a poor prognosis before the introduction of 
a monoclonal antibody against HER2 (Trastuzumab), which drastically 
improved the survival rate of patients bearing this breast cancer subtype (Eroles 
et al., 2012). Trastuzumab is the first successful antibody used in breast cancer 
targeted therapy (Roy and Perez, 2009). The mechanism of action is still not 
fully understood, but it has been proposed that the bond of Trastuzumab with 
the juxstamembrane portion of HER2 results in increased receptor endocytosis, 
hampers the receptor dimerization, and activates the immune system (Hudis, 
2007). Moreover, downregulating the signalling cascades downstream HER2 
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(Such as PI3K and MAPK signalling), Trastuzumab can activate the cyclin 
dependent kinase inhibitor p27kip1, leading to cell cycle arrest and apoptosis 
(Nahta and Esteva, 2006). 
 
1.2.3 Basal-like breast cancer 
 
The basal-like group of breast tumours have a genetic expression profile that 
resembles the basal/myoepithelial cells of the mammary gland. These tumours 
are recognisable by the positive immunohistochemical staining of cytokeratins 
5, 14 and 17 (CK5, CK14 and CK17), and the expression of other basal 
markers such as P-cadherin, caveolin1/2 and nestin (Sims et al., 2007).  This 
breast cancer subtype is the most aggressive and the one with the poorest 
prognosis (Liedtke et al., 2008). Basal-like breast cancers account for 10-20 % 
of all breast carcinomas (Eroles et al., 2012).  
 
1.2.4 Triple negative breast cancer 
  
Triple negative breast cancers (TNBC) are defined as breast tumours negative 
for ER, PGR and HER2 in immunohistochemical analysis. The vast majority of 
basal-like tumours (around 80%) are also triple negative (Goldhirsch et al., 
2013). Often the terms basal-like and triple negative are used as synonyms, 
although not all the basal-like tumours are also triple negative and vice versa 
(Eroles et al., 2012; Rakha, Reis-Filho and Ellis, 2008). Indeed, 18 to 40 % of 
the basal tumours do not show a triple negative phenotype (Bertucci et al., 
2008). TNBC is characterized by a bigger tumour mass and a higher 
histological grade compared to the other breast cancer subtypes (Dent et al., 
2007). The incidence of TNBC is higher in black and in Hispanic women 
compared to other ethnic groups (Lara‐Medina et al., 2011; Stead et al., 2009; 
Bauer et al., 2007) and  more common in young women (Dent et al., 2007). An 
increasing waist-to-hip ratio and parity raises the risk of TNBC (Millikan et al., 
2008). 
Several lines of evidence have linked the phenotypical characteristics of 
TNBC/basal-like breast cancers with the ones deriving from germline mutations 
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of the BRCA1 gene (Reis‐Filho and Tutt, 2008). In fact, the vast majority of 
patients carrying a mutation of BRCA1 exhibit a triple negative/basal like 
phenotype (Haffty et al., 2006; Foulkes et al., 2003). 
Triple negative breast cancer patients have a poorer outcome compared to 
patients bearing other subtypes (Dent et al., 2007). Few therapeutic options for 
TNBC are available, since hormone and HER2 targeted therapies are not 
beneficial for these patients (Foulkes, Smith and Reis-Filho, 2010). Although the 
response to chemotherapy is usually good, the recurrence and disease 
progression are more common than in any other breast cancer subtype (Perou, 
2011). Therefore, the development of novel therapeutic approaches is urgently 
needed.  
Another feature of TNBC is that, contrarily to other subtypes, it is more likely to 
metastasize to organs such as the lungs and the brain, and less likely to 
metastasize to the bones (Foulkes, Smith and Reis-Filho, 2010; Dent et al., 
2009). 
 
1.2.5 Claudin low breast cancer 
 
In 2007 a new breast cancer subtype, the claudin low subtype, was identified by 
Herschkowitz and colleagues. This subtype is characterized by low expression 
of genes involved in cell adhesion such as Claudins 3, 4 and 7, Occludin and E-
Cadherin. Claudin-low subtypes also have a low expression of luminal genes 
and high expression of lymphocyte markers (Herschkowitz et al., 2007). Most 
tumours of this subtype are TNBC, although about 20% of them are positive for 
hormones receptors (Prat and Perou, 2011). Another feature of this group is the 
low expression of proliferation genes which are usually high in luminal B, basal 
like and HER2 enriched subtypes (Eroles et al., 2012; Prat and Perou, 2011)  
Interestingly, this subtype expresses a class of genes which are associated with 
cancer stem cells, such as ALDH1A1. Some authors hypothesized that all of the 
previously described breast cancers subtypes derive from cancer stem cells, 
with claudin-low subtype being an early progenitor (Hennessy et al., 2009).    
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1.2.6 Normal like breast cancer 
 
This group is a heterogeneous subset of tumours characterized by having 
similar features to the normal breast tissue. Common aspects of this class are 
the high expression of genes typical of adipose cells and other non-epithelial 
cells, and low expression of luminal genes. Clinical outcome for these tumours 
varies from good to very poor prognosis (Eroles et al., 2012; Rakha, Reis-Filho 
and Ellis, 2008).This class accounts for 5 to 10% of all breast tumours and can 
also be classified as TNBC, as they lack ER, PGR and HER2. Since normal like 
breast cancer cells are negative for CK5, they cannot be considered basal-like. 
This subtype is still poorly studied, and some authors hypothesize it derives 
from artefacts caused by sample contamination with normal tissue before 
microarray analysis (Eroles et al., 2012). 
 
1.3 Breast cancer therapy  
 
Therapy for breast cancer varies depending on the different molecular 
subtypes, but the first act is the surgical resection of the tumour, followed or not 
by radiotherapy (Beers, 2006). When the size of the tumour is large, patients 
receive chemotherapy before surgery (Neoadjuvant chemotherapy) to facilitate 
tumour excision, improve breast conservation and suppress occult systemic 
metastases (Smith et al., 2002). Physical or chemical treatments can be used to 
eliminate cancer cells that have been left after surgery, referred to as adjuvant 
therapy. These treatments include chemotherapy, hormonal therapy, 
monoclonal antibodies, radiation therapy, or a combination of these (Davidson 
and Abeloff, 1994). 
 
1.3.1 Hormone therapy 
 
The hormone therapy includes two classes of drugs, anti-oestrogens and 
progestins. The anti-oestrogens strategy includes the selective oestrogen-
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receptor modulators (SERM), selective oestrogen-receptor downregulators 
(SERD) and the aromatase inhibitors (AI). The therapeutic effect is due to the 
anti-proliferative action of antagonizing the ER pathway (Goodman, 1990). 
When other therapies have failed, progestins are used as second line defence 
in advanced breast cancer. Progestins reduce the levels of systemic oestrogens 
and the expression of ER (Lundgren et al., 1990; Blumenschein, 1983).  
One of the most widely used drugs in the treatment of breast cancer is 
Tamoxifen.  It is used both in early and late stages of the disease, in women of 
all the ages and also as preventive treatment in women carrying BRCA1 or 
BRCA2 mutations. It belongs to the class of SERM and works antagonizing 
oestrogens in the mammary gland (Goodman, 1990).  
Fulvestrant is a member of the SERD family and it is a pure antagonist of the 
oestrogen receptor. It is often used in women with advanced disease when the 
treatment with tamoxifen has failed (Goodman, 1990; Lundgren et al., 1990; 
Blumenschein, 1983). 
Anastrozole, letrozole and exemestane belong to the class of the aromatase 
inhibitors which act reducing the levels of circulating oestrogens. The enzyme 
aromatase converts the androstenedione in the oestrogens oestrone and 
estradiol. This conversion occurs predominantly in the ovaries of pre-
menopausal women and peripherally in post-menopausal women.  For this 
reason these drugs are often used in the treatment of breast tumours in post-
menopausal women, where the side effects affecting the ovarian hormonal 
homeostasis are reduced (Goodman, 1990).  
Megestrol acetate is one of the most used progestin in the therapy of breast 
cancer. Progestins are used in patients with metastatic relapsing breast cancers 
as second choice therapy where treatment with tamoxifen failed (Goodman, 
1990).  
 
1.3.2 Monoclonal antibodies  
 
Trastuzumab and Pertuzumab are humanized monoclonal antibodies used 
alone or in combination for the treatment of HER2 positive breast cancers. 
HER2 activation generates downstream signal that increase the metastatic 
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potential and reduce apoptosis. HER2 overexpression is associated with 
resistance to cytotoxic and hormonal therapy (Baselga et al., 2012; Vogel et al., 
2002). The mechanisms of action of the monoclonal antibodies in killing breast 
cancer cells are still unclear. Different theories have been proposed, such as 
direct toxicity mediated by the antibody itself, toxicity mediated by the 
complement, or induction of cell apoptosis (Beers, 2006; Goodman, 1990). 
Lapatinib is an inhibitor of both the Epidermal Growth factor receptor 1 (EGFR1) 
and HER2, and can be used in the treatment of HER2 positive metastatic breast 
cancer (Source: Cancer Research UK, http://www.cancerresearchuk.org/about-
cancer/type/breast-cancer/treatment/which-treatment-for-breast-
cancer#hormchem). 
 
1.3.3 Chemotherapy 
 
Chemotherapy includes a number of cytotoxic and cytostatic drugs that are 
used to eliminate fast dividing cells. It cannot be used as a single therapy in 
breast cancer, but always together with surgery, radiation therapy or other 
adjuvant therapies (Beers, 2006). Commonly used drugs in breast cancer are 
cyclophosphamide, doxorubicin, epirubicin, 5-fluorouracil, methotrexate, 
mitomycin, mitozantrone, docetaxel, gemcitabine and paclitaxel (source: Cancer 
Research UK). 
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1.4 WNT signalling pathway 
 
The WNT (Wingless‐related integration site protein) pathway consists of a 
group of cell signalling cascades activated by a class of lipoglycoproteins called 
WNTs (Wingless‐related/integration site proteins). In humans, there are 19 
WNTs (WNT1, WNT2, WNT2B, WNT3, WNT3a, WNT4, WNT5a, WNT5b, 
WNT6, WNT7a, WNT7b, WNT8a, WNT8b, WNT9a, WNT9b, WNT10a, 
WNT10b, WNT11 and WNT16). WNTs ligands mediate the signal transduction 
from the extracellular environment to the cell through the activation of 7-
segments transmembrane receptors called frizzled (FZDs). In human, there are 
ten frizzled receptors (FZD1-10) (Schulte, 2010).  
The first WNT gene was discovered by Nusse et al. in 1982, during experiments 
where mice were infected with the mouse mammary tumour virus (MMTV). 
They found that the MMTV oncogenic properties derived from the capacity to 
activate a gene, following viral genome integration, that was first called int-1 
(integration 1) (Nusse et al., 1984). It was later discovered that the gene int-1 
was the homologous of the gene Wingless in drosophila melanogaster (Sharma 
and Chopra, 1976). Due to the discovery of new Int-1 related genes and to 
avoid confusion in the nomenclature, the name Int-1 was later changed to WNT-
1, (Wingless‐related integration site protein 1).  
WNT signalling is divided into two different branches, the canonical and the non 
canonical pathways. The WNT canonical pathway is characterised by the 
stabilization and translocation into the nucleus of the protein β-catenin. β-
catenin has a dual function: together with other proteins constitutes the cellular 
adherens junctions (Hartsock and Nelson, 2008) and also promotes the 
transcription of WNT-associated genes in the nucleus (Daniels and Weis, 
2005). The term non-canonical pathway usually refers to a group of signalling 
pathways activated by WNTs which do not lead to the cytoplasmic stabilization 
of soluble β-catenin (Pandur, Maurus and Kühl, 2002). Two of these pathways 
have been well characterised: the planar cell polarity (PCP) and the WNT-
Calcium pathway (Strutt, 2003). 
Although for simplicity the WNT signalling is often dichotomized in two 
branches, the canonical and the noncanonical pathways often overlap and 
cross interact to coordinate complex cellular responses. The two investigators 
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that first discovered the WNT pathway, Renée van Amerongen and Roel Nusse, 
recently proposed an integrated model where the total net balance of canonical 
and non canonical signals ultimately determines the response of the receiving 
cell (van Amerongen and Nusse, 2009). 
The WNT pathway regulates several cellular functions during embryonal 
development and is also required for the homeostasis of adult tissues. WNT 
signalling has been shown to regulate multiple cellular functions, such as 
proliferation, stem cell maintenance, cell motility and polarity, cell differentiation 
and fate, in multiple physiological processes (van Amerongen and Nusse, 
2009). Despite recent advances, many aspects of the WNT pathway are still 
poorly understood (Cadigan and Nusse, 1997). The existence of 19 ligands and 
10 receptors makes the WNT pathway intrinsically complicated. Several 
aspects such as the specificity of ligand-receptor interactions and the signal 
specificity for each frizzled receptor are still poorly characterised (Wodarz and 
Nusse, 1998).  
The WNT pathway is further complicated by the need of co-receptors like the 
low-density lipoprotein receptor related proteins 5 and 6 (LRP5/6). These co-
receptors don’t bind directly to WNT ligands but form a FZD/WNT/LRP5/6 
ternary complex which is required for the activation of the WNT canonical signal 
(Zeng et al., 2008; Mao et al., 2001; Tamai et al., 2000).  
The WNT pathway can be inhibited by several secreted antagonists which act 
either binding the WNT ligands or the FZD/LRP5/6 receptor complex (Kawano 
and Kypta, 2003). Amongst these are some members of the Dickkopf family of 
proteins (Niehrs, 2006). Dkk1 is the most characterised member of the family. It 
inhibits the canonical WNT pathway by inducing the endocytosis of the LRP5/6 
co-receptor following the formation of a complex with LRP5/6 and the family of 
transmembrane proteins Kremen (Niida et al., 2004; Huelsken and Behrens, 
2002).  
Another class of WNT pathway inhibitors act primarily by binding with WNT 
ligands and preventing their interaction with the frizzled receptors. This class 
includes the secreted frizzled related proteins (sFRPs), the WNT inhibitory 
factor 1 (WIF) and Cerberus. 
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1.4.1 Canonical WNT pathway 
 
 
 
Figure 1.3: Schematic representation of the WNT canonical pathway: (A) In the 
absence of WNT ligand the levels of cytoplasmic soluble β-catenin are kept low by a 
heteromeric complex constituted by Axin, CK1, GSK3 and APC (refer to the main text for 
details). This complex phosphorylates β catenin which is then degraded through an 
ubiquitin/proteasome mechanism. (B) When the WNT ligand binds to FZD, dishevelled is 
recruited and phosphorylated; this induces the binding with the co-receptor LRP5/6 and the β-
catenin destruction complex, leading to the increase of stabilized β-catenin in the cytoplasm. β-
catenin can then translocate in the nucleus where it displaces the protein Groucho to bind to the 
transcription factor LEF/TCF. This induces the transcriptions of several WNT-associated genes 
(adapted from Clevers and Nusse, 2012). 
 
In the WNT canonical pathway, in the absence of canonical WNT ligands, β-
catenin cytoplasmic levels are kept low by a β-catenin destruction complex 
(fig.1.3 A). The destruction complex is constituted of Axin, Adenomatous 
Polyposis Coli (APC) and the two protein kinases CK1α/δ and GSK3α/β 
(Clevers and Nusse, 2012). Axin constitute a scaffold for the destruction 
complex binding with β-catenin, GSK3 and APC (Luo and Lin, 2004; Nakamura 
et al., 1998). APC is a large protein that binds both β-catenin and Axin. Its 
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function is required for the activity of the destruction complex, although its 
specific molecular role is still unclear (Clevers and Nusse, 2012). The two 
kinases CK1 and GSK3 phosphorylate β-catenin in multiple residues (Liu et al., 
2002). Phosphorylated β-catenin is a target of the SCF-βTRCP ubiquitin ligase 
complex, which catalyses the addition of ubiquitin residues (Winston et al., 
1999). Ubiquitinated β-catenin is then degraded by the ubiquitin-proteasome 
complex (Aberle et al., 1997). 
In the presence of WNT ligands (fig. 1.3 B), the frizzled receptor changes 
conformation and associates with the co-receptor LRP5/5 (He et al., 2004). 
LRP5/6 is then phosphorylated by GSK3 and CK1, leading to the association of 
Axin and the β-catenin destruction complex to the receptors heteromer (Zeng et 
al., 2008). In these conditions the destruction complex is saturated by 
phosphorylated β-catenin and cannot induce further β-catenin phosphorylation, 
leading to the accumulation of stabilized β-catenin in the cytoplasm (Li et al., 
2012). The scaffold protein Dishevelled also binds to FZD and is 
phosphorylated upon WNT activation; although its specific function remains 
unclear, it is required for the phosphorylation of LRP5/6 (Zeng et al., 2008; Bilic 
et al., 2007; Wallingford and Habas, 2005; Wong et al., 2003). Recent findings 
suggest that dishevelled might have a role in facilitating the interaction between 
LRP5/6 and Axin and in the formation of the FZD/LRP5/6 complex (Clevers and 
Nusse, 2012). 
Stabilized β-catenin is then transported inside the nucleus where it interacts 
with the family of TCF/LEF transcription factors (Fagotto, Glück and Gumbiner, 
1998; Behrens et al., 1996; Molenaar et al., 1996). β-catenin directly displaces 
the transcription inhibitor Groucho, which normally binds to TCF/LEF 
transcription factors; this in turns promotes the TCF/LEF mediated transcription 
of WNT target genes (Daniels and Weis, 2005).  
The β-catenin-dependent activation of TCF/LEF1 leads to the transcription of 
several genes involved in a plethora of functions, including cell proliferation, 
tissue homeostasis, stem cell maintenance and cell differentiation (Clevers, 
2006). The overexpression of WNT target genes such as c-myc and cyclin D1 
were shown to be key factors in the development of colon cancer and other 
tumours (Anastas and Moon, 2012; Bejsovec, 2005; Tetsu and McCormick, 
1999). 
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1.4.2 WNT Planar Cell Polarity 
 
During development cells are organised in tissues through mechanisms that 
require cell polarization. The regulation of cell polarity is also essential during 
physiological processes requiring the directional migration of cells, for example 
during convergent extension movements (i.e. the narrowing and lengthening of 
a group of cells occurring during gastrulation) or wound healing (Caddy et al., 
2010; Roszko, Sawada and Solnica-Krezel, 2009). The acquisition of a specific 
position of a cell in a plane is referred to as planar cell polarity. This process 
has been extensively studied in drosophila and requires WNT signalling (Seifert 
and Mlodzik, 2007). A schematic overview of the PCP pathway is shown in 
figure 1.4. 
Several PCP proteins have been identified in vertebrates through gene 
loss/gain experiments, but their specific molecular functions remain largely 
obscure (Simons and Mlodzik, 2008; van Amerongen and Berns, 2006). The 
principal core components of the PCP signalling cascade in vertebrates are 
FZD (FZD3 and FZD6 have been shown to mediate PCP signalling in mice 
(Stuebner et al., 2010), Dishevelled (Dvl1, Dvl2), Vangl1/2, Celsr 1, Prickle (Pk1 
and Pk2) and Diversin (or Ankrd6) (Seifert and Mlodzik, 2007; Wang and 
Nathans, 2007). Two WNT ligands, WNT5a and WNT11, have been implicated 
in the control of the PCP/WNT pathway, although it is likely that more WNT 
ligands can activate this pathway (Strutt, 2003).  
Vangl2 is a membrane bound protein required for the stereociliary bundle 
orientation in the mouse cochlea and to regulate the convergent extension 
movements during neural tube closure in humans (Lei et al., 2010; 
Montcouquiol et al., 2003). Vangl 1/2 binds to Dishevelled and to Pk1/2 (Jenny 
et al., 2005; Torban et al., 2004).  
Celsr1 is a 7 pass transmembrane protein required for the patterning of sensory 
hair cells and neural tube closure in mice (Curtin et al., 2003). Recently, it was 
found that Celsr1 physically interacts with Vangl2 (Lei et al., 2014).  
Mutations of the Prickle 1/2 genes in humans, mice and zebrafish have been 
associated with seizures (Tao et al., 2011). Studies in drosophila and zebrafish 
suggest that Pk1/2 are cytoplasmic proteins that physically interact with 
dishevelled, Strabismus (Vangl in humans) and Diego (Diversin or Ankrd6 in 
46 
 
humans) (Das et al., 2004; Bastock, Strutt 2003; Tree et al., 2002), and 
modulate PCP signalling by competing with Diego for the binding with 
Dishevelled. In drosophila the binding of Diego with Dishevelled facilitates the 
FZD/Dishevelled interaction, while the interaction between Pk and Dishevelled 
exerts the opposite effect (Jenny et al., 2005).  
Ankrd6 has been involved in the PCP-dependent orientation of the inner ear 
sensory organs (Jones et al., 2014). The ankyrin repeat domain of Ankrd6 binds 
to the DEP domain of Dishevelled. This was shown to be required to activate 
the WNT/JNK pathway in HEK293 cells (Jones et al., 2014). In silico studies 
predicted that the ankyrin repeats present in this protein are putative binding 
domains for Prickle1, Prickle2, Vangl1, and Vangl2 (Katoh, 2005). In drosophila 
the homologous of Ankrd6, Diego, is a cytoplasmic protein recruited by 
Dishevelled that facilitates FZD/PCP signal (Jenny et al., 2005). 
Although it is still unclear how the PCP core elements regulate cell polarity, it 
seems that their subcellular localization during PCP signalling is a key factor. In 
drosophila, before the onset of a FZD/PCP signal, the core components are 
localized around the apical-lateral cortex, while following a PCP stimulus, they 
distribute asymmetrically to form functional complexes (Seifert and Mlodzik, 
2007). In other words, the precise localization of PCP core components in the 
cell is a prerequisite for PCP-dependent functions such as convergent 
extension movements and tissue polarity (Strutt, 2003). 
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Figure 1.4: Schematic representation of the WNT/PCP pathway: The WNT/PCP 
pathway is activated by WNT ligands and requires the core components FZD, Vangl 1/2, Prickle 
1/2, Ankrd6, Celsr1 and Dishevelled. Although their molecular functions are not fully 
understood, their presence is required for PCP functions such as the orientation of hairs and 
stereocilia in the ear and during gastrulation. The most characterised effectors of the WNT/PCP 
signalling are the small GTPAses Rho and Rac, which are involved in the regulation of actin 
dynamics (refer to the main text for more details). 
 
Downstream the PCP core components are several effectors which mediate 
different cell behaviours; these include the Rho family of GTPases (Rho, Rac 
and Cdc42) and JNK (Roszko, Sawada and Solnica-Krezel, 2009).  
The Rho family of GTPases belong to the family of Ras-related small GTP 
binding proteins, comprising RhoA, RhoB and RhoC, Rac1 and Rac2, Cdc42, 
48 
 
RhoG and TC10 (Boguski and McCormick, 1993). Rho GTPases are in an 
active state when bound to GTP and in an inactive state when bound to GDP 
(Symons, 1996). The WNT/FZD-dependent activation of Rho GTPases is 
mediated by Dishevelled (Schlessinger, Hall and Tolwinski, 2009). Dishevelled 
activates RAC1 by direct binding with the DEP domain (Habas, Dawid and He, 
2003), whereas Rho interacts with Dishevelled through the protein Daam1, 
which forms a complex with Rho and Dishevelled (Habas, Kato and He, 2001). 
Rho and Rac collaborate together in the reorganization of the actin cytoskeleton 
during polarized cell shape changes and cell movement (Schlessinger, Hall and 
Tolwinski, 2009). Rac is involved in the formation of actin ruffles and focal 
adhesions at the leading edge of motile cells. These actin structures, called 
lamellipodia, constitute a molecular motor that push the cell forward during cell 
migration (Machesky and Hall, 1997; Nobes and Hall, 1995). This is achieved 
through the activation of the WAVE and Arp2/3 complexes (Jaffe and Hall, 
2005). Rac can also induce genes transcription through the activation of the c-
Jun N-terminal Kinase (JNK) pathway (Boutros et al., 1998; Minden et al., 
1995). JNK signalling is required for the correct gastrulation in Xenopus, 
suggesting that this pathway is relevant in the morphogenic cell movements 
controlled by WNT/PCP (Yamanaka et al., 2002). However, little is known about 
the molecular mechanisms by which JNK participates to PCP. A possible 
mechanism is through the phosphorylation of a protein that specifically interacts 
with the F-actin capping protein (CapZIP) that is involved in the remodelling of 
actin filaments (Eyers et al., 2005). Moreover, JNK was shown to participate in 
the WNT/PCP by controlling microtubules stability (Ciani and Salinas, 2007). 
JNK can activate the transcription of target genes by phosphorylating c-Jun, 
which together with c-Fos forms the AP-1 transcription factor complex (Chiu et 
al., 1988; Halazonetis et al., 1988); through this pathway, JNK can activate 
genes involved in cell proliferation and survival (Leppa and Bohmann, 1999). It 
is likely that JNK could promote the transcription of genes which are relevant for 
PCP, although this aspect is still poorly investigated (Roszko, Sawada and 
Solnica-Krezel, 2009). 
Rho can control different aspects of the actin cytoskeleton through the 
activation of the downstream effectors mDIA1 and the Rho associated kinase 
(ROCK) (Yamana et al., 2006; Maekawa et al., 1999). Rho has been implicated 
in the formation of actin stress fibres and focal adhesion, and regulates the 
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contractility of the actin cytoskeleton (Chrzanowska-Wodnicka and Burridge, 
1996; Ridley and Hall, 1992). 
Several experiments have demonstrated a requirement for WNT dependent 
Cdc42 activation during convergent extension movements in frog gastrulation, 
but it is not clear if this is activated by dishevelled or other Frizzled-dependent 
pathways (Schlessinger, Hall and Tolwinski, 2009). 
 
1.4.3 WNT Calcium pathway 
 
In some systems WNTs can increment calcium release through the activation of 
the WNT/Calcium pathway. This was demonstrated for the first time in the zebra 
fish model, where WNT5a and WNT11 were shown to increase the intracellular 
level of calcium (Westfall et al., 2003; Slusarski et al., 1997). The WNT/Calcium 
pathway is an important regulator of the embryonic development and also 
regulates physiological functions in adult tissues, such as slow muscle fibres 
formation and intracellular signalling in the retina (Kohn and Moon, 2005).  
Calcium concentration is finely regulated in the cytoplasm, and temporary 
increments of Ca2+ function as important signal mediators in cells (Clapham, 
1995). FZD receptors can activate heterotrimeric G-proteins, which in turn 
activate Phospholipase C (PLC) through the G-protein β/γ dimers (Slusarski et 
al., 1997) (fig. 1.5). PLC catalyses the formation of inositol-1,4,5-
trisphosphonate (IP3) and diacylglycerol (DAG) from the membrane 
phospholipid phosphatidylinositol-4,5-bisphosphate (PIP2);  IP3 binds to 
intracellular receptors that lead to the release of Ca2+ from intracellular stores 
(Kuhl, 2004). Both Ca2+ and DAG activate the Protein Kinase C (PKC) 
(Sheldahl et al., 1999; Liu and Heckman, 1998).  
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Figure 1.5: Schematic representation of the WNT/Calcium pathway: WNT ligands 
activate G-protein signals through the interaction with FZD. FZD receptors interact with the G 
protein subunits β/γ to activate PLC, which in turn catalyses the production of PIP3 and DAG 
from PIP2. The production of PIP3 leads to the release of intracellular Ca2+ and to the 
activation of the Ca2+ dependent proteins CAMK2 and Calcineurin. DAG and Ca2+ also 
activate PKC. PKC, CAMK2 and Calcineurin modulate the cellular response through the 
transcriptional control of target genes and cytoskeletal rearrangements. 
 
Other proteins which are activated by the release of calcium are the calmodulin-
dependent protein kinase II (CAMK2) and/or Calcineurin (Hogan et al., 2003; 
Kuhl et al., 2000). 
WNT-dependent PKC activation was shown to regulate cell-cell adhesion, cell 
movement during gastrulation and tissue separation during embryogenesis 
(Kinoshita et al., 2003; Winklbauer et al., 2001; Pauken and Capco, 1999). PKC 
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can also control cytoskeletal dynamics through the activation of the small 
GTPase Cdc42 during gastrulation (Choi and Han, 2002).  
CAMK2 is essential during embryonic development and is involved in the dorso-
ventral axis formation in the Xenopus embryo (Kuhl et al., 2000). Moreover 
CAMK2 signal was shown to inhibit the WNT canonical pathway through the 
activation of the MAP kinases TAK1 and NLK, which block the transcriptional 
activation of TCF/LEF (Ishitani et al., 2003; Ishitani et al., 1999).  
Calcineurin is a serine/threonine protein phosphatase which regulates the 
activity of several target proteins (Jain et al., 1993), including the Nuclear Factor 
of activated T-cells (NF-AT). When NF-AT is dephosphorylated by calcineurin, it 
enters the nucleus and regulates the expression of target genes. The 
WNT/Calcineurin/NF-AT signalling was shown to be required for the embryo 
dorsoventral axis formation in Xenopus, T-cells differentiation and activation, 
and cardiac valves development in mice (Saneyoshi et al., 2002; Serfling et al., 
2000; Ranger et al., 1998). 
 
1.4.4 WNT signalling in the development and maintenance of 
the mammary gland 
 
Studies in mice have shown that the WNT pathway is essential for the normal 
development of the mammary gland. Canonical WNT signalling is required 
during the early stages of mammary gland development, and mice embryos 
stimulated with WNT3A or the WNT pathway activator lithium chloride (LiCl) 
show increased formation of mammary placodes. Conversely, the expression of 
the secreted WNT inhibitor Dickkopf 1 blocks mammary placode formation (Chu 
et al., 2004). WNT10b and WNT6 display specific spatio-temporal expression 
patterns during mouse mammary gland development (Veltmaat et al., 2004). 
The activation of canonical WNT signalling during mammary gland development 
was demonstrated in transgenic mice that express a TOPGAL Wnt reporter 
gene. This is based on a multimerized TCF binding site that drives the 
expression of LacZ, allowing a colour-base identification of the regions were 
TCF promoter is activated. These experiments showed that the β-catenin-
dependent activation of the transcription factor TCF/LEF1 is required for the 
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formation of the mammary gland in mice (Chu et al., 2004; van Genderen et al., 
1994). 
The non canonical WNT pathway was also shown to be involved in mammary 
gland development. For example WNT5a, a non canonical ligand, is required for 
the correct extension and lateral branching of milk ducts in mice (Roarty and 
Serra, 2007). 
The mammary gland undergoes numerous morphologic changes to adapt to the 
different stages of sexual development. These modifications require a tight 
control in cell proliferation, differentiation and migration. For example, during 
puberty, the rudimentary ductal tree develops in an elaborate epithelial network 
that constitutes the adult mammary gland; further modifications are required 
during pregnancy to adapt the gland for lactation. The plasticity of the mammary 
tissue implies the involvement of mammary stem cells (van Amerongen, 
Bowman and Nusse, 2012). WNT signalling is important for the maintenance of 
mammary stem cells both in the embryo and adult tissue (Zeng and Nusse, 
2010). Van Amerongen and colleagues used a recombinant mice model were 
the expression Axin2 is traceable through a fluorescent reporter system. Axin2 
is a well established target gene of the β-catenin pathway and also marks 
mammary stem cells. In these mice, WNT/β-catenin responsive stem cells 
localize in specific regions of the mammary epithelial network in a time 
dependent manner: Axin2 positive cells mark the prospective luminal cell in the 
embryo, while they become committed exclusively to the basal cell lineage in 
the 2 week-old pups (van Amerongen, Bowman and Nusse, 2012).  
Ovarian hormones are essential to regulate the development of the mammary 
gland. Indeed, ovariectomy causes abnormalities in the development of the 
mammary buds and ducts during embryogenesis. Weber-Hall et al. observed 
that ovariectomy causes the reduction of WNT2, WNT4 and WNT5b mRNAs in 
the mammary gland, suggesting that ovarian hormones could control the 
mammary gland development through the expression of WNTs (Weber‐Hall et 
al., 1994). Indeed, the absence of PGR leads to the failure in the ductal side-
branching of the mammary gland, but this can be rescued by the ectopic 
expression of WNT-1. Moreover, the same authors observed that progesterone 
controls the expression of WNT4 during pregnancy (Brisken et al., 2000). 
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1.4.5 WNT Signalling in cancer 
 
The first observation of the oncogenic effects of WNT signalling was made by 
Nusse and Varmus in 1982, when they found that MMTV infection induces 
mammary tumours in mice through the activation of WNT1 (Nusse et al., 1984). 
Since then, several other mutations in components of the WNT pathway have 
been observed during carcinogenesis (Polakis, 2000). Deregulation in β-catenin 
target genes such as cyclin D1 and c-MYC could lead to uncontrolled 
proliferation in several tissues and, therefore, give rise to tumour formation 
(Shtutman et al., 1999; He et al., 1998). The over activation of the β-catenin 
pathway is often originated by mutations in β-catenin itself, or in onco-supressor 
genes that control its degradation (Polakis, 2000). 
Mutations affecting the amino-terminal region of the β-catenin gene hamper the 
interaction with APC and, therefore, prevent its degradation; this in turn leads to 
the constitutive activation of β-catenin and to oncogenic transformation (Polakis, 
2000; Morin et al., 1997; Rubinfeld et al., 1997). β-catenin mutations occur with 
low frequency (Polakis, 2000), but mutations of the β-catenin destruction 
complex component APC are common in human cancers and considered the 
principal gatekeeper mutations in sporadic and familial colon tumours (Hussain 
and Harris, 1998; Morin et al., 1997). 
Axin1 is another protein of the destruction complex which is essential for the 
degradation of β-catenin (Clevers and Nusse, 2012). Mutations in Axin1 have 
been reported in hepatocarcinoma, particularly those lacking mutations of APC 
or β-catenin (Satoh et al., 2000). Axin downregulation is also associated with 
poor prognosis in lung cancer (Xu et al., 2007; Xu et al., 2006). 
Although the non canonical WNT pathway has been understudied in cancer, 
more scientists are now focusing the attention to the role of β-catenin 
independent signals in tumorigenesis (Wang, 2009). For example, WNT5a, 
generally considered a noncanonical ligand (although it was shown that it can 
stabilize β-catenin depending on the receptor context (Mikels and Nusse, 2006), 
promotes melanoma cells invasion and metastases through the activation of 
PKC (Weeraratna et al., 2002). Moreover, WNT5a was shown to enhance 
motility and invasion of gastric cancer cells (Kurayoshi et al., 2006). FZD10 has 
been implicated in the tumorigenesis of human synovial sarcomas through the 
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activation of the non canonical WNT/RAC1/JNK pathway (Fukukawa et al., 
2009). VANGL1, a member of the PCP core component (fig 1.4), has been 
implicated the polarity and migration of breast cancer cells (Anastas et al., 
2012).  
Recently, a new role for PCP in the communication between stroma and cancer 
cells has emerged. Luga and Wrana showed that cancer-associated fibroblasts 
promote the mobilization of PCP proteins in cancer cells through the secretion 
of exosomes; this in turn promotes the migration and invasion of breast cancer 
cells (Luga and Wrana, 2013; Luga et al., 2012). However, the activation of 
noncanonical WNT signalling has been associated with tumour-suppressive 
effects in leukaemia (Roman-Gomez et al., 2007; Liang et al., 2003). In other 
studies, non-canonical signalling mediated by WNT5a promoted leukaemia, 
probably by deregulation of stem cells maintenance (Sugimura and Li, 2010). 
The WNT/Calcium pathway has also been linked to tumorigenesis, particularly 
in relation to cell motility and invasiveness (Le Floch et al., 2005; Weeraratna et 
al., 2002).  
 
1.4.6 WNT signalling and cancer stem cells 
 
Stem cells can produce differentiated cells and new undifferentiated stem cells 
by asymmetric cell division(Tuch, 2006). There are two subtypes of stem cells: 
embryonic stem cells, which are totipotent and can generate all tissues, and 
adult stem cells, which only differentiate into specific tissues (Bajada et al., 
2008). While embryonic stem cells are essential for embryogenesis, adult stem 
cells provide a source of new differentiated cells in tissues with high cells 
turnover and during tissue repair (Young and Black, 2004). 
Many human cancers contain cells with stem like features, responsible for 
several aspects of cancer malignancy such as drug resistance, tumour 
recurrence, metastasis and tumour heterogeneity (Merlos-Suárez et al., 2011; 
Campbell and Polyak, 2007; Li et al., 2007; Jordan, Guzman and Noble, 2006; 
Dean, Fojo and Bates, 2005). 
WNT signalling is involved in stem cells self-renewal and differentiation. 
Alterations in tightly regulated signals in cancer stem cells are implicated in the 
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malignant proliferation and metastasis of human tumours (Reya and Clevers, 
2005). An emblematic example is the deregulation of β-catenin signalling in 
colon cancer, which leads to the activation of the same genetic programs 
characteristic of the stem/progenitor cells of the colon crypt (Vermeulen et al., 
2010; Reya and Clevers, 2005; Van De Wetering et al., 2002). Similarly, the 
deregulation of WNT signalling is required for the maintenance of leukaemia 
stem cells (Wang et al., 2010; Reya and Clevers, 2005).  
The WNT pathway is thought to contribute to tumorigenesis by stimulating the 
transition between a differentiated epithelial state to an undifferentiated 
mesenchymal phenotype (epithelial-mesenchymal transition, EMT). Cells that 
undergo EMT present stem cells features and are considered the principal 
responsible for the onset of cancer metastasis (Singh and Settleman, 2010; 
Morel et al., 2008; Neth et al., 2007). 
 
1.4.7 WNT signalling in breast cancer 
 
As previously mentioned, the oncogenic effect of the WNT pathway in the 
mammary gland was firstly demonstrated by the seminal work of Nusse and 
Varmus that lead to the discover of WNT-1 as an oncogene in 1982 (Nusse et 
al., 1984). Following studies have demonstrated that MMTV viral insertion can 
cause cancer through the activation of other WNTs, such as WNT3 and 
WNT10b (Howe and Brown, 2004; Smalley and Dale, 2001; Bowcock, 1999). 
The role of canonical WNT signalling in human breast tumorigenesis has been 
confirmed with immunohistochemical studies in patients tissues: Two 
independent studies showed that about 60 % of the clinical samples analysed 
present nuclear/cytoplasmic localization of β-catenin corresponding to an 
activated status (Ryo et al., 2001; Lin et al., 2000). Moreover, in the study of Lin 
et al., it was shown that the activation of β-catenin positively correlated with 
increased Cyclin D1 expression, which is a poor prognostic factor in breast 
cancer (Lin et al., 2000; McIntosh et al., 1995). Collectively, these findings 
suggest a pivotal role of WNT canonical signalling in breast tumorigenesis. 
However, since mutations of β-catenin, APC or Axin are very rare in breast 
cancer, it is likely that the deregulation of the WNT canonical pathway is caused 
by other unknown factors (Howe and Brown, 2004). 
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Several studies have been carried out to understand abnormalities in the 
expression of WNT ligands, and many authors reported mRNA overexpression 
of several WNTs in breast cancer (table 1.2); however, there is still a lack of 
information regarding WNTs proteins expression and its correlation with breast 
tumorigenesis, mainly for the lack of high quality antibodies (Howe and Brown, 
2004). 
 
Table 1.2: Selected studies reporting alteration of WNT signalling proteins in breast 
cancer (Adapted from Howe and Brown, 2004) 
Signalling 
component 
Reported abnormality % cases 
(Numbers) 
Tumor type/sample 
 
SFRP1 
 
Loss or underexpression 
 
80% (85/107) 
 
Carcinomas 
WIF1 
 
Reduced imunostaining 60%  (21/35) Carcinomas 
WNT2 
WNT2 
WNT5a 
WNT5a 
WNT7b 
WNT10b 
WNT13/2b 
WNT14 
 
APC 
 
 
 
 
 
β-Catenin 
Overexpression, RNA 
Overexpression, RNA 
Overexpression, RNA 
Loss of immunostaining 
Overexpression, RNA 
Overexpression, RNA 
Overexpression, RNA 
Overexpression, RNA 
 
Truncation mutation 
Truncation mutation 
Truncation mutations 
Reduced immunostaining 
 
 
Nuclear/cytoplasmic staining 
Nuclear/cytoplasmic staining 
Increased protein 
45% (5/11) 
22% (2/9) 
80%(4/5) 
36%(10/28) 
10% (2/20) 
6% (3/50) 
14%(2/14) 
11%(1/9) 
 
4% (1/24) 
0.5% (1/227) 
6% (3/54) 
41% (11/27) 
 
 
60% (74/123) 
63%(25/40) 
13% (7/54) 
 
Carcinomas 
Primary breast cancer 
Carcinomas 
Carcinomas 
Carcinomas 
Carcinomas 
Carcinomas 
Primary breast cancer 
 
Cell lines 
Carcinomas 
Carcinomas 
Carcinomas 
 
 
Primary breast cancer 
Primary breast cancer 
Carcinomas 
 
Deregulation of WNT signalling in breast cancer could be a consequence of the 
altered expression of secreted WNT inhibitors. Indeed, epigenetic 
downregulation of WNT antagonists such as SFRP1/2 and DKK1 were reported 
to be common in breast cancer (Suzuki et al., 2008; Ugolini et al., 2001). The 
tumour suppressor activity and the prognostic significance of SFRP1 have been 
described by several independent authors (Matsuda et al., 2009; Shulewitz et 
al., 2006; Klopocki et al., 2004). Another secreted WNT inhibitor, Wif1, was 
shown to be hypermethylated and consequently downregulated in a large 
number of tumour samples and breast cancer cell lines (Ai et al., 2006). These 
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findings were confirmed independently by other investigators (Veeck et al., 
2009; Wissmann et al., 2003). Overall, these results suggest that epigenetic 
alterations of WNT antagonists, rather than mutations of β-catenin and APC, 
can explain the over-activation of canonical WNT signalling in breast cancer. 
The role of β-catenin independent WNT pathways in breast cancer is still largely 
unknown. However, recent findings suggest that the noncanonical signalling 
could have a role in regulating the interaction of cancer cells with the tumour 
microenvironment and might be important to regulate the metastatic spread of 
invasive breast cancers (Alderton, 2013). The ground-breaking work from Luga 
et al. demonstrated that fibroblasts can induce the invasion, motility and 
protrusive activity of breast cancer cells through the activation of the PCP 
pathway (Luga and Wrana, 2013; Luga et al., 2012). 
 
1.5 Frizzled receptors 
 
Frizzled receptors (FZDs) are seven-transmembrane-spanning proteins 
considered as a sub-class of the G protein-coupled receptor family. In humans 
there are ten FZDs. The name “frizzled” derives from the irregularly organized 
and curled hairs and bristles on thorax, wings, and feet of the frizzled mutants of 
Drosophila Melanogaster (Schulte, 2010). Human FZDs can be clustered in 4 
groups depending on the protein homology: A first group includes FZD1, 2, 7 
with 75% homology; a second group includes FZD5,8 with 70% of protein 
homology; a third group includes FZD4,9,10 with a 50% homology, and the last 
group consist of FZD3 and 6 with 50% of homology (Fredriksson and Schioth, 
2005).  
FZD receptors contain 7 transmembrane domains, an extracellular N-terminus 
and an intracellular C-terminus (fig. 1.6) (Foord et al., 2005; Vinson, Conover 
and Adler, 1989). The extracellular region of all FZDs feature a conserved 
Cysteine Rich Domain (CRD) which is believed to be the binding site for WNTs 
(Xu and Nusse, 1998) and Soluble Frizzled-related proteins (Rattner et al., 
1997). The seven transmembrane regions are connected by 3 extracellular 
loops and 3 intracellular loops and a c-terminus which varies depending on the 
specific FZD (Schulte, 2010). The intracellular domain is required for the 
interaction with a plethora of proteins, which include, amongst others, 
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heterotrimeric G-proteins (Slusarski, Corces and Moon, 1997) and Dishevelled 
(Wong et al., 2003).  
All Frizzled receptors present a KTxxxW domain in the C terminus which is 
required for the binding with proteins containing the PDZ domain, such as 
Dishevelled (Wong et al., 2003). A second PDZ motif is present in some, but not 
in all FZDs, at the terminal end of the C-terminus (Schulte, 2010).  
FZDs bind to WNT ligands, but the specificity of the ligand/receptor interaction 
is largely obscure. Moreover, there is a certain degree of promiscuity for the 
binding to different WNT ligands (Hsieh et al., 1999). Table 1.3 summarises the 
known FZDs/WNTs combinations.  
Interestingly, studies in Xenopus embryos have shown that that Xfz3, the 
homologous of human FZD3, can dimerize to activate the canonical WNT 
signalling (Carron et al., 2003). This study indicates that receptors dimerization 
could further increase the complexity of the WNT pathway.  
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Figure 1.6: Schematic representation of the class of frizzled receptors : The 
frizzled receptors consist of 7 transmembrane domains, a N- terminus extracellular domain and 
a C-terminus intracellular domain. The extracellular CRD domain interacts with WNT ligands 
and secreted WNT inhibitors. The intracellular domain is a docking site for heteromeric G 
proteins and Dishevelled. FZD receptors also present 1 or 2 intracellular PDZ ligand domains 
for the interaction with PDZ proteins (adapted from Schulte, 2010). 
 
Table 1.3: Reported interactions between FZD receptors and WNT ligands: “x” indicate 
binding interactions demonstrated with immunoprecipitation, while “o” indicate co-localization or 
other methods of receptor/ligand interaction identification (adapted from Dijksterhuis, Petersen 
and Schulte, 2014).   
 WNTs 
 1 2 2b 3 3a 4 5a 5b 6     7a 7b 8a 8b 9a 9b 10
a 
10
b 
11 16 
FZD1 x x  o x  x o  o x         
FZD2  o  o o  x  o o o  o       
FZD3  x x  o  o    x         
FZD4                    
FZD5  o   x  x   x     o  o   
FZD6     x x x o  o        o  
FZD7    x x  o   o          
FZD8               o     
FZD9  x                  
FZD10           x         
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 1.5.1 Frizzled receptors in cancer 
 
Several studies have shown that FZD receptors could promote tumorigenesis 
by controlling proliferation or cancer invasion. For example, FZD1 and 2 were 
found overexpressed in breast cancer compared to normal tissue (Milovanovic 
et al., 2004). Moreover, FZD1 was shown to enhance drug resistance in breast 
cancer and neuroblastoma through the activation of a β-catenin dependent 
signal (Zhang et al., 2012; Flahaut et al., 2009). 
FZD3 is overexpressed in chronic lymphocytic leukaemia and associated with 
increased transendothelial migration, and poorer prognosis in patients (Kaucka 
et al., 2013; Lu et al., 2004). 
FZD4 was reported to be a mediator of EMT in prostate cancer with TMPRSS2-
ERG fusions (Gupta et al., 2010). Moreover a siRNA targeting FZD4 was shown 
to reduce the motility and migration of bladder cancer cells (Ueno et al., 2012). 
Ueno et al. reported that the overexpression of FZD7 in colon cancer cells leads 
to increased activation of the WNT canonical pathway and augmented invasion 
and proliferation of tumour cells (Ueno et al., 2009; Ueno et al., 2008). FZD7 
overexpression and β-catenin stabilization were also suggested as the initiating 
events in hepatocellular carcinomas in mice models (Merle et al., 2005). FZD7 
was found overexpressed in TNBC compared to non TNBC tumours, and 
downregulation of FZD7 in TNBC cell lines resulted in a reduction of cell 
proliferation and invasion in vitro and in vivo (Yang et al., 2011).  
Wang et al. reported that FZD8 is overexpressed in lung cancer compared to 
matched normal tissue. Knock down of FZD8 resulted in reduced proliferation 
and colony number formation of lung cancer cell lines in vitro, and reduced 
tumour growth in mice xenografts (Wang et al., 2012). 
FZD9 was shown to have tumour suppressor activity in non-small cells lung 
cancer by activating JNK and supressing the anchorage-independent growth 
and proliferation of lung cancer cells (Winn et al., 2005). 
FZD10 mRNA was found upregulated in colorectal cancer compared to normal 
matched tissue by Terasaki et al, although the number of colon cancer cases 
analysed were only two (Terasaki et al., 2002). FZD10 was also found 
overexpressed in synovial sarcomas, and the use of a monoclonal antibody 
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against FZD10 was effective in reducing cancer cells growth in vivo and in vitro 
(Fukukawa et al., 2009). 
 
1.6 Frizzled receptor 6  
 
FZD6 receptor 6 (Fzd6) is the product of the FZD6 gene, located in 
chromosome 8 (8q22.3-q23.1). Fzd6 is a single peptide sequence of 706 
aminoacids and like other FZDs, contains an extracellular CRD and seven 
transmembrane domains. However, in contrast to other FZDs, it does not 
contain a C-terminal PDZ domain-binding motif (McEntyre et al., 2012; 
Tokuhara et al., 1998). 
Golan et al. reported that FZD6 does not transduce a canonical signal, but acts 
as a repressor of the FZD1-dependent activation of β-catenin in HEK293 cells. 
This is mediated by the activation of TAK1/NLK kinases (Golan et al., 2004).  
These findings are in agreement with Sato et al., who showed that FZD6 does 
not mediate the activation of β-catenin (Sato et al., 2010). The same group also 
reported that the CRD of FZD6 does not bind to WNT5a and WNT3a (Sato et 
al., 2010). However, Fröjmark et al. reported that the stabilization of β-catenin, 
induced by WNT3a in primary fibroblasts was abolished in fibroblasts of patients 
affected by nail Dysplasia bearing FZD6 mutations (Fröjmark et al., 2011).  
Moreover, a Fzd6 dependent stabilization of β-catenin after activation with 
WNT3a was observed in human mesenchymal stem cells (Kolben et al., 2012). 
Consistent with a non-canonical role for Fzd6, Lyons et al showed that Fzd6 
strongly binds WNT4 and does not transduce a β-catenin canonical pathway in 
kidney epithelial cells (Lyons et al., 2004). Heinonen et al. suggested that 
WNT4 activates the PCP pathway through Fzd6 in murine hematopoietic 
precursor cells (Heinonen et al., 2011). A recent study of Kilander et al., based 
on fluorescence recovery after photobleaching (FRAP), showed that 
WNT3A,WNT4, WNT-1, WNT5A, WNT9B, WNT10B and WNT16B all cause, to 
a different extent, the membrane shift of Fzd6 conjugated with GFP, suggesting 
a possible interaction of these WNTs with Fzd6 and a broad receptor/ligand 
promiscuity (Kilander, Dahlström and Schulte, 2014).  
A role of FZD6 in PCP is further suggested by the phenotype observed in FZD6 
-/- mice and patients affected by neural tube defects bearing germ line 
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mutations of FZD6 (De Marco et al., 2012; Wang, Guo and Nathans, 2006; 
Guo, Hawkins and Nathans, 2004). FZD6 -/- and FZD3 -/- double mutants (but 
non mice with single knock down) present defects in neural tube closure and in 
the orientation of a subset of auditory and vestibular cells (Wang, Guo and 
Nathans, 2006). This suggests a certain level of redundancy between FZD6 and 
FZD3. FZD6 is also important for the hair patterning in mammals; FZD6 null 
mice are healthy and viable, but show a phenotype with disorganized 
orientation of the hair follicles (Wang, Chang and Nathans, 2010; Guo, Hawkins 
and Nathans, 2004). A role in platelet number regulation has been reported in 
FZD6 double knock down mice, where the number of platelets was increased in 
comparison to control mice (Steele et al., 2009). 
In humans, mutations of FZD6 have been associated with neural tube defects 
and a congenital nails disorder called Autosomal-Recessive Nail Dysplasia (De 
Marco et al., 2012; Fröjmark et al., 2011; Naz et al., 2011). 
 
1.6.1 Frizzled receptor 6 in cancer 
 
Frizzled 6 is overexpressed in breast cancer, hepatocarcinoma, colon cancer, 
prostate cancer, leukaemia and squamous cell carcinoma (Ma et al., 2009; Wu, 
Zierold and Ranheim, 2009; Bengochea et al., 2008; Finak et al., 2008; Smid et 
al., 2008; Vincan and Barker, 2008; Haider et al., 2006; Saramäki et al., 2006). 
However, few studies have investigated the role of FZD6 in tumorigenesis. Wu 
et al. reported that ablation of FZD6 in chronic lymphocytic leukaemia B cells 
results in a delay in tumour progression and reduction of active β-catenin in 
mice (Wu, Zierold and Ranheim, 2009). Our group reported that FZD6 
expression is associated with drug resistance and increased invasiveness in 
neuroblastoma, marking a cancer stem cell subpopulation (Cantilena et al., 
2011). Finally, a FZD6 polymorphism was associated with a greater risk of 
papillary thyroid cancer (Neta et al., 2011). 
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1.7 Aims  
 
On the basis of previous studies that suggested that FZD6 is implicated in 
tumorigenesis, we aimed to elucidate its role breast cancer. We wanted to 
determine whether FZD6 was overexpressed in breast cancer cells compared 
to normal breast tissue and if its expression is correlated with clinical features in 
patients. Next, using a loss of function approach, we wanted to assess the 
potential role of FZD6 in the proliferation and invasion of breast cancer cells and 
the signalling pathway downstream of the Fzd6 receptor.  
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CHAPTER II 
 
Materials and methods 
 
2.1 Reagents 
 
All reagents, if not otherwise stated, were purchased from Fisher Scientific UK.  
 
2.2 Oncomine data mining  
 
In silico expression studies were made using the online software Oncomine 
(https://www.oncomine.org, powered by Life Technologies). Only datasets 
containing normal tissue compared to tumour tissue were considered for the 
analysis (fig. 2.1).  
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Figure 2.1: Search criteria in the Oncomine platform . 
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2.3 Kaplan Meier plotter survival studies 
 
 
Figure 2.2: Search criteria in the Kaplan Meier plotter platform . 
 
FZD6-associated survival studies were obtained using the online tool Kaplan 
Meier plotter (http://kmplot.com/analysis/) (Györffy et al., 2010). The software 
uses microarrays expression data and the matched clinical information of breast 
cancer patients to generate survival curves. The expression data is provided by 
databases such as GEO (Gene Expression Omnibus), EGA (European 
Genome-Phenom Archive), and TCGA (The Cancer Genome Atlas).  
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Kaplan Meier curves correlate the survival of a cohort of patients for a certain 
amount of time with parameters such as the expression level of a certain gene 
or a given therapy. In this study three parameters were analysed in correlation 
with FZD6 expression: 
- The overall survival of patients, expressed as the probability of survival 
from the time of diagnosis. 
- The relapse free survival, intended as the probability of survival without 
symptoms after primary treatment. 
- Distant relapse free survival, expressed as the probability of survival 
without the onset of metastasis after primary treatment.  
Curves were generated selecting the best cut-off, i.e. all the percentiles 
between the lower and the upper quartiles were computed, and the best 
performing threshold was used as a cut off (figure 2.2). 
Patients were then stratified in three different breast cancer subgroups: Luminal 
A, Luminal B and Basal, and further stratified in lymph node positive and lymph 
node negative using the appropriate drop-down lists (figure 2.2). All the other 
settings were maintained as default. The affimetrix probe 203987_at was used 
for FZD6. 
 
2.4 COSMIC analysis 
 
The Catalogue of somatic mutations in cancer (COSMIC) is a collection of 
published databases containing gene expression data and the record of somatic 
mutations of a large amount of tumours specimens. The repository is available 
through the web page 
http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/ and is managed by 
The Sanger Institute in Cambridge. 
The cancer browser was used to filter results of breast cancer samples 
containing expression data for FZD receptors. Copy number variation and gene 
expression were computed and displayed as in figure 2.3. 
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Figure 2.3: Analysis of the copy number var iation and expression of FZD6 in 
breast cancer samples using the online platform COSMIC. 
2.5 Cell lines 
 
All the cell lines used in this study, except for the cell lines HMEC-184D, HMEC-
184D-HT, HEK 293FT and L-cells were validated and certified by the accredited 
company DDC medical. 
BT474: Derived from a luminal-like metastatic ductal breast carcinoma, isolated 
for the first time by Lasfargues and colleagues from the primary tumour 
(Lasfargues, Coutinho and Redfield, 1978). This cell line is positive for ER, PG 
and HER2 (Neve et al., 2006). The cell line was a kind gift of Professor Robert 
Newbold, Brunel University. 
MDA-MB-231:  This cell line was isolated in 1976 from the metastatic pleural 
effusion of a breast adenocarcinoma (Cailleau et al., 1976). It does not express 
the receptors for oestrogen and progesterone, and it is negative for HER2, 
thereby it is classified as triple negative cell line. This cell line is also basal-like. 
The cell line was a kind gift from Dr Pier Francesco Marra, King’s College 
London. 
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MDA-MB-436: This cell line is derived from the pleural effusion of a triple 
negative ductal metastatic breast carcinoma (Neve et al., 2006). It was isolated 
for the first time by Cailleau and colleagues in 1978 (Cailleau, Olivé and 
Cruciger, 1978). The cell line was a kind gift from Dr Pier Francesco Marra, 
King’s College London. 
HCC1143: Derived from an invasive ductal breast carcinoma, this cell line is a 
basal like, triple negative cell line that was isolated by Gazdar and colleagues in 
1994 (Neve et al., 2006; Gazdar et al., 1998). The cell line was a kind gift from 
Dr Pier Francesco Marra, King’s College London. 
MCF7: This cell line derives from the pleural effusion of a metastatic ductal 
breast carcinoma. It presents luminal characteristics and expresses ER and PR, 
but it is negative for HER2. It was isolated for the first time in the 1973 by Soule 
and colleagues (Soule et al., 1973). The cell line was a kind gift of Professor 
Robert Newbold, Brunel University. 
SKBR3: This cell line was isolated from the pleural effusions originated from a 
breast adenocarcinoma in 1970 (ATCC website, http://www.lgcstandards-
atcc.org/Products/All/HTB-30.aspx#history). The cell line is hormone receptors 
negative, but expresses HER2. SKBR3 cell line was a kind gift of Dr Gianluca 
Sala, G.D’Annunzio University, Italy. 
BT20:  This breast tumour line was established by E.Y. Lasfargues and L. 
Ozzello in 1958. It derives from the primary mass of an invasive ductal 
carcinoma and it is a basal triple negative cell line (Neve et al., 2006; 
Lasfargues and Ozzello, 1958). The cell line was a kind gift of Professor Robert 
Newbold, Brunel University. 
T47D: This breast cancer cell line was isolated by I. Keydar from a pleural 
effusion obtained from a female patient with an infiltrating ductal carcinoma of 
the breast. This cell line is luminal-like and positive for PR and ER (Neve et al., 
2006; Keydar et al., 1979). The cell line was a kind gift of Dr Gianluca Sala, 
G.D’Annunzio University. 
HMEC-184D: The 184D strain of human mammary epithelial cells was originally 
isolated by Professor Martha Stampfer and was obtained via reduction 
mammoplasty of a 21 years old disease-free individual. The primary HMEC-
184D cell line has a finite lifespan of 20-40PD when grown in a stress-free 
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medium formulation of M87A supplemented with 0.5 ng/mL cholera toxic and 
0.1nM oxytocin (Garbe et al., 2009). The cell line was kindly provided by Dr 
Hemad Yasaei and Professor Robert Newbold, Brunel University. 
HMECT-184D-HT: This cell line was a kind a gift from Dr Hemad Yasaei and 
Professor Robert Newbold, and derives from a small population of pre-stasis 
HMEC-184D transfected with the pCi neo-hTERT plasmid using Neon 
electroporation system. Subsequently, the cells were put in selection for 2-3 
weeks in the presence of G418 Geneticin at a concentration of 150µg/mL. A 
small population of cells originating from a single transfected clone emerged 
and was named HMEC-184D-HT. When assayed for post-splice hTERT gene 
expression, it was shown to be 4-5 fold overexpressed compared to an empty 
vector counterpart. These cells proliferated for an extra 100 passages and are 
now deemed immortal. 
HEK 293 FT: These cells are human embryonic kidney cells transformed with 
the SV40 large T antigen under the control of the human cytomegalovirus 
promoter. The SV40 antigen derives from the polyomavirus SV40 and it is 
capable to transform a vast number of cells through the perturbation of the 
Retinoblastoma and p53 proteins. The SV40 large T antigen also promotes the 
episomal replication of transfected plasmids containing the SV40 origin of 
replication (Fanning, 1992). In this study HEK 293 FT cells were used for the 
expression of viral packaging vectors and virus production. HEK 293 FT cells 
were purchased from Life Technologies. 
Control, WNT3a and WNT5a L cells: These cells are mouse fibroblasts that 
have been stably transfected with empty vector or vectors expressing human 
WNT3a, or WNT5a (Willert et al., 2003). Conditioned media produced by these 
cells can be therefore used in signalling experiments involving WNT3a and 
WNT5a. L-cells were a kind gift from Professor J.P. Medema. 
 
2.6 Cell culture 
 
MDA-MB-231, HCC1143, MDA-MD-436 cell lines were grown in RPMI medium 
(Gibco) supplemented with 1mM in sodium pyruvate (Gibco) and 10% foetal 
bovine serum (FBS) (Gibco). HEK 293 FT, MCF7, SKBR3, T47D and L cells 
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were grown in DMEM (Gibco) supplemented with 10% FBS. BT20 and BT474 
were grown in a mixture of 50% DMEM and 50% F12 (Gibco), supplemented 
with 10% FBS. HMEC-184D and HMEC-184D-HT cells were grown in M87A 
medium (Lonza) supplemented with 0.25%FBS, 0.5 ng/ml cholera toxic (Sigma) 
and 0.1nM oxytocin (Bachem). WNT3a L-cells were maintained in constant 
selection with 125 μg/mL of Zeocin (Life Technologies) and WNT5a L-cells with 
400μg/mL G418 (Life Technologies).  All the cell lines were maintained in an 
incubator (Sanyo) at 37°C in a humidified atmosphere with 5% CO2 and 
regularly sub-cultured, using phosphate saline buffer (PBS) (Sigma) for 
washings and trypsin-EDTA (Sigma) to harvest cells. Cells were grown in 
flasks, dishes or multi-well plates (Nunc). Cells manipulations were carried out 
with graduated serological pipettes (Fisher Brand) in a class II sterile cabinet 
(Gelman Sciences). All the cells centrifugations were carried out in a Thermo 
Scientific Haraeus Biofuge Primo at 1200 rpm unless otherwise specified.  
Cell number was estimated pipetting 10 μL in an improved Neubauer 
haemocytometer (Marienfeld) with a depth of 0.1 mm and by averaging the 
number of cells in 4 areas of 1 mm each.    
For long term storage, cells were resuspended in 10% DMSO (Fisher), 40% 
FBS and 50% complete medium, and kept in 2 mL cryovials (Nalgene). To 
ensure a gradual freezing and to avoid the formation of intracellular ice crystals, 
the cryovials were kept overnight in a container containing isopropanol at – 80 
°C and were then stored in liquid nitrogen. To recover cells from liquid nitrogen 
the vials were rapidly immersed in a water bath at 37°C until the cell suspension 
was thawed. Next, cells were resuspended in 20 mL of pre-warmed medium 
and pelleted at 1200 rpm for 5 minutes. The supernatant was discarded and the 
cells were resuspended in fresh medium and plated in flasks or dishes. 
 
2.6.1 Preparation of WNT conditioned media 
 
Supernatants from confluent 10 cm dishes containing mouse fibroblasts L cells 
expressing control plasmid, WNT3a, or WNT5a plasmids, were harvested and 
stored at + 4 °C. For signalling experiments, the conditioned media were used 
diluted 1:10. 
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2.7 Protein extracts preparation 
 
Cells were counted and seeded in equal number for each experimental 
condition. When cells had to be exposed to an exogenous activator, a 24 hours 
starvation was performed beforehand. Cells were then washed with cold PBS 
and lysed by adding ice cold RIPA (Radio Immuno Precipitation Assay buffer, 
150 mM sodium chloride (Fisher), 1.0% Igepal (Sigma),  0.5% sodium 
deoxycholate (Sigma), 0.1% SDS (Fisher), 50 mM Tris pH 8.0 (Fisher), 1nM 
sodium orthovanadate (New England Biolab), HALT protease inhibitor cocktail 
(Thermoscientific ). Cells were scraped with a cell scraper, collected in 
Eppendorf tubes and kept on ice for 30 minutes. Every 5 minutes the lysates 
were vortexed. To separate the cell debris from soluble extracts, the lysates 
were centrifuged at 15.000 rpm at 4C̊ for 15 minutes in a Thermos Scientific 
Haraeus Fresco 21 table-top centrifuge. Next, supernatants were collected in 
fresh tubes and stored at – 80 ° C, or used for proteins analysis. 
For the signalling experiment showed in figure 6.7, cell lysis was performed by 
adding 100μL of 2X Laemli buffer (8% SDS, 20% 2-mercaptoehtanol (Sigma), 
40% glycerol (Fisher), 0.008% bromophenol blue (Fisher), 0.25 M Tris-HCl pH 
6.8)(Laemmli, 1970) and scraping cells with a cell scraper on ice. Cell lysate 
were briefly sonicated and boiled at 100 °C for 5 minutes, then stored at - 20°C 
or used for acrylamide gel electrophoresis. 
 
2.8 Estimation of total proteins concentration with the 
Bradford method 
 
To estimate the concentration of total proteins in RIPA lysates, a microliter of 
the protein extract was resuspended with 200 μL of Bradford reagent (SIGMA). 
In parallel, 1 μL of different BSA standards (0, 2, 5, 6, 8 and 9 μg/μL) was 
resuspended in Bradford reagent with the same ratio to generate a standard 
curve. The samples were assayed after 5 minutes in a plate spectrophotometer 
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(Biorad) at the wavelength of 595 nm. The incognito concentration of the protein 
samples was extrapolated from the standard curve. 
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2.9 Western blot analysis 
 
The lysates were mixed with 4x Laemmli Buffer and water to obtain a 4 fold 
dilution of the laemmli buffer. The samples were then vortexed and boiled at 
100 ̊C for 5 minutes in a heat block, then stored at -20 ̊C or used for SDS-PAGE 
(Sodium Dodecyl Sulphate – Poly Acrylamide Gel Electrophoresis). 
Polyacrylamide gels were made using gel casting cassettes from Biorad. The 
resolving gels were made according to the Table 2.1, varying the acrylamide 
percentage depending on the size of the proteins to be resolved. Stacking gels 
were casted according to the table 2.2 to obtain a concentration of acrylamide 
of 4% v/v.  
 
Table 2.1: SDS-PAGE resolving gel composition for 10 mL 
 
Table 2.2: SDS-PAGE stacking gel composition for 10 mL 
 
Solution Volume 
Water 6 mL 
0.5 M Tris-HCl pH 6.8, 0.4 % SDS 2.5 mL 
30% acrylamide/0.8% 
bisacrylamide 
1.3 mL 
10 % APS  0.1 mL 
TEMED  0.02 mL 
 
 Acrylamide final concentration % v/v  
Solution 8% 9% 10% 12% 
Water 7.25 mL 6.75 mL 6.25 mL 5.25 mL 
1,5 M Tris-HCl 
pH 8.8, 0,4% 
SDS 
3.75 mL 3.75 mL 3.75 mL 3.75 mL 
30% 
acrylamide/0.8% 
bisacrylamide 
(National 
Diagnostic) 
4 mL 4.5 mL 5 mL 6 mL 
10 % APS 
(Sigma) 
0.1 mL 0.1 mL 0.1 mL 0.1 mL 
TEMED (Fisher) 0.02 mL 0.02 mL 0.02 mL 0.02 mL 
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Protein samples were loaded in equal amount into polyacrylamide gels and 
electrophoresed using a Biorad electrophoresis apparatus. A constant voltage 
of 100 V was kept until the protein bands were well resolved. To estimate the 
proteins molecular weight the samples were run in parallel with a protein ladder 
(Thermoscientific). The electrophoresis buffer composition was the following: 25 
mM Tris base, 192mM glycine (Fisher), SDS 0.1% in distilled water (Green and 
Sambrook, 2012). Proteins were then transferred into nitrocellulose membranes 
(Amersham) using a Biorad apparatus and a transfer buffer with the following 
composition: 24 mM Tris base, 192 mM glycine, 20% SDS and 0.0375 % SDS 
in distilled water (Green and Sambrook, 2012). The transfer was performed on 
ice, applying a constant current of 350 mA. The membranes were then blocked 
in 5% non-fat dry milk (Marvel) dissolved in TBS-tween (TBS-t, 50 mM TRIS-
HCl, pH 7.5, 150 mM NaCl, 0.1 % Tween 20 (Fisher).  
The primary antibodies used and the corresponding experimental conditions are 
summarized in table 2.3. All the primary antibodies were incubated overnight, 
except for anti β-Actin, which was incubated for 1 hour at room temperature. To 
remove the excess of primary antibody and reduce the unspecific binding, the 
membranes were washed thrice with TBS-t for 10 minutes. The membranes 
were then incubated for 45 minutes with the appropriate secondary HRP-
conjugated antibody. The secondary antibodies used in this study are listed in 
table 2.4. Membranes were then washed in TBS-t thrice for ten minutes and 
incubated for one minute in ECL (Enhanced chemiluminescence substrate, 
Pierce). The membranes were then placed in an autoradiography cassette and 
overlapped with light sensitive films (GE Healthcare) in the dark. The films were 
developed with a Kodak automatic developer.  
If the nitrocellulose membrane had to be re-probed with a different primary 
antibody, the following stripping protocol was performed: membranes were 
incubated for 20 minutes in stripping buffer (0,6 M Tris-HCl pH 6.8,  0.7 % β-
mercapto-ethanol and 2 %SDS in water) pre-warmed at 50 ° C, then washed 5 
times for 4 minutes each with TBS-t and re-blocked in TBS-t 5 % milk. 
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Table 2.3: List of primary antibodies used in western blot analysis 
 
Antibody Company Origin Buffer  Dilution  
FZD6 (D16E5) Cell Signaling  Rabbit PBS-t 1:1000 
Β-Actin (I-19)  Santa Cruz Goat TBS-t 5% 
milk 
1:1000 
Phospho-
SAPK/JNK 
(Thr183/Tyr185) 
Cell Signaling Rabbit TBS-t 5% 
BSA 
1:1000 
Active  
β-Catenin (8E7) 
Millipore Mouse TBS 5% milk 1:1000 
Phospho-AKT 
(Ser473) 
Cell 
Signalling 
Rabbit PBS-t 1:1000 
AKT Cell Signaling  Rabbit PBS-t 1:1000 
Phospho- 
p44/42 MAPK 
(Erk1/2) 
Thr202/Tyr204 
Cell Signaling  Rabbit PBS-t 1:1000 
p44/42 MAPK 
(Erk1/2) 
Cell Signaling Rabbit PBS-t 1:2000 
Phospho-
PLCγ1 (Tyr783) 
Cell Signaling Rabbit PBS-t 1:1000 
PLCγ1 Cell Signaling Rabbit PBS-t 1:1000 
E-Cadherin Santa Cruz Mouse TBS-t 5% 
milk 
1:500 
Vimentin Sigma Aldrich Mouse TBS-t 5% 
milk 
1:1000 
 
Table 2.4: List of HRP secondary antibodies used in western blot analysis  
 
Antibody Company Origin Buffer Dilution 
Anti-rabbit 
HRP 
GE-
healthcare 
Goat TBS-t 5% 
milk. 
1:10000 
Anti- Mouse 
HRP 
GE-
healthcare 
Sheep TBS-t 5% 
milk. 
1:10000 
Anti-Goat 
HRP 
Santa Cruz Donkey TBS-t 5% 
milk. 
1:10000 
 
2.10 RNA extraction and purification 
 
To extract the total RNA, cells were harvested and resuspended in complete 
medium, then pelleted and washed with PBS. The cell pellet was thoroughly 
resuspended in 1 mL of Trifast reagent (Peqlab) in 1.5 mL Eppendorf tubes and 
kept at room temperature for 5 minutes. Samples were then shaken vigorously 
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after the addition of 0.2 mL of chloroform (Fisher). Next, Samples were 
centrifuged at 12000 g for 5 minutes to allow a neat separation between the 
aqueous phase and the phenol phase. The aqueous phase containing the RNA 
was transferred in a fresh tube. The RNA was precipitated by adding 0.5 mL of 
isopropanol (Fisher) and the sample were vortexed. Following an incubation of 
ten minutes on ice, the samples were centrifuged at 12000 g for 10 minutes at 4 
°C and the isopropanol was discarded. Next, the RNA pellet was washed twice 
with 75 % ethanol, let to air-dry and resuspended in water. 
 
2.11 RNA retrotranscription and cDNA synthesis 
  
Purified RNA was assayed with a Nanodrop spectrophotometer 
(Thermoscientific) to estimate the RNA concentration. To remove the 
contaminant DNA remaining from the previous purification steps, 1 μg of 
purified RNA was treated with DNAase I (Invitrogen) following the manufacturer 
instructions. The RNA was then retrotranscribed using the High Capacity RNA-
cDNA Reverse Transcription Kit (Invitrogen). The retrotranscription reaction was 
carried out in a thermal cycler by incubating the samples for 1 hour at 37 °C and 
stopped by heating at 95 °C for 5 minutes. The c-DNA obtained was used for Q-
RT-PCR (quantitative real time PCR) or stored for further use at – 20 °C. 
 
2.12 Quantitative Real Time PCR (Q-RT-PCR) 
 
The c-DNA deriving from the retrotranscription reaction was diluted 1:50 in 
RNAse/DNAse free water, and 5 μL of this solution were used for real time 
PCR. TAQman mastermix, FAM-conjugated probes (Applied Biosystems), and 
a 7900HT Fast Real-Time PCR System (Applied Biosystems) were used 
following the manufacturer instructions. Each sample was run in triplicate in a 
96 well microtiter plate. The Q-RT-PCR was carried out by pre-incubating the 
samples for 2 minutes at 50 °C and at 95 °C for ten minutes. The samples were 
then subjected to 40 cycles of amplification, constituted of a first step of 
incubation at 95 °C for 15 seconds, followed by a second step of incubation at 
60 °C for one minute.   GAPDH was used as housekeeping reference gene. 
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The probes used in this study were FZD6 (Hs00171574_m1) and GAPDH 
(Hs99999905_m1). The expression data were analysed using the software SDS 
2.3 from Applied Biosystems. Relative quantities were calculated using the 
comparative Ct method (ΔΔCt). 
 
2.13 FZD6 indirect immunostaining and flow cytometry  
 
Cells were harvested with trypsin EDTA, resuspended in complete medium and 
washed in PBS. The cell pellet was then resuspended in 100 μL of blocking 
solution (BSA 2% (Sigma) in PBS) and incubated on ice for 30 minutes. Cells 
were then pelleted and resuspended in 100μL of blocking solution containing 20 
ng/μL of goat anti-FZD6 antibody (R&D systems). Following an incubation of 30 
minutes on ice, cells were washed with 3 mL of blocking buffer and 
resuspended in 100μL of either fluorescein-conjugate donkey anti-goat 
secondary antibody (20ng/μL R&D systems) or anti-goat APC-conjugated 
antibody (20ng/μL, R&D) for 30 minutes on ice and in the dark. Cells were then 
washed with 3 mL of PBS, pelleted and resuspended in 100μL of blocking 
buffer. Samples were then analysed either with the Imagestream imaging 
cytometer or a standard flow cytometer. Mock stainings without the primary 
antibody were carried out in parallel to assess the unspecific binding of the 
secondary antibodies and used as a blank for flow cytometry. All the 
centrifugations were performed at 1200 rpm at 4 °C. 
The samples were then assayed with a BD Facscalibur, an EPICS XL flow 
cytometer (Beckman Coulter), or an Imagestream X (Amnis). Cells 
resuspended in secondary antibody only, but not primary antibody, were used 
to set a gate for FZD6 negative cells. Test samples were run afterwards, and 
only the cells with fluorescence intensity above this gate were considered FZD6 
positive.  The Imagestream combines the functions of a flow cytometer with the 
ones of a fluorescence microscope. Cells running in a liquid flow are 
photographed, allowing the localization of the protein of interest (fig.3.9).   
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2.14 siRNA transfections 
 
Cells were harvested and counted with a haemocytometer. 170000 cells/well 
were plated in a 6 well plate the day before transfection in 2 mL of complete 
medium. Transfections were carried out using 5 µL of Lipofectamine 2000 
(Invitrogen) and 10 µL of a 10µM siRNA solution in water, following the 
transfection reagent manufacturer instructions. The medium was changed 24 
hours after the transfection and cells were used for biological assays 48h after 
transfection. A pool of 4 different siRNA targeting FZD6 and a negative control 
siRNA were purchased from Qiagen. The pool was assessed firstly by real time 
PCR, and the two best performing siRNAs were used for the biological assays.  
The siRNAs target sequences used in this study were: (siRNA1 FZD6) 
CAGGGAGGTGGTTGTCATTCA; (siRNA2 FZD6) 
AAGAGAGATCCAATCAGTGAA. 
 
2.15 Preparation of competent TOP10 F’ Escherichia 
Coli (E.Coli) 
 
TOP10F´ Chemically Competent E. coli were purchased from Life Technology. 
Bacteria were inoculated from the glycerol stock in 3mL of LB medium (Luria 
Broth, 1% NaCl, 1% tryptone (Fisher), 0.5 % yeast extract (Fisher) and 
incubated at 37 °C for two hours, at constant agitation. The culture was then 
centrifuged at 3000 rpm for 3 minutes and the supernatant was discarded. The 
bacteria pellet was resuspended in 100 μL of LB which were streaked in LB-
agar plates (1.5 % Agar in LB). Following a 37 °C overnight incubation, one 
single colony was picked from the plate and inoculated in 50mL of LB medium. 
The culture was incubated overnight at 37 °C at constant agitation. 10 mL of the 
overnight culture were transferred into 200 mL of pre-warmed LB medium. This 
culture was incubated at 37 °C, at constant agitation, until the 600 nm optical 
density was between 0.4 and 0.6. The culture was then pelleted at 5000 rpm at 
4 °C and the supernatant was discarded. The pellet was resuspended in 80mL 
of ice cold 0.1M MgCl2 (Sigma) and incubated for 30 minute on ice. Bacteria 
were centrifuged at 5000g for 5 minutes at 4 °C, and the supernatant was 
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discarded. Next, the bacteria pellet was resuspended in 80 mL of ice cold CaCl2 
(Sigma) and incubated for 30 minutes on ice. Following another centrifugation, 
the supernatant was discarded and the pelleted was resuspended in a mixture 
of 8 mL ice cold 0.1 M CaCl2 with 2.2 mL of glycerol (Fisher). Bacterial stocks 
were aliquoted in pre chilled 1.5 mL Eppendorf tubes and stored at -80 °C. 
 
2.16 Lentiviral shRNA plasmids 
 
The pGIPZ-shRNA lentiviral vector allows the stable expression of a human 
microRNA-30 which was modified to yield an efficient target silencing of the 
gene of interest (Silva et al., 2005). This vector also contains a green 
fluorescent protein (GFP) expression cassette which allows the identification of 
cells transducing the viral construct. The map of the pGIPZ plasmid is shown in 
figure 2.4. This vector allows ampicillin selection in bacteria and puromycin 
selection in mammalian cells.  
Bacterial cultures expressing three different pGIPZ-shRNA constructs used for 
FZD6 silencing were purchased from Life Technology. The antisense shRNA 
sequences were (Sh1 FZD6: ATCTGAATGACAACCACCT; Sh2 FZD6: 
TTAACTTTAGAATTGTGCT; Sh3 FZD6: TAACCTGCACATTTTCTGT). The 
negative control unspecific sequence (Scrambled) was 
ATCTCGCTTGGGCGAGAGTAAG. 
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Figure 2.4: The pGIPZ-shRNA lentiviral vector map. (Extracted from the product 
manual available online at 
http://dharmacon.gelifesciences.com/uploadedFiles/Resources/GIPZ%20Lentiviral%20shRNA%
20Technical%20Manual.pdf). 
 
2.17 Expansion of bacterial cultures and plasmids 
purification 
 
Bacteria expressing pGIPZ-shRNA constructs were inoculated from the glycerol 
stocks into 3mL of selective LB medium (100 μg/mL ampicillin in LB) and 
incubated at 37 °C for two hours, at constant agitation. The bacteria were then 
pelleted and resuspended in 100 μL of selective LB medium which were 
streaked onto LB agar plates containing 100 μg/mL of ampicillin. The plates 
were incubated at 37 °C overnight and a single colony was picked and 
82 
 
inoculated in 5 ml of LB selective medium. The culture was incubated overnight 
with vigorous shaking. 3 mL of this culture were then inoculated into 500 mL of 
selective LB medium and incubated at 37 °C overnight with constant agitation. 
Plasmid DNA was purified using a Genopure Plasmid Maxi Kit (Roche) 
according to the manufacturer instructions. 
 
2.18 Transformation of competent TOP 10 F’ 
Escherichia Coli with plasmid DNA 
 
Plasmid propagation was carried out transforming TOP 10 F’ competent E. Coli. 
Approximately 200ng of plasmid DNA were added to a 100μL suspension of 
competent bacteria which were then left on ice for 20 minutes. Next, bacteria 
were heat shocked at 42 ° C for 45 seconds, placed on ice for two minutes and 
resuspended in LB broth. 100 μL of bacterial suspension were then streaked 
into selective agar plates containing ampicillin. The plates were then incubated 
overnight at 37 °C, and a single colony was inoculated in selective LB broth. 
Bacterial colonies were expanded and plasmid purified as described in the 
paragraph 2.18.  
 
2.19 Virus production in HEK 293 FT cells 
 
3x106 HEK 293 FT cells were plated in 10 cm dishes in 7 mL of complete 
medium. 24 hours later, cells were co-transfected with 3.75 μg of pPAX2 and 
1.75 μg of pMDG2 lentiviral packaging plasmids (a kind gift of Dr Owen 
Williams), and 5 μg of shRNA encoding vector, using lipofectamine 2000 and 
following the manufacturer instructions. The medium was replaced 24 hours 
after the transfection. Supernatants containing the viruses were harvested 48 
hours after the transfection and filtered through a 0.45-mm filter unit (Sartorius). 
The supernatants were immediately used to infect MDA-MB-231 cells. 
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2.20 Lentiviral transduction in MDA-MB-231 cells 
 
2.5 x 105 MDA-MB-231 cells were plated onto 6 well plates in 3 mL of complete 
medium. The following day media were replaced with 2.5 mL of supernatants 
containing the viral particles, in the presence of 8 μg/mL polybrene (Sigma). 
Media were replenished 24 hours after infection. 48 hours following the 
infection, cells were observed with a UV light microscope (NanoEntek) to 
assess the expression of GFP indicating a successful viral transduction (fig. 
2.5). Next, culture media were replaced with complete media containing 1 
μg/mL puromycin to select infected cells. 4 days after the infection, the 
puromycin concentration was increased to 2 μg/mL and kept at this 
concentration for the expansion and growth of cells. After several passages, 
approximately 100% of the cells resulted GFP positive (fig.2.5). 
The FZD6 knock down efficiency in these cells was assessed by real time PCR, 
FACS and western blot analysis following one week of puromycin selection.  
 
Figure 2.5: Viral transduction efficiency in MDA-MB-231 cells. Cells were observed 
at to assess the expression of the viral GFP cassette as indication of the infection efficiency. 
The photographs shown are overlays Bright field/GFP and were taken 48 hours post infection 
and after several passages in culture.  
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2.21 Proliferation assays 
 
To assess the cell viability I used the MTS and XTT assays. MTS (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) is a compound which in the presence of phenazine methosulfate 
(PMS) and cellular reducing enzymes, produces a red formazan product that 
has an absorbance maximum at 490-500 nm and a colour intensity that is 
proportional to the number of living cells (figure 2.6).  
Similarly, The XTT (2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-
5-Carboxanilide) assay is based on the cleavage of the yellow tetrazolium salt 
XTT to form an orange formazan dye by the metabolic enzymes of living cells. 
Hence, these two formazan assays can be used to assess cell viability in vitro. 
Cells transfected with siRNA or stably expressing shRNAs were counted and 
plated in complete medium at a seeding density of 5000 cells/100 μL into 96 
well microtiter plates. 20 μL of CellTiter 96 AQueous One Solution (Promega) 
containing MTS and PMS were added to each well 24 hours or 48 hours later. 
Alternatively, 50μL of XTT reagent (1 μL of electron coupling reagent in 49 μL of 
XTT (Roche), were used. Cells were placed back in the incubator, and the 
absorbance at 490 nm was read 2 hours later using a plate spectrophotometer 
(Biorad). 
 
 
Figure 2.6: Schematic representation showing the principle of the formazan 
assays. 
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2.22 Cell cycle analysis 
 
Propidium Iodide (PI) is a fluorescent intercalating agent that binds 
stoichiometrically to nucleic acids with a ratio of 1 molecule for 4-5 base pairs. 
When bound to DNA, PI fluorescence increases 20 to 30 fold. This feature is 
exploited to estimate the amount of DNA in cells. In proliferating cells the 
amount of DNA changes depending on the phases of the cell cycle: Cells in G2 
phase have two fold the amount of DNA of cells in G0 and G1. The amount of 
DNA during The S phase is in between the amount found during the G0 and the 
G1 phases. Thus, PI is commonly used in flow cytometry to quantify the 
percentage of cells in different phases of the cell cycle (Krishan, 1975). With 
this method it is also possible to identify apoptotic cells by their lower 
florescence emission caused by the loss of DNA fragments during apoptosis 
(Nicoletti et al., 1991). Since PI also binds to RNA, a RNA digestion step must 
be carried out before cell cycle analysis.  
120000 cells were seeded in 6 cm dishes and grown for 72 hours to reach 
about 80% confluency.  Cells were then harvested together with the medium in 
order to retain floating apoptotic cells. The cell suspension was centrifuged at 
1500 rpm for 5 minutes and the supernatant was discarded. The pellet was then 
washed in PBS and resuspended in 200 μL of PBS. Cells were fixed by adding 
70 % ice cold ethanol in constant agitation and then were stored overnight at -
20 °C. Next, fixed cells were centrifuged at 1500 rpm for five minutes and the 
ethanol discarded. The cell pellet was washed twice with PBS, resuspended in 
100μL RNAse (0.1 μg/μL in PBS, Sigma) and incubated at room temperature 
for 5 minutes. Next, 2 μL of PI (50μg/mL in PBS) were added, and samples 
were incubated for 15 minutes at room temperature. Cells were analysed with 
an Imagestream X. All the cell cycle data was analysed using the software 
Ideas (Amnis). 
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2.23 Invasion assay 
 
 
Figure 2.7: Schematic representation of the invasion assay  
 
A rapid in vitro invasion assay to assess the metastatic potential of cancer cells 
was described for the first time in 1987 by Albini et al. (Albini et al., 1987). A 
schematic representation of this assay is shown in figure 2.7. The assay uses 
Boyden chambers consisting of an upper compartment where cells are seeded, 
and a lower compartment which is replenished with medium containing a 
chemoattractant (e.g. EGF or FBS). In the bottom of the upper compartment lies 
a porous membrane that maintains a chemical gradient across the two 
compartments. The upside of the porous membrane is covered with Matrigel, a 
gelatinous protein mixture derived from mouse tumour cells. This matrix is rich 
in laminin, collagen IV and heparan sulphate proteoglycans, therefore is often 
used as a model of basal membrane and stromal tissue in a variety of biological 
assays (Hughes, Postovit and Lajoie, 2010). Malignant cells must invade basal 
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membranes to migrate towards distal organs (Liotta, 1984). In the invasion 
assay the basal membrane is mimicked by a layer of Matrigel. Metastatic cells 
are able to digest the matrigel and to migrate towards the underside of the filter 
attracted by a chemotactic gradient, whereas the cells that did not migrate 
remain in the upper side of the filter. The latter are removed with a cotton bud, 
and the membrane is stained with crystal violet. In this way, the cells that 
invaded the matrigel can be visualised and counted. 
BioCoat Matrigel Invasion Chambers were purchased from BD biosciences. 
Chambers were rehydrated filling both compartments with 0.5 mL of serum free 
medium and placed in the incubator for 2 hours before each experiment.  
Cells were harvested with trypsin/EDTA, washed in PBS, and resuspended in 
serum free medium. The hydration medium was removed from the chambers, 
and 0.750 mL of serum free medium plus a chemoattractant (FBS or EGF) were 
added in the lower compartment, while 20000 cells/well were plated in 0.5 mL of 
medium in the upper compartment. The invasion chambers were then incubated 
at 37 °C in a humidified incubator for 22 hours. The upper compartment was 
then displaced, and the cells from the upside of the filter were removed with a 
cotton bud. Next, the filters were fixed with methanol for two minutes and 
incubated in a solution of crystal violet (0.1% w/v,10% methanol in water) for 20 
minutes. The excess of crystal violet was washed away by submerging the 
filters in distilled water three times. The filters were then let to air-dry and were 
removed from the chambers with a scalpel. Glass coverslips were used to 
mount the filters in glass slides with a drop of microscope oil. The filters were 
divided in 4 quadrants as shown in figure 2.8, and photographs of each 
quadrant were taken with an Axioskop 2 microscope (Zeiss) using a 5 X 
magnification. Cells in each quadrant were counted using the software ImageJ 
(NIH), and for each sample, an average of 3 filters (a total of 12 quadrants) was 
counted.  
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Figure 2.8: Representative photograph showing the porous filter of the 
invasion assay. The filters were fixed in methanol and incubated in a crystal violet solution. 
To facilitate the counting, the filters were divided with a fine tip marker in 4 quadrants, and 
pictures of each quadrant were taken. Cells were then counted using the multi-point tool in 
imageJ.  
 
2.24 Wound healing assay 
 
The wound healing assay is commonly used to study the directional migration of 
cells in vitro. When a confluent layer of adherent cells is scratched with a pipette 
tip, cells at the edge of the wound migrate towards the scratch, mimicking what 
happens during wound healing (Rodriguez, Wu and Guan, 2005). Cell migration 
is also a key step in the development of cancer metastasis, therefore, the 
wound healing assay can be used to assess migration rates of cancer cells in 
vitro.  
Control cells and FZD6 depleted cells were analysed in parallel using bipartite 
chamber for live imaging (Fisher). 3.8 x 105 Cells were seeded into each 
compartment of the bipartite chamber and let to grow for 24 hours in 2 mL of 
complete medium. The medium was then replaced with 2 mL of Leibovitz's L-15 
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medium (Gibco), and the cells were placed back in the incubator for 4 hours. 
Cells were then wounded with a sterile pipette tip and placed in a live imaging 
microscope (Nikon Eclipse Ti). 4 different areas of each wound were 
photographed every 20 minutes for 24 hours.  Cells trajectories were then 
tracked and their length measured over a period of 4 hours with the image 
analysis software NIS-Elements (Nikon). The speed of a minimum of 10 cells 
was scored in 4 areas of each wound analysed.  
 
2.25 Threedimensional cultures data analysis 
 
 
Figure 2.9: Representative photographs describing the assessment of the 
geometrical features of breast cancer acini growing in 3D cultures : The software 
ImageJ was used to draw a perimeter (indicated by a yellow line) around the image of the acini. 
The software computes the geometrical parameters of the shape delineated by this perimeter. 
(A) Representative photograph of a typical irregular acinus characterized by low circularity, 
aspect ratio >> 1 and low roundness (<<1). (B) An example of a regular acinus, characterized 
by circularity, aspect ratio and roundness close to 1.   
 
Image analysis was performed by assessing, using the imageJ software, a 
minimum of 20 images of acini per well in a blinded fashion. The perimeter of 
each acinus was drawn using the free hand tool on the software imageJ as 
shown in figure 2.9. The software computes the geometrical features of the 
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acini delineated by the drown perimeter.  Parameters analysed were roundness 
(defined as 4 × (Area of the acinus):(π × [Major axis of the acinus]2) ); circularity 
(defined as 4π × ([Area of the acinus]/[Perimeter of the acinus]2), aspect ratio 
(defined as (Major Axis)/(Minor Axis) of the acinus). Value of 1.0 of circularity 
indicates a perfect circle. As the value approaches 0.0, it indicates an 
increasingly elongated shape. Data analysis was performed using the Prism 
Software (GraphPad Software, version 5.04, La Jolla, CA, USA). ANOVA 
followed by Bonferroni’s post-hoc test was used to compare the samples. 
 
2.26 Active Rho pull down assay 
 
The Active Rho Pull-Down and Detection Kit (Pierce) was used to assess the 
levels of active Rho A, B and C in cultured breast cancer cells, following the 
manufacturer protocol. Cells were grown in T75 flasks until 60-70 % confluent, 
then were washed twice with PBS and starved overnight in serum free medium. 
Cells were then washed once with cold TBS-t and lysed in 300 μL of the 
lysis/washing buffer (25mM Tris•HCl, pH 7.2, 150mM NaCl, 5mM MgCl2, 1% 
NP-40, 5% glycerol, HALT protease inhibitor cocktail, 1nM sodium 
orthovanadate). 270 μL of total lysate were then pipetted into spin columns that 
were previously loaded with glutathione resin and 400 μg of GST-Rhotekin-
RBD, which binds selectively to the active form of Rho binding GTP. The 
columns were then incubated at 4 ° C with gentle rocking for 1 hour. The resin 
was then washed three times with 400 μL of lysis/washing buffer. The complex 
GST-Rhotekin/Rho-GTP was then precipitated from the resin with 50 μL of 2 X 
Laemmli buffer and boiled at 100 °C for 5 minutes. 30μL of these preparations 
were electrophoresed into 12 % acrylamide gels and analysed by 
immunoblotting as described in the paragraph 2.10. To perform a loading 
control, 30 μL of the original total lysate which were excluded from the pull down 
were mixed with 10 μL of 4X Laemmli buffer, boiled for five minutes at 100 °C 
and resolved in a separate gel. Proteins were then transferred into nitrocellulose 
membranes which were blocked in 3 % BSA in TBS and incubated overnight 
with a rabbit anti-Rho antibody, diluted 1:1000 in TBS-t 3 % BSA. A goat anti-
rabbit IgG (H+L) peroxidase-conjugated antibody and ECL were used to detect 
the Rho band. Densitometric analysis was carried out using the software 
ImageJ. 
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2.27 Fibronectin immunofluorescence 
 
2.5 x 105 Cells were resuspended in 1 mL of complete medium and seeded onto 
10 mm diameter coverslips in 24 wells plates. The cells were let to settle at 37 
°C in a humidified incubator for 24 hours and then were starved overnight 
following two washes in PBS. Next, the coverslips were washed twice with PBS 
and the cells were fixed with PFA (4% in PBS) for ten minutes. The coverslips 
were then washed in PBS thrice and incubated with permeabilization buffer (0,1 
% Triton X in PBS) for 10 minutes. Cells were then washed thrice with PBS and 
incubated in blocking solution (1% BSA in PBS) for 30 minutes. 100 μL of 
mouse anti-Fibronectin clone 10 antibody (BD biosciences), diluted 1:100 in 
blocking solution, were added on top of the coverslips for 1 hour at room 
temperature. The coverslips were then washed three times with PBS and 
incubated in 120 μL of horse anti-mouse texas red conjugated antibody, diluted 
1:100 in blocking solution, for 1 hour at room temperature. After three washes of 
5 minutes each with PBS, cells were incubated in DAPI (4', 6-diamidino-2'-
phenylindole, dihydrochloride, Thermo Scientific) diluted 1:1000 in PBS for 10 
minutes and washed three times with PBS. The coverslips were then mounted 
in microscope glass slides with a drop of FluorSave reagent (Calbiochem) and 
analysed with a Leica DM4000 microscope. For each cell line, pictures of ten 
random fields from 2 separate coverslips were taken using a 20 X magnification 
objective. Images were acquired under non-saturating conditions and using the 
same exposure settings for all the samples. The software Leica Application 
Suite was used to measure the intensity of fluorescence. The background 
fluorescence of an area of the coverslip without cells was subtracted to each 
measure.  
 
2.28 Fibronectin competitive inhibition enzyme-linked 
immunosorbent assay (CI-ELISA) 
 
To assess the levels of soluble fibronectin released in the culture medium of 
breast cancer cells, the QuantiMatrix Human Fibronectin ELISA (Millipore) was 
used according to the manufacturer instructions. 
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2.5 x 105 Cells were resuspended in 1 mL of complete medium and seeded onto 
24 wells plates in triplicate. The cells were let to settle at 37 °C in a humidified 
incubator for 24 hours. The culture medium was then discarded and the cells 
starved in serum free medium following two washes in PBS. The supernatants 
were harvested at 72 hours and the cells lysed directly in the plate by adding 30 
μL of 2x Laemmli buffer. Supernatants and cell lysates were stored at – 20 ° C 
until use. 30μL of cells supernatant were then diluted with 30μL of diluent buffer 
(1% BSA in PBS + 0.01% Thimerosal) and 60μL of Rabbit anti-Human 
Fibronectin, and incubated at room temperature for 30 minutes. 100 μL of this 
solution were pipetted into pre-hydrated fibronectin coated strips and incubated 
at room temperature for 30 minutes. In parallel, fibronectin standards were 
analysed to build a standard curve. The strips were then washed four times with 
200 μL of washing buffer (0.05% Tween-20 and 0.01% Thimerosal in water) 
and incubated with 100 µL of Goat anti-Rabbit IgG-HRP at room temperature 
for 30 minutes. Following 4 washes with 200 µL of wash buffer, 100 µL of 
TMB/E substrate were added to each well containing the strips. When the 
colour of the wells with the highest concentration became bright blue, the 
reaction was stopped by adding 100 µL of Stop Solution (0.5M HCl in water) to 
each well. The absorbance was immediately read at 450 nm with a plate 
spectrophotometer (Biorad), and the concentration of the samples was 
determined by extrapolation from the fibronectin standard curve.  
To ensure that the assayed fibronectin was secreted by a similar amount of 
cells amongst the samples, the cells lysates were immunoblotted for β-actin 
following the procedure described in paragraph 2.10.  
 
2.29 Statistical analysis 
 
All the experiments were carried out in triplicate three times, unless otherwise 
stated. The unpaired two-tailed t-test was used to compare the differences 
amongst the experimental groups, unless otherwise specified. Differences were 
considered significant when the p values obtained were ≤ 0.05. NS indicates 
non significant differences (P > 0.05), * indicates p ≤ 0.05, ** indicates p ≤ 0.01 
and *** indicates p ≤ 0.001. 
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RESULTS  
 
CHAPTER III 
 
Deregulation of FZD6 gene structure and 
expression in breast cancer 
 
3.1 Introduction 
 
To understand the role of FZD6 in breast cancer, we carried out a comparative 
analysis between normal and tumour samples in in silico databases, patients 
tissue arrays and breast cancer cell lines. The recent advances in sequencing 
technologies made available to public consultation a large amount of genomic 
data. Using specific tools, it is possible to compare gene expression of tumour 
specimens with the matched normal tissues. Moreover, it is possible to identify 
the frequency of mutations and to associate the expression of specific genes to 
the clinical condition of patients. In breast cancer, genomics studies allowed to 
identify different molecular signatures that can predict different outcomes and 
different responses to therapies (Bild et al., 2005; Sorlie et al., 2001). 
Databases are important tools to study oncogenes and oncosupressors, and 
also to help clinicians deciding the correct therapeutic strategies. The first step 
in this study was to use bioinformatic tools to investigate whether FZD6 
expression and/or mutations were relevant in breast cancer. The in silico 
findings were integrated with immunohistochemical analysis on a large cohort of 
Italian breast cancer patients. The expression of FZD6 was also assessed in a 
panel of breast cancer cell lines, both at the mRNA and protein level. 
 
 
  
94 
 
3.2 In silico analysis of FZD6 expression in microarrays 
datasets 
 
We used the online platform ONCOMINE (www.oncomine.org) to investigate 
whether FZD6 expression was altered in breast cancer compared to normal 
tissue. We found that FZD6 mRNA levels were higher in tumour samples 
compared to normal tissue (Fig. 3.1 A) and in the tumour stroma compared to 
the normal stroma (fig. 3.1 B). In the Ma database (Ma et al., 2009), we found 
that FZD6 expression in ductal breast carcinoma in situ was 1.673 fold higher 
than normal tissue (fig. 3.1 A). In the Finak dataset (Finak et al., 2008), FZD6 
expression was 1.7 fold higher in invasive carcinomas stroma when compared 
to normal breast stroma (fig. 3.1 B). In the cancer genome atlas (TCGA), we 
found a 1.33 fold increase in the FZD6 gene copy number of ductal breast 
carcinomas compared to normal tissue or blood (fig.3.1 D). 
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Figure 3.1: FZD6 expression in breast cancer datasets. The online platform 
ONCOMINE was used to assess FZD6 mRNA levels in normal breast and breast cancer from 
available microarrays datasets. (A) FZD6 Expression in the Ma dataset. 1, normal breast (n= 
14); 2, ductal breast carcinoma in situ (n= 9). Fold change: 1.673, p= 0.018.  (B) FZD6 
Expression in the Finak dataset. 1, normal breast stroma (n= 6); 2, invasive breast carcinoma 
associated stroma (n=53). Fold change: 1.708; p= 2.81E-9.  (C) FZD6 Expression in the Farmer 
dataset. 1, basal-like invasive breast carcinoma (n=16); 2, luminal-like invasive breast 
carcinoma (n=27) fold change: 2.303; p= 4.47E-5.  (D) FZD6 copy number in TCGA dataset. 1, 
Blood (n=702); 2. Normal breast (n=111); 3. Invasive ductal breast carcinoma (n=639). Fold 
change 1.33; p=1.12E-101. • indicates extreme values. 
 
These observations were consistent with the data extracted from the online 
platform COSMIC (Catalogue of Somatic Mutations in Cancer, 
http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/), where on 900 
breast cancer samples analysed, 172 (19,11%) showed  gene copy number 
gains for FZD6, and 185 out of 989 samples displayed FZD6 overexpression 
(18.71%) (table 3.1). Amongst all the FZD receptors, FZD6 was the most 
frequently amplified and overexpressed in breast cancer (Table 3.1). 
To understand if FZD6 overexpression was linked to specific breast cancer 
subtypes, we performed a comparative analysis using the Farmer dataset 
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(Farmer et al., 2005). We found that FZD6 expression was 2.3 fold higher in 
basal-like breast carcinoma compared to luminal-like carcinoma (fig. 3.1 C).  
 
Table 3.1: Copy Number Variation (CNV) and overexpression of Frizzled (FZD) receptor 1 
to 10 in primary breast cancer samples. Data was mined using the COSMIC repository 
(http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/about).  
FZD Loss/gain (out of 900 samples) Overexpression (out of 989 
samples) 
1 Loss 2 (0.22%) 
Gain 0 
21 (2.12%) 
2 Loss 3  (0.33) 
Gain 0 
47 (4.75) 
3 Loss 40 (4.44%) 
Gain 3 (0.33%) 
59 (5.97%) 
4 Loss 4 (0.44%) 
Gain 14 (1.56%) 
31 (3.13) 
5 Loss 1 (0.11) 
Gain 0 
41 (4.15) 
6 Loss 0 
Gain 172 (19.11%) 
185 (18.71%) 
7 Loss 2 (0.22)  
Gain 0 
40 (4.04%) 
8 Loss 0 
Gain 9 (1%) 
12 (1.21%) 
9 Loss 1 (0.11%) 
Gain 9 (1%) 
27 (2.73%) 
10 Loss 0 
Gain 1 (0.11%) 
40 (4.04%) 
 
 
3.3 In silico survival studies  
 
In order to understand the clinical significance of FZD6 overexpression in 
patients, we used the online tool Kaplan-Mayer Plotter 
(http://kmplot.com/analysis/) that allows the generation of Kaplan-Meier curves 
linking patients gene profiling to their outcome (Györffy et al., 2010). 
High expression of FZD6 was associated with a lower overall survival 
(HR=1.48, C.I. 95% 1.17-1.89, p=0.0013), lower relapse free survival (HR=1.42, 
C.I. 95% 1.26-1.6, p=8.9x10-9) and lower distant relapse free survival (HR=1.48 
C.I. 95% 1.2-1.82, p=0.00022) of the totality of breast cancer patients (fig.3.2). 
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Figure 3.2: Kaplan Meier survival analysis of breast cancer patients with high 
or low expression of FZD6: The online tool Kaplan Meier plotter was used to predict  
overall survival, relapse free survival and distant relapse free survival of breast cancer patients 
with high (red)  or low (black) FZD6 expression. * Indicates statistical significance. Hazard 
ratios, 95% confidence intervals and p values are indicated in the top-right corner of each plot.  
 
We also compared the survival plots of patients with basal like, luminal A and 
luminal B breast cancer. HER2 positive patients were excluded due to the 
insufficient number of cases to carry out the analysis. Patients were further 
divided into those having or not having tumour spread in the lymph nodes at the 
time of diagnosis. We found that FZD6 expression status was not sufficient to 
predict overall survival when patients were divided into subgroups, except for 
basal like, lymph node positive patients, where high FZD6 expression was 
associated with lower overall survival (HR=3.36, C.I. 95% 0.94-11.97, p=0.048 
(fig.3.3). 
High expression of FZD6 was associated with a lower relapse free survival 
independently from the lymph node status when patients were not stratified into 
subgroups (fig. 3.4). When considering only the lymph node negative patients 
instead, a significant association was observed only for the luminal A subgroup. 
In the lymph node positive cohort high FZD6 was associated with a higher 
probability of tumour relapse in all the subgroups, particularly in those patients 
affected by basal breast cancer, where the hazard ratio was 1.9, C.I. 95% 1.09-
3.31, p=0.022 (fig.3.4). 
High FZD6 expression correlated with lower distant relapse free survival when 
all the lymph node negative subgroups were considered together (fig.3.5). A 
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significant association was also observed in basal like patients and luminal A 
patients with lymph node negative status, but not in the luminal B cohort 
(fig.3.5). FZD6 expression was not able to predict distant relapse free survival in 
those patients that were lymph nodes positive at the time of diagnosis, 
independently from the tumour subtype (fig.3.5). The risk of metastatic relapse 
was particularly high in basal like, lymph node negative patients with high FZD6 
(HR=2.35 C.I.95% 1.16-4.75, p=0.014) (fig.3.5). 
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Figure 3.3: Kaplan-Meier survival analysis in different breast cancer subtypes: 
Plots were obtained as described in fig.3.2 and stratifying patients belonging to different breast 
cancer subgroups and with different lymph nodes status. Black lines indicate low FZD6, red 
lines high FZD6. Hazard ratios, 95% confidence intervals and p values are indicated in the top-
right corner of each plot. * indicates statistical significance, N.S. indicates non significant 
differences and ● indicates that the number of patients available was low. 
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Figure 3.4: Kaplan-Meier relapse-free survival analysis: plots were obtained as 
described in figure 3.3. Black lines indicate low FZD6, red lines high FZD6. Hazard ratios, 95% 
confidence intervals and p values are indicated in the top-right corner of each plot. N.S. 
indicates non significant differences whereas * indicates statistical significance. 
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Figure 3.5: Kaplan-Meier distant relapse free survival analysis: plots were 
obtained as described in figure 3.3. Black lines indicate low FZD6, red lines high FZD6. Hazard 
ratios, 95% confidence intervals and p values are indicated in the top-right corner of each plot. 
N.S. indicates non significant differences whereas * indicates statistical significance. 
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3.4 Immunohistochemical analysis of FZD6 expression 
in an Italian cohort of breast cancer patients 
 
The data presented in this section was produced by our collaborators Dr 
Rossano Lattanzio and Professor Mauro Piantelli from the Department of 
Experimental and Clinical Sciences, University G. D’Annunzio, Chieti, Italy, and 
Marcella Mottolese and Letizia Perracchio from the Regina Elena Cancer 
Institute, Rome, Italy. 
FZD6 immunohistochemical staining was carried out on tissues arrays as 
described in material and methods. The study includes 352 primary infiltrating 
breast cancers from N0 and T1/T2 tumours from patients that were presenting 
primary unilateral breast carcinoma. Patient and tumour characteristics are 
summarized in table 3.2. 
20.2% of the specimens showed membrane expression of FZD6, with or without 
concurring cytoplasmic staining (Figure 3.6).  When considering the whole 
patient cohort, expression of Fzd6 was not significantly associated with clinical 
features (Table 3.3). However, Kaplan–Meier analysis indicated that expression 
of Fzd6 was significantly associated with lower distant relapse-free survival 
(DRFS) in the triple negative breast cancer patients subgroup (fig. 3.7). In 
multivariate analysis, membranous Fzd6 expression was an independent 
prognostic indicator for low disease free (DFS) and DRFS survival in triple 
negative cases (table 3.4). Tumour grade was the only independent factor 
influencing DFS and DRFS in the whole patient population (table 3.3).  
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Table 3.2: Patients and tumour Characteristics (n = 352) 
 
Variable Value (%) 
  
Age at diagnosis (years)  
    Median   60.5 
    <50      78 (22.1) 
    50-65   147 (41.8) 
    >65   127 (36.1) 
Menopausal status  
    Pre/perimenopausal     84 (23.9) 
    Postmenopausal   268 (76.1) 
Molecular subtypes  
    Luminal A-like   128 (36.4) 
    Luminal B-like (HER2 negative) 
  
  123 (34.9) 
 Luminal B-like (HER2 positive)    33 ( 9.4) 
 HER2 positive (non-luminal)   21 ( 6.0) 
    Triple negative (ductal)   47 (13.4) 
Tumor size  
    ≤ 2 cm   228 (64.8) 
    > 2 cm   124 (35.2) 
Tumour grade  
    1   58 (16.5) 
    2-3 294 (83.5) 
ER  
    Negative   74 (21.0) 
    Positive 278 (79.0) 
PGR  
    Negative 161 (45.7) 
    Positive 191 (54.3) 
Ki-67  
    Low   237 (67.3) 
    High   115 (32.7) 
HER2     
    Negative  298 (84.7) 
    Positive    54 (15.3) 
Fzd6  
    Negative  281 (79.8) 
    Positive    71 (20.2) 
Patient outcome  
    Without recurrence 266 (75.6) 
    Local recurrence  32  ( 9.1) 
    Distant recurrence   54 (15.3) 
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Figure 3.6: Immunohistochemical analysis of Fzd6 expression in breast 
cancer. (A, C) Images showing Fzd6 expression in two invasive triple negative human breast 
cancers (magnification 40X). (B, D) Enlargement of the images shown in panels A and C. Bars 
indicate 50μm. 
 
Table 3.3: Multivariate analysis of Fzd6 expression in the totality of breast 
tumours 
    Variable HR 95% CI P 
        Disease-free survival    
Tumor size, cm (≤ 2 vs > 2) 1.0      0.7-1.6 0.840 
Tumor grade (2-3 vs 1) 2.5      1.1-5.8 0.038* 
ER (positive vs negative) 1.1      0.6-1.9 0.844 
PGR (negative vs positive) 1.4     0.8-2.3 0.210 
Ki-67 (high vs low) 1.5     0.9-2.4 0.096 
HER2 (positive vs negative) 1.3      0.8-2.2 0.308 
Fzd6 (negative vs positive) 1.3      0.7-2.2 0.417 
    Local Relapse-Free Survival    
Tumour size, cm (> 2 vs ≤ 2) 1.3      0.7-2.6      0.425 
Tumor grade (2-3 vs 1) 1.5      0.5-4.5    0.445 
ER (positive vs negative) 1.6      0.6-4.2      0.349 
PGR (negative vs positive) 1.6      0.8-3.3    0.226 
Ki-67 (high vs low) 1.2     0.6-2.5      0.658 
HER2 (negative vs positive) 1.2      0.4-3.1      0.744 
Fzd6 (negative vs positive)   1.1      0.5-2.5      0.833 
    Distant Relapse-Free Survival    
Tumour size, cm (≤ 2 vs > 2) 1.3      0.7-2.3      0.376 
Tumor grade (2-3 vs 1) 4.8     1.1-20.2      0.032* 
ER (positive vs negative) 1.1      0.5-2.2      0.875 
PGR (negative vs positive) 1.4      0.7-2.6      0.291 
Ki-67 (high vs low) 1.6      0.9-3.0      0.102 
HER2 (positive vs negative) 1.5      0.8-2.8      0.244 
Fzd6 (positive vs negative)    1.4     0.7-2.8      0.384 
    *Statistically significant 
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Table 3.4: Multivariate analysis of Fzd6 expression in triple negative tumours 
 
*Statistically significant 
 
 
 
    
Variable HR 95% CI P 
    
    
Disease-free survival    
Tumor size, cm (> 2 vs ≤ 2) 4.1        0.7-21.5        0.098 
Tumor grade (1 vs 2-3) 1.7        0.3-11.5      0.879 
Fzd6 (positive vs negative) 5.7        1.5-22.9      0.011* 
    
Local Relapse-Free Survival    
Tumour size, cm (>2 vs ≤2) 1.1        0.2-10.6     0.950 
Tumor grade (1 vs 2-3) 1.0        0.1-10.4     0.941 
Fzd6 (negative vs positive)     2.5        0.3-25.0     0.421 
    
Distant Relapse-Free Survival    
Tumour size, cm (> 2 vs ≤ 2) 2.1        0.3-12.6     0.435 
Tumor grade (1 vs 2-3) 1.0        0.1-15.2       0.992 
Fzd6 (positive vs negative)   6.8        1.2-37.4     0.027* 
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Figure 3.7: Survival curves. Kaplan–Meier estimates of disease-free survival (DFS), local 
relapse-free survival (LRFS) and distant relapse-free survival (DRFS) in breast cancer cases (n 
= 352) with high (green solid line) or low (blue dashed line) expression of Fzd6 assessed by 
immunohistochemistry. Statistical significance was assessed using the log-rank test. 
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3.5 Expression of FZD6 in breast cancer cell lines 
 
 
Figure 3.8: Expression of FZD6 in breast cancer cell lines: (A) Reverse 
transcription, Q-PCR analysis of FZD6 mRNA expression in a panel of breast cancer cell lines.  
(B) Western blot analysis showing expression of Fzd6 in different breast cancer cell lines. RNAi 
depleted MDA-MB-231 cells (MDA-MB-231-Sh1) were used as a negative control in comparison 
with the control cell line (MDA-MB-231-Scrambled) to unequivocally identify Fzd6-specific 
bands. (C) Imagestream analysis demonstrating increased percentages of human mammary 
epithelial cells (HMEC) expressing Fzd6 in the cell membrane after immortalization with the 
hTERT enzyme.  Inset shows representative images of cells in bright field (BF) or stained with 
the Fzd6 antibody (green). 
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To complete our analysis we assessed FZD6 expression levels in a panel of 
breast cancer cell lines. Expression levels were compared to those of normal 
human mammary epithelial cells (HMEC-184D). HMEC-184D cells immortalized 
with H-TERT plasmid were also included in the analysis. FZD6 mRNA 
expression was assessed by RT-QPCR (fig.3.8 A), whereas protein levels were 
assessed by western blot analysis and Imagestream analysis (fig.3.8 B and C).  
HMEC-184D-HT transformed cells showed a 5.45 fold increase in the mRNA 
levels and increased Fzd6 protein expression compared to normal HMEC-184D 
(Fig.3.8 A and B). Moreover, HMEC-184D-HT showed a 2.9 fold increase in the 
percentage of cells positive to membranous FZD6 expression compared to the 
normal conterparts (Fig. 3.8 C). Overall, the majority of breast cancer cell lines 
expressed higher levels of FZD6 mRNA compared to HMEC cells. However, the 
same difference was not evident at a total protein level (Fig. 3.8 B). 
Furthermore, basal like cells expressed more Fzd6 than non basal cell lines (fig. 
3.8 B). 
Imagestream analysis in a panel of breast cancer cell lines was carried out to 
assess membrane expression of the FZD6 receptor (fig.3.9). All the cell the cell 
lines, to different extent, showed membrane staining of FZD6, with the only 
exception of MDA-MB-436 cells. 
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Figure 3.9: Expression of Fzd6 on the surface of breast cancer cell lines: (A) 
Cells were labelled with a Fzd6 antibody and subjected to flow cytometry-Imagestream analysis. 
The percentages of positive cells and the geometrical mean fluorescence intensities of the Fzd6 
signal are indicated in the graph plot. (B) Representative photographs of cells from each of the 
cell lines taken during the Imagestream analysis and showing different degrees of Fzd6 staining 
on the cell surface.  
 
3.6 Discussion 
 
The results presented in this chapter demonstrate that the overexpression of 
FZD6 is a common event in breast cancer. It is likely that the up-regulation of 
FZD6 is a consequence of gene amplification, since a high percentage of the 
breast cancer cases in the COSMIC database (19.11%) showed a FZD6 copy 
number gain (table 3.1). A similar percentage of cases (18.71%) also showed 
110 
 
high FZD6 expression, suggesting that the two events could be causally linked 
(table 3.1). Given the importance of WNT signalling in cancer, altered 
expression of FZD6 has the potential to have an important role in breast 
tumorigenesis. Indeed, increased activation of the WNT pathway through 
overexpression of frizzled receptors has been reported in many tumours. 
Moreover, overexpression of FZD receptors has been shown to be critical in 
promoting tumour progression, metastasis and drug resistance in breast cancer 
(Zhang et al., 2012; Yang et al., 2011; Ueno et al., 2008; Milovanovic et al., 
2004).  
Our results indicate that FZD6 might have a specific role in breast cancer. This 
is suggested by the comparison between normal mammary epithelial cells 
(HMEC) and their immortal counterpart expressing hTERT (human Telomerase 
Reverse Transcriptase). Indeed, we observed a marked upregulation of FZD6 in 
HMEC in the presence of ectopic expression of hTERT, both at mRNA and 
protein levels (fig. 3.8). The forced expression of hTERT is widely used to 
immortalize primary cells that would otherwise rapidly undergo senescence in 
culture. This is achieved by the synthesis of new telomeres at the end of the 
chromosomes by hTERT. Telomeres are repeated nucleotide sequences that 
protect chromosome ends from degradation. Every time a somatic cell 
undergoes mitosis, telomeres are shortened, reducing the lifespan of the cell. 
This is thought to be a control mechanism that reduces the risk of propagation 
of cells with chromosome instability and mutations (Lee, Choi and Ouellette, 
2004). The activation of telomerases is also a common event in cancer and is 
required by cancer cells to escape senescence and become immortal. 
Immortalization of primary cells with hTERT also promotes the acquisition of 
new mutations, as observed in tumorigenesis. For example, Noble et al. 
showed that ectopic expression of hTERT in human fibroblasts could result in 
deletions of p16 and mutations of p53 (Noble et al., 2004). Mutations in relevant 
check point proteins can lead to genomic instability and the acquisition of 
mutations. We therefore hypothesise that genome instability in breast cancer 
cells might promote FZD6 rearrangements that results in its overexpression.  
To understand the clinical implications of the overexpression of FZD6, we 
carried out survival studies based on gene expression, microarrays and protein 
expression in patients. Up-regulation of FZD6 reduces overall survival, relapse 
free survival and distant relapse free survival, suggesting that FZD6 
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upregulation could be a general risk factor in breast cancer. When patients were 
divided into different cohorts, i.e. in lymph node negative or positive and in 
breast cancer subtypes, FZD6 expression was not informative in terms of 
overall survival (fig. 3.3). Nevertheless, high FZD6 expression was associated 
with a lower relapse free survival, particularly in patients with positive lymph 
nodes (fig.3.4). This suggests that the upregulation of FZD6 could play a role in 
tumour recurrence.  High expression of FZD6 was also associated with high risk 
of metastatic relapse in all the lymph node negative subgroups, but not in lymph 
node positive patients (fig.3.5). A possible explanation for this is that FZD6 
could be important to trigger metastatic spread, but its expression might be 
irrelevant for the survival of patients with late stage disease, i.e. with lymph 
node positive for the presence of cancer cells.  
The basal-like cohort was the one with the higher hazard ratio between high 
and low FZD6 expression for the metastatic relapse survival, suggesting a 
particular importance of FZD6 up-regulation in the metastatic progress for this 
subtype. These observations are consistent with the multivariate analysis 
carried out in a cohort of Italian patients. In these patients, high FZD6 
expression was predictive of low relapse free survival and distant relapse free 
survival specifically in the triple negative breast cancer subgroup. We also 
observed higher expression of FZD6 in basal cell lines when compared to 
HMEC or luminal cell lines. Basal carcinomas are usually associated with a 
poorer prognosis and a more invasive phenotype when compared to luminal 
subtypes (Sorlie et al., 2001). We therefore hypothesize that FZD6 expression 
could be relevant in explaining the phenotypic differences between luminal and 
basal breast cancers. Although triple negative tumours initially show a good 
response to therapy, they tend to relapse at distant sites more frequently than 
other subtypes (Carey et al., 2010; Foulkes, Smith and Reis-Filho, 2010; 
Nguyen et al., 2008). Altogether, our findings suggest that surface expression of 
Fzd6, besides serving as a strong predictive marker of distant relapse, could be 
exploited as a target for therapy of triple negative cancers. The need to predict 
patients outcome in early breast cancer is of primary importance in order to 
select the appropriate therapeutic regimens. For example, in lymph node 
negative patients adjuvant systemic chemotherapy could be unnecessary and 
even harmful for low risks patients, whereas it could be crucial for high risk 
patients (Cianfrocca and Goldstein, 2004). FZD6 expression status could be 
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used to discern high risk lymph-node negative patients from the ones with low 
risk, helping clinicians to design adequate therapies.    
Understanding the role of FZD6 in breast cancer could give new insights in the 
biological mechanisms underlying tumour recurrence and metastasis. This is of 
primary importance, since a vast number of tumours recur, even many years 
after primary treatment (Karrison, Ferguson and Meier, 1999). Different 
explanations have been proposed to explain tumour recurrence, but this 
process is still poorly understood. Recurrence is originated by cancer cells that 
remain in the patient’s body after primary treatment and that cannot be detected 
with conventional diagnostic techniques. These cells undergo a period of 
quiescence, but eventually proliferate to reform the tumour (Aguirre-Ghiso, 
2007). Many investigators argue that tumour repopulation is caused by cancer 
stem cells that survived surgery or adjuvant therapy (Merlos-Suárez et al., 
2011; Donnenberg and Donnenberg, 2005). Stem cells resist chemotherapy 
due to their high expression of membrane transporters that excrete cytotoxic 
drugs (Dean, Fojo and Bates, 2005). Cancer stem cells have also a pivotal role 
in the development of metastases. This is thought to be caused by the aberrant 
activation of pathways that are responsible of cell migration during 
organogenesis (Singh and Settleman, 2010; Karnoub et al., 2007; Li et al., 
2006). In this contest, the role of the WNT pathway is well established (Reya 
and Clevers, 2005).The WNT pathway has been shown to be required for the 
activation of the epithelial to mesenchymal transition (EMT), essential for cancer 
cells to leave the primary tumour site and invade to distant organs (Neth et al., 
2007). Indeed, our group previously reported that FZD6 marks stem-like cells 
and confers drug resistance in neuroblastoma cells (Cantilena et al., 2011). In 
breast cancer, the overexpression of FZD6 could provide a survival advantage 
to cancer stem cells to overcome primary treatment. Patient bearing high FZD6 
would therefore have a higher risk for tumour recurrence and metastatic 
relapse.  
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CHAPTER IV 
 
Depletion of FZD6 expression affects motility, 
invasion and three-dimensional growth, but not 
proliferation of breast cancer cell lines 
 
4.1 Introduction 
 
Several investigators have linked abnormalities in the WNT pathway with 
increased proliferation and invasion of breast cancer cells (Zhang et al., 2012; 
Klemm et al., 2011; Yang et al., 2011; Matsuda et al., 2009; Lindvall et al., 
2007). In the previous chapter I have shown that FZD6 overexpression is 
common in breast cancer and associated with low survival. To understand the 
role of the FZD6 receptor in breast cancer, we used RNA interference to 
downregulate its expression in cell lines. This approach is commonly used to 
understand the function of a gene by observing the phenotypic effects caused 
by its depletion (Hannon, 2002). Transient knock down was obtained using 
siRNAs, whereas stable knock down was achieved through the infection of cells 
with lentiviral vectors targeting FZD6. Non-specific RNA sequences were used 
as controls.  
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4.2 FZD6 knock down validation 
 
Firstly, I transiently transfected two small interfering RNA (siRNA1 FZD6 and 
siRNA2 FZD6) targeting different regions of the FZD6 transcript. A nonspecific 
siRNA sequence was used as a negative control. RT-QPCR analysis 
demonstrated robust knock down in all the cell lines analysed (fig.4.1). 
 
Figure 4.1:  Quantification of FZD6 knockdown in breast cancer cells. Real-time 
Q-PCR showing knockdown of FZD6 mRNA expression levels in breast cancer cell lines 
transfected with the indicted siRNAs. FZD6 expression was normalized to GAPDH and 
expressed as relative quantities to the control siRNA. Error bars indicate standard deviation, 
asterisks indicate statistical significance (Student t-test, HCC1143, n=3; BT474, n=3; MDA-MB-
231, n=1) 
 
Knock down efficiency was also evaluated at protein level using flow cytometry 
and Imagestream analysis. Indirect immunostaining was performed on living 
cells using a FZD6 antibody and a FITC-conjugated secondary antibody. Cells 
were analysed with an EPICS XL flow cytometer (Beckman Coulter) or an 
Imagestream X Imaging flow cytometer (Amnis). FZD6 membrane staining was 
drastically reduced in the presence of both the siRNAs (Fig. 4.2 and 4.3) in the 
HCC1143 and MDA-MB-231 cell lines.  
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Figure 4.2: FACS analysis of the HCC1143 cell line transfected with siRNAs 
targeting FZD6.  HCC1143 cells were transfected with the indicated siRNAs and subjected to 
FZD6 indirect immunostaining. Cells stained with secondary antibody only were used as a 
blank. FZD6-positive cells are shown in green. 
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Figure 4.3: Knock down efficiency on MDA-MB-231 cells. (A) Imagestream analysis 
showing quantification of FZD6 expression in MDA-MB-231 cells after transfection with siRNAs-
FZD6 or control siRNAs. Cells stained with secondary antibody only were used as a blank.  (B) 
Imagestream analysis showing single cells with surface expression of FZD6 in the presence of 
the indicated siRNAs. 
 
For a stable knock down the cell line MDA-MB-231 was infected with lentiviral 
vectors expressing shRNAs targeting FZD6 (Sh1 and Sh2 FZD6). A nonspecific 
shRNA (Scrambled) was used as a negative control. Infected cells were then 
selected with puromycin and analysed with RT-QPCR, western blot and FACS 
to assess knock down efficiency. Both sh1 and sh2 lentiviral constructs were 
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able to produce an almost complete abrogation of FZD6 protein expression 
(fig.4.4). 
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Figure 4.4: Knock down efficiency on MDA-MB-231 cells stably expressing 
control shRNA (Scrambled) or FZD6 shRNAs (Sh1 and Sh2 FZD6) . (A) RT-QPCR 
analysis (B) Western blot analysis (C) FACS analysis of live cells showing membrane staining 
of FZD6. Wild type cells (WT) were also included in the analysis. Knock down assessment was 
carried out regularly throughout this research. Cells resuspended with secondary antibody, but 
not primary antibody, were used as a blank.   
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4.3 FZD6 knock down does not affect cellular 
proliferation 
 
We used the MTS or XTT assays to assess cell metabolism/proliferation. These 
assays exploit the capacity of tetrazolium salts (MTS and XTT) to develop a red 
colour when reduced in a formazan product by living cells. The intensity of the 
colour is proportional to the cell metabolic activity and, indirectly, to cell number 
(Buttke, McCubrey and Owen, 1993). To test the effects of FZD6 knock down in 
cellular proliferation, the different breast cancer cell lines were transfected with 
FZD6 or control siRNAs and then plated in 96 well plates. 24 hours later, MTS 
was added to the cells and the absorbance read after 2 hours. Relative cell 
proliferation/metabolic activity of cells was expressed as optical density relative 
to controls. FZD6 knock down did not perturb metabolism/proliferation of breast 
cancer cells with the exception of the HCC1143 cell line (Fig. 4.5). 
 
 
Figure 4.5: MTS assay of breast cancer cells after FZD6 knock down with 
siRNAs. Cells were transfected with control siRNA or siRNAs targeting FZD6 (siRNA 1 and 
siRNA 2). Metabolic activity is expressed as optical density (O.D.) units normalized to the 
control siRNA. Absorbance was read 24 hours after the cells were plated. Error bars indicate 
standard errors and asterisks indicate statistical significance (student t-test, n=3). N.S. indicates 
non significant differences.  
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Figure 4.6: XTT assay of the MDA-MB-231 cell line expressing FZD6-shRNAs or 
control shRNA. Metabolic activity is expressed as optical density (O.D.) units normalized to 
the scrambled shRNA. Absorbance readings were made 24 hours and 48 hours after cells were 
plated. Three independent experiments were carried out in triplicate, error bars indicate 
standard errors. No significant differences were observed (student t-test, n=3).   
 
Next, I assessed the proliferation of MDA-MB-231 cells stably expressing 
shRNAs targeting FZD6 (sh1-FZD6 and sh2-FZD6) or control shRNA 
(Scrambled). Cells were plated in 96 well plates, and the XTT assay was 
performed after 24 or 48 hours (fig.4.6). No significant differences were 
observed in cell proliferation in the presence of FZD6 downregulation. 
Cell cycle analysis was also carried out on these cells (fig.4.7). The knock down 
of FZD6 did not alter significantly cell cycle profiles nor the Sub G1 DNA content 
of MDA-MB-231 cells.  
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Figure 4.7: Cell cycle analysis on MDA-MB-231 cells in the presence of control 
shRNA or FZD6 shRNAs. (A) Representative experiment showing cell cycle profiles after 
propidium iodide staining and FACS analysis. (B) Plot showing the percentage of cells in 
different phases of the cell cycle. Error bars indicate standard error. The results shown 
represent the average of three independent experiments. No significance differences were 
observed (student t-test, n=3).  
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4.4 FZD6 knock down reduces the invasion and motility 
of breast cancer cells  
 
To assess the invasion of breast cancer cells in vitro, I carried out invasion 
assays based on the capacity of cells to trespass a matrigel membrane. Cells 
were resuspended in serum free medium and seeded in the upper compartment 
of a Boyden chamber. The bottom of this compartment consists in a porous 
membrane covered in matrigel. The lower compartment of the Boyden chamber 
was replenished with medium containing a chemoattractant (FBS or EGF) to 
generate a chemotactic gradient.  
In the presence of FZD6 siRNAs, the invasion capacity of breast cancer cells 
was drastically reduced (fig. 4.8). The cell line MDA-MB-436, that does not 
express membranous FZD6 (fig. 3.9), was used to rule out off-target effects of 
the siRNAs. Transfection of FZD6 siRNAs in MDA-MB-436 cells did not produce 
any effect in cell invasion, confirming siRNA specificity.  
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Figure 4.8: In vitro invasion assays of breast cancer cell lines transfected with 
control siRNA or siRNAs targeting FZD6. Invasive cells are expressed as percentage 
relative to the control siRNA. Medium containing 10% FBS was used as chemoattractant. Error 
bars indicate standard errors and asterisks indicate statistical significance (student’s t-test, n=3). 
N.S. indicates non significant differences.   
 
In agreement with the siRNA experiments, we also observed a marked 
reduction of the FBS-mediated invasion of MDA-MB-231 cells stably expressing 
FZD6 shRNAs (Fig.4.9). Similar results were observed when invasion was 
stimulated with EGF. Cells expressing control shRNA were 2.5 fold more 
invasive in the presence of EGF compared to non stimulated cells. Conversely, 
Sh1-FZD6 cells were not responsive to EGF stimulation (fig. 4.9). 
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Figure 4.9: Invasion assays of the MDA-MB-231 cell line in the presence of 
control ShRNA or shRNAs targeting FZD6: (A) EGF mediated invasion. Cells 
resuspended in serum free media were seeded in a Boyden chamber where the bottom well 
was replenished with serum free medium (Control) or serum free medium with the addition of 
100ng/mL EGF. (B) FBS mediated invasion. Cells were resuspended in serum free media and 
seeded in a Boyden chamber where the bottom well was replenished with medium containing 
10% FBS. Invasion rates are expressed as percentage of the controls. Error bars indicate 
standard error. Asterisks indicate statistical significance (student t-test, n=3).  
 
To assess whether FZD6 was important for cell motility, I carried out wound 
healing assays. This technique is widely used to assess directional motility of 
cells in vitro (Rodriguez, Wu and Guan, 2005). Confluent cells growing in 
monolayer are scratched with a pipette tip and placed in a live imaging system 
microscope. The scratch induces a migratory response that stimulates cells to 
migrate in a polarized fashion towards the wound. MDA-MB-231 cells 
expressing scrambled or sh2 FZD6 shRNAs were analysed simultaneously after 
the wound. Photographs from 4 different areas of the scratch were taken every 
20 minutes over the range of 24 hours. Control cells were able to close the 
wound completely after 14h, whereas the wound was still visible in FZD6 
depleted cells at 14 and 19 hours (Fig. 4.10 A). Cell motility was quantified 
tracking single cells trajectories and quantifying average speed using image 
analysis software. FZD6 knock down reduced cell speed to 16μm/h compared 
to the 22 μm/h of control cells (fig.4.10 B). 
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Figure 4.10: Wound healing assay. MDA-MB-231 cells infected with lentiviruses 
containing control (Scrambled) or Fzd6 shRNA (Sh2) were grown as a monolayer and then 
scratched with a pipette tip. Cells were placed in a live imaging system and filmed for 24 hours. 
(A) Examples of pictures taken at the indicated times showing the closure of the wound in 
control (scrambled) but not in FZD6 downregulated (Sh2 –FZD6) cells. (B) Quantification of 
locomotion of FZD6-expressing versus non-expressing cells. The average speed of 10 cells for 
each wound was calculated. 4 wounds per shRNA type were analysed. Error bars indicate 
standard errors and asterisks statistical significance (student’s t-test, n=4). 
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4.5 FZD6 knock down changes the shape of breast 
cancer acini in a 3D culture system 
 
The data described in this section was produced in collaboration with Sibylle 
Ermler and Elisabete Silva from the Institute for the Environment, Department of 
Life Sciences, Brunel University London. Sibylle Ermler and Elisabete Silva 
carried out the 3D cultures and the immunofluorescence staining, and I 
performed the image analysis on the acini photographs.  
Many features of cells are not reproducible in a bidimensional culture, as they 
require the interaction with a tridimensional matrix (Lee et al., 2007). The 
morphology of organoids growing in a tridimensional environment can be 
indicative of the malignancy of cells. For example, transformed mammary 
epithelial cells maintain the capacity to form organized acini in 3D culture, 
whereas breast cancer cells generate organoids in which the normal tissue 
organization and architecture are lost (Petersen et al., 1992).   
To study the role of FZD6 in the structural organization of breast cancer 
organoids, we cultured MDA-MB-231 cells expressing control or FZD6 shRNAs 
in a 3D matrigel matrix. Notably, in the absence of FZD6 the symmetrical shape 
of breast cancer acini, measured as aspect ratio, circularity and roundness, was 
significantly increased (fig. 4.11). 
The acini were also stained for laminin (data not shown). All the samples did not 
express laminin. Acini were also stained for fibronectin, but the stain did not 
work well enough to make conclusions about expression levels, especially 
because only 2 dimensional pictures were available.  
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Figure 4.11: 3-D cultures of MDA-MB-231 cells. (A) Photographs of organoids formed 
by the different MDA-MB-231 cell lines expressing (scrambled) or non expressing (Sh1 and 
Sh2) FZD6 after 3 weeks in culture (DAPI staining). (B-D) Quantification of the aspect ratio, 
circularity and roundness, of the organoids described in A. The software imageJ was used to 
analyse the geometrical characteristics of the organoids. Error bars indicate standard errors and 
asterisks statistical significance (ANOVA followed by Bonferroni’s post-hoc test on a minimum of 
20 images of acini per well). The data shown is representative of two independent experiments. 
.   
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4.6 Discussion 
 
The results described in this chapter demonstrate that FZD6 receptor is 
important for the motility and invasion of breast cancer cells (fig. 4.8, 4.9 and 
4.10). On the other hand, FZD6 is not involved in cell proliferation (fig. 4.5, 4.6 
and 4.7). The marginal reduction in proliferation of HCC1143 cells, in the 
presence of siRNA1 FZD6, is likely caused by off target effects, since the 
transfection of siRNA2 FZD6 did not perturb proliferation (fig. 4.5). 
Downregulation of FZD6 did not alter the cell cycle, nor induced apoptosis in 
MDA-MB-231 cells. Several investigators reported that the Wnt β-catenin-
dependent pathway regulates cell proliferation. Conversely, the non-canonical 
pathway has been implicated mostly in cell migration (Reya and Clevers, 2005). 
Thus, our findings may suggest a non-canonical function for FZD6. Indeed, the 
knock down of FZD6 strongly supressed the invasion of all the breast cancer 
cell lines tested, with the exception of the MDA-MB-436 cell line which does not 
express membranous FZD6 (fig. 4.8 and 4.9). These results might help to 
explain why patients bearing tumours expressing high level of FZD6 have a 
higher chance to incur into metastatic relapse. Other frizzled receptors were 
previously linked to metastasis. For example, FZD7 and FZD5 play a role in the 
proliferation and invasion of colon, breast, and melanoma cancer cells, 
respectively (Yang et al., 2011; Ueno et al., 2008; Weeraratna et al., 2002). It is 
therefore likely that FZD6 regulates breast cancer metastasis in a similar 
fashion.  
FZD6 might be important to coordinate the polarized motility of breast cancer 
cells, as suggested by the wound healing assay (fig.4.10).  Cell movements are 
necessary for the coordination of many biological functions during 
morphogenesis, tissue healing and immune response (Ananthakrishnan and 
Ehrlicher, 2007). During morphogenesis, the WNT/planar cell polarity plays an 
important role in the regulation of embryonic cells polarized movements. This is 
a well conserved mechanism that was observed in the organogenesis of 
drosophila, caenorhabditis elegans and in vertebrates (Seifert and Mlodzik, 
2007). Aberrant activation of these signals, normally active solely during 
morphogenesis, was also reported in cancer (Wang, 2009). Despite the 
canonical pathway has been an object of more studies, the PCP pathway has 
emerged as an important component of cancer development and progression 
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(Kaucka et al., 2013; Luga and Wrana, 2013). Recently, Luga and colleagues 
showed that FZD6 co-localise with PCP components in breast cancer cell 
protrusions during cell locomotion (Luga et al., 2012). It is thus likely that the 
upregulation of FZD6 in breast cancer cells could lead to increased motility and 
invasion through the activation of the PCP pathway. A further confirmation of 
these assumptions is given by studies on the nervous system. FZD6 is required 
for correct convergent cell extension during neurulation and its abrogation or 
mutation results in neural tube and midbrain morphogenetic defects in mice (De 
Marco et al., 2012; Stuebner et al., 2010; Wang et al., 2006). Thus, we could 
hypothesize that FZD6 mediates the polarized extension movement of breast 
cancer cells during the metastatic process activating similar signalling 
pathways.  
The role of FZD6 in regulating invasion is further suggested by 3D culture 
experiments. Non-transformed breast epithelial cells, growing in a 3D 
extracellular matrix, form normal and structurally organized acini. Malignant 
cells instead, form irregular organoids that lack tissue polarity (Petersen et al., 
1992). The architecture of breast cells in a 3d matrix influences cellular 
behaviour. For example, the disruption of the three dimensional organization 
with the ectopic expression of a dominant RAC mutant (RAC is an important 
member of the PCP signalling), results in increased VEGF secretion and cell 
migration of breast cancer cells (Chen et al., 2009). Highly malignant MDA-MB-
231 cells form “stellate” structures with disorganized nuclei and elongated 
invasive processes (Kenny et al., 2007). The depletion of FZD6 in these cells 
resulted in the formation of more regular acini, similar to the ones formed by 
non-malignant breast cells (fig.4.11). Furthermore, FZD6 depletion caused the 
reduction of elongated invasive protrusion branching from the acini’s central 
bulk. These results suggest that the overexpression of FZD6 in breast cancer 
cells could disrupt tissue architecture and promote invasion.  
All together these findings underline the importance of FZD6 in promoting 
breast cancer cells invasion and motility and its role in the maintenance of 
tissue polarity.   
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CHAPTER V 
 
Assessment of the role of FZD6 in the in vivo 
growth of breast cancer cells 
 
5.1 Introduction 
 
To understand the role of FZD6 in tumour growth and metastatic spread, we 
carried out orthotopic transplantations of MDA-MB-231 cells, with or without 
FZD6 expression, in immunodeficient mice. MDA-MB-231 cells are highly 
tumorigenic when injected into immunodeficient mice and are commonly used 
to model breast cancer metastasis in vivo. Mice used in the study belong to the 
strain NOD-SCID-γ (NSG). These animals bear mutations that result in the 
complete loss of immunity, allowing xenotransplantation of human cells. The 
first is a mutation of the PRKDC gene, commonly known as Prkdcscid, a loss of 
function mutation that results in the disruption of adaptive immunity by 
drastically reducing the number of mature B and T cells (Greiner, Hesselton and 
Shultz, 1998). The second is the Il2rgtm1Wjl mutation, which affects the gene 
encoding the interleukin 2 receptor gamma chain, resulting in the arrest of the 
differentiation of natural killer cells (Willerford et al., 1995).  
The in vivo transplantation and the analysis of tumour tissue sections were 
carried out by our collaborators Dr Manuela Iezzi and Dr Alessia Lamolinara at 
the Aging Research Center, G. D’Annunzio University, Chieti, Italy. 
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5.2 FZD6 depletion does not affect the growth of MDA-
MB-231 primary tumours 
 
 
Figure 5.1: Orthotopic xenotransplantation of MB-MDA-231 cells with or 
without Fzd6 expression in NSG mice. MB-MDA-231 cells infected with a lentivirus 
containing a FZD6 (Sh1) or control shRNA (scrambled) were injected into the fat pad of 
immunocompromised NSG mice. Growth of the primary tumour was measured two times per 
week using callipers. Error bars indicate standard errors. 10 mice per group were used in this 
study. This experiment was carried out by our collaborators Dr Manuela Iezzi and Dr Alessia 
Lamolinara at the Aging Research Centre, G. D’Annunzio University, Chieti, Italy. 
 
Mice were divided in two groups: 10 mice were injected with MDA-MB-231 cells 
infected with the control shRNA. A second cohort of 10 mice was injected with 
FZD6 depleted MDA-MB-231 cells. Despite the growth of FZD6 negative cells 
was slightly delayed in comparison to control cells, at the end of the experiment 
the size of the primary tumour masses was similar in the two groups (fig.5.2).  
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5.3 FZD6 depletion inhibits the invasion of breast 
cancer cells to the bone, liver and the heart of mice 
 
Mice were sacrificed after 96 days from tumour cells injection or when tumour 
size reached the volume of 0.3 cm3. The organs were harvested, fixed and 
embedded in paraffin. Histological sections were stained with haematoxylin 
/eosin and analysed by two pathologists independently.  
The number of mice bearing metastases is plotted in figure 5.3. Tumour 
metastases were detected in lymph nodes, kidneys, pancreas, heart, bones, 
lungs and liver, but not in brain, stomach and intestine (figure 5.4 and 5.5).  
 
Figure 5.2: Metastatic occurrence in NSG mice injected with MDA-MB-231 
cells, with or without FZD6 expression. The graph shows the number of mice with 
breast cancer metastasis in specific organs, as determined after histological analysis. This 
experiment was carried out by our collaborators Dr Manuela Iezzi and Dr Alessia Lamolinara at 
the Aging Research Centre, G. D’Annunzio University, Chieti, Italy. 
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Depletion of FZD6 only marginally changed the frequency of metastasis in the 
lymph nodes, kidneys, pancreas, lungs and liver compared to the FZD6 
proficient counterparts. However, FZD6 negative cells were less prone to 
invade the heart (Scrambled group = 6/10 mice, Sh1 FZD6 group 2/10 mice) 
and bones (Scrambled group 8/10, sh1 group 3/10). 
 
 
Figure 5.3: Representative photographs of MDA-MB-231 tumours in NSG mice: 
Breast cancer tumour cells are easily identifiable, since the lentiviral construct used to infect 
cells also express GFP.  
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Figure 5.4: haematoxylin-eosins staining of representative organ sections 
showing metastatic dissemination of MDA-MB-231 cells. Tissue sections were 
prepared and stained by our collaborators Dr Manuela Iezzi and Dr Alessia 
Lamolinara at the Aging Research Centre, G. D’Annunzio University, Chieti, Italy.  
To quantify microscopic metastases, lungs and livers were cut into thin 
sections. A semiquantitative evaluation based on the number and size of 
metastases was carried out (Table 5.1). 
In the lungs, metastases were similar in number and shape in the two groups, 
whereas in the liver, metastases originated from FZD6 positive cells where 
bigger and more numerous compared with the FZD6 negative counterparts 
(metastatic score scrambled: 27, metastatic score sh1 FZD6: 13).  
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Table 5.1: Metastatic score in lungs and liver of NGS mice injected with MDA-MB-231 
cells with or without FZD6. A semiquantitative evaluation was performed on organs sections, 
attributing to each sample a value from 0 to 4, based on the number and size of metastases; 0 
was assigned to mice without metastases; 1 was attributed to organs with few small 
metastases, 4 to organs with numerous large metastases. Asterisk indicates statistical 
significance, p=0.0265, (student t-test, n=10). This experiment was carried out by our 
collaborators Dr Manuela Iezzi and Dr Alessia Lamolinara at the Aging Research Centre, G. 
D’Annunzio University, Chieti, Italy. 
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5.4 Discussion 
 
The results described in this chapter are in agreement with the in vitro studies, 
further suggesting a role for FZD6 in breast cancer metastasis. FZD6 is largely 
dispensable for breast cancer cell proliferation in vivo, but is important to drive 
the metastatic spread of breast cancer cells to the bone, liver and heart of mice.   
Cancer cells acquire a metastatic phenotype in a complex multistep process 
that involves modification of a number of signalling pathways. The first step in 
this process is the loss of the molecular bonds that keep cells together, such as 
cell adhesion molecules (CAM) and cadherins (Cavallaro and Christofori, 2004; 
Edelman and Crossin, 1991). In order to migrate, metastatic cells need to 
promote dynamic interaction with the extracellular matrix (ECM). In this process, 
the receptors for the integrins play a key role (Desgrosellier and Cheresh, 
2010). Metastatic cells also require the secretion of proteases to open a way 
through the stroma (Koblinski, Ahram and Sloane, 2000) and reach blood or 
lymph vessels. The most common way of dissemination of cancer cells is 
through the blood stream. Metastatic cells are capable to traverse the blood 
vessels in a process called intravasation (Wyckoff et al., 2000). An alternative 
transportation way is through the lymph vessels. The inverse process, the 
extravasation, allows metastatic cells to get from the blood stream to distant 
organs, where eventually, they can initiate new tumour colonies (Chambers, 
Groom and MacDonald, 2002). The capability of malignant cells to form 
metastases largely depends on the characteristics of the microenvironment that 
harbour these cells in the host organ (often referred as metastatic niche), 
according to the “seed and soil” model described for the first time by Paget 
(Paget, 1889). The metastatic niche could also be induced by the primary 
tumour through the secretion of growth factors, which in turn, lead to 
biochemical changes in distal organs. These changes could result in a receptive 
microenvironment defined as a “pre-metastatic niche”, which promotes the 
migration and spread of metastatic cells at these sites (Psaila and Lyden, 
2009).  
 It is a widely held view that cancer stem cells are crucial in the malignant 
progression of tumours (Li et al., 2006). Cancer stem cells are characterized by 
a mesenchymal, motile phenotype, therefore are likely candidates to promote 
cancer metastasis (Mani et al., 2008). Although a lot of progresses have been 
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made to uncover the molecular basis of cancer metastasis, it is still unclear how 
certain tumours have privileged sites of metastatization. For example, breast 
and prostate cancer often metastasise in the bones. This selectivity cannot be 
explained merely by the anatomical disposition of the blood vessels draining the 
primary tumours, but implies the existence of biological processes that promote 
the specific engraftment to these organs (Nicolson, 1988). The WNT pathway 
has a pivotal role in controlling cancer stem cells maintenance and self-renewal, 
through both autocrine and paracrine signals (Reya and Clevers, 2005). It is 
thus possible that tissue specific WNT signals are required for harbouring 
cancer stem cells migrating from a primary tumour to a metastatic site. The 
tissue specific expression of WNT proteins could thus explain the selective 
organotropism of certain tumours.  
The metastatic niche is maintained also through the recruitment of stromal cells 
such as macrophages and fibroblasts that intimately interact with cancer cells 
(Mantovani and Sica, 2010; Kalluri and Zeisberg, 2006; Pollard, 2004). Since 
these cells have a different morphology and secrete different growth factors 
depending on the tissue of origin (Baum and Duffy, 2011), it is likely that they 
also play a role in the organ-specific tropism of cancer cells. The WNT pathway 
is important in the communication between cancer cells and stromal cells. For 
instance, it has been shown that mammary murine fibroblasts secrete WNT-1 to 
promote breast tumorigenesis in mice (Jue et al., 1992). Furthermore, human 
mammary fibroblasts release exosomes that stimulate breast cancer cells to 
produce WNT11 that in turn promotes cell motility through the PCP pathway 
(Luga et al., 2012). Mammary fibroblasts also have a role in promoting a pre-
metastatic niche: Melanchi and colleagues showed that mouse mammary 
cancer cells stimulate fibroblasts to produce periostin, a component of the 
extracellular matrix, in the lungs. Periostin in turn, recruits WNT signals that are 
essential for maintenance of cancer stem cells colonizing to the lungs. Block of 
Periostin prevents lungs metastasis in mice (Malanchi et al., 2012). 
Macrophages might also be important in defining the organ colonization of 
metastatic cells by releasing tissue specific factors (Stout and Suttles, 2004). 
Macrophages are involved in all the limiting steps of cancer metastasis, 
including the generation of the metastatic niche. Their role in tumorigenesis is, 
at least in part, controlled by the secretion of WNT ligands. It is therefore 
possible that macrophages could be important in controlling the WNT signals 
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that are responsible for the homing of metastases in secondary site (Qian and 
Pollard, 2010; Oguma et al., 2008; Pukrop et al., 2006). 
The selective organotropism of cancer metastasis is well documented for the 
bones, since this is the elected site of metastasis for two of the most common 
tumours, prostate and breast cancer (Bubendorf et al., 2000; Coleman and 
Rubens, 1987). The Bone is mainly structured in a hard calcified matrix, 
therefore early events should occur to degrade this matrix (osteolysis) and 
make it receptive to harbour cancer cells. Furthermore, release of growth 
factors trapped within the bone matrix could be important survival signals for the 
colonization of metastatic cells (Yoneda and Hiraga, 2005). The WNT pathway 
is essential for bone development and bone remodelling from early to adult life 
(Macsai, Foster and Xian, 2008). Indeed, DKK1 or sFRP-1 knock-out mice, two 
endogenous WNT inhibitors, have severe bone development deficiency (Hall 
and Keller, 2006). The knock down of LRP5, which is a frizzled co-receptor, 
leads to low bone mass, deformities, and fractures.  Not surprisingly, the WNT 
pathway also mediates molecular events that are important for the metastatic 
spread of certain cancers to the bones. For example, in mice models of prostate 
cancer metastasis, Dickkopf-1 (DKK-1), which antagonizes WNT activity, is 
secreted by prostate cancer cells in early stage to promote osteolysis and 
colonization in the bone. As metastases progress, DKK1 is downregulated and 
this results in abnormal production of bone tissue (osteoblastic metastasis) 
through the inhibition of the WNT pathway (Hall et al., 2005). This would 
suggests that cross talk of cancer cells with the metastatic niche through the 
WNT pathway could be, at least in part, responsible for the organ selectivity of 
pancreatic cells. The WNT inhibitor DKK-1 could be also involved in the 
organotropism of multiple myeloma metastases, where its overexpression has 
been linked to the onset osteolytic lesions (Tian et al., 2003). In breast cancer 
numerous secreted factors are known to enhance tropism of cancer cells to the 
bones, although the mechanisms are still largely unknown. It is a widely held 
view that osteoclasts and osteoblasts, that respectively digest and produce new 
bone tissue, play an important part in the onset of breast cancer bone 
metastases. Indeed, it has been reported that breast cancer cells can alter the 
balance between the activity of osteoblasts and osteoclast, leading to osteolytic 
and, less frequently, osteoblastic lesions (Yoneda and Hiraga, 2005). It has 
been proposed that breast cancer cells mimic in the bones what happens during 
lactation. Normal mammary cells release the parathyroid hormone-related 
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protein (PTHrP) that stimulates osteoclasts, resulting in bone resorption and 
calcium release. This is a physiological process aimed to the enrichment of 
calcium in the milk. Breast cancer cells use the same mechanism to digest the 
bone matrix and create docking sites to colonize these organs (Lu and Kang, 
2007). PTHrP also regulates the epithelial and mesenchymal expression of 
LEF1 and β catenin during breast development, suggesting a cross talk with the 
WNT pathway (Foley et al., 2001). Moreover, it has been shown that PTHrp and 
WNT pathway cross talk to regulate endochondral bone development (Guo et 
al., 2009). As previously mentioned, osteolysis results in the release of 
numerous growth factors from the bone matrix. This in turn stimulates cancer 
cell growth and the release of new bone metastasis factors, creating a vicious 
loop. Amongst these factors are IGFs, TGFβ, PDGF and BMP, which all 
activate pathways that have been shown to interact with the WNT signalling 
(Reis et al., 2012; Kamiya et al., 2008; Nakashima, Katagiri and Tamura, 2005; 
Richard-Parpaillon et al., 2002; Nishita et al., 2000; Coleman and Rubens, 
1987). It is thus likely that the WNT pathway plays an important role in the 
organotropism of breast cancer cells to the bone.  
In our model, the ablation of FZD6 resulted in the reduced engraftment of breast 
cancer cells to the bone, the heart and the liver of immunodeficient mice. 
Although we demonstrated that FZD6 knock down leads to a reduction of 
motility and invasion in vitro, cells with the downregulation of FZD6 are still able 
to metastasise efficiently in lungs and other organs. Preliminary analysis on 
lung tissue sections suggests that Fzd6 expression could have been re-
activated in metastases originating from cells infected with the FZD6 shRNA 
targeting retrovirus, probably due to the absence of selective pressure (data not 
shown). However, since the knock down of FZD6 did not lead to a general 
reduction of metastasis, but resulted in an organ specific reduction, the 
decreased invasion and motility alone are not sufficient to justify this effect. A 
possible explanation could be that the different WNT signalling landscapes 
present in different organs contribute to create a selective metastatic niche. 
Thus, it is possible that the knock down of FZD6 could reduce the interactions 
between cancer cells and their niche in specific organs, reducing the intensity of 
survival signals necessary for a successful colonization.  FZD6 might be also 
relevant in mediating the interaction between cancer cells and macrophages 
and/or fibroblasts in a tissue dependent manner, since these stromal cells are 
able to secrete WNT ligands and to stimulate cancer cell to release WNTs. 
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However, further experiments are necessary to elucidate the role of FZD6 in the 
selective organotropism of breast cancer.  
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CHAPTER VI 
 
Assessment of the signalling pathways regulated 
by FZD6 in breast cancer cells 
 
6.1 Introduction 
 
In the previous chapters I have demonstrated the involvement of FZD6 in the 
modulation of cell invasion and migration in breast cancer. To further these 
findings, we investigated which signalling pathways are activated by FZD6 
using a loss of function approach.  
Deregulation of EGF signalling is observed in the majority of solid cancers, 
contributing to tumorigenesis (Woodburn, 1999). One of the effectors of the 
EGF receptor (EGFR) is PLC-γ1, which mediates downstream signals that 
regulate cell motility and cancer progression (Chen et al., 1994). EGFR also 
mediates the activation of AKT through the PI3K signalling cascade. The AKT 
pathway has a crucial role in survival, proliferation and motility of cancer cells 
(Vivanco and Sawyers, 2002; Kim et al., 2001). Two other important effectors 
downstream EGFR are the Extracellular-signal Regulated kinases 1 and 2 (ERK 
1 and 2) which belong to the family of the MAP kinases. They also have been 
implicated in processes like cell proliferation, differentiation and cell invasion in 
breast cancer (Jorissen et al., 2003; Krueger et al., 2001). Several researches 
have previously reported interactions between EGFR and WNT signalling (Hu 
and Li, 2010). For instance, Schroeder et al. found that EGFR and β-catenin 
form heterodimers in breast tumours growing in mice, demonstrating for the first 
time, a direct interaction between the two pathways (Schroeder et al., 2002). 
Moreover, ectopic expression of WNT5a and WNT-1 activates ERK 1/2 and 
EGFR in mammary cells (Civenni, Holbro and Hynes, 2003). Therefore, we 
investigated whether FZD6 could have a role in mediating the activation of 
EGFR in breast cancer.  
We also assessed the expression of markers of the Epithelial to Mesenchymal 
Transition (EMT). EMT is defined as the process by which epithelial cells 
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acquire a mesenchymal phenotype, i.e. become motile, are able to invade in the 
surrounding tissue, acquire resistance to apoptosis and are able to produce 
extracellular matrix components (Kalluri and Weinberg, 2009). The WNT 
pathway participates in the activation of the EMT program in cancer (Vincan 
and Barker, 2008), suggesting that frizzled receptors could be involved in this 
process. Vimentin belongs to the family of intermediate filaments and 
participates to the organization of the cytoskeleton. This protein is generally not 
expressed in epithelial cells, but it is present primarily in cells of mesenchymal 
origin. For this reason vimentin is also widely considered a marker of EMT in 
cancer. In breast cancer, vimentin expression is associated with an aggressive 
phenotype and poor prognosis and is relevant in the coordination of cell 
invasion (Vuoriluoto et al., 2010). Loss of cell-cell adhesion is a fundamental 
step that confers to cells the capacity to migrate from the native epithelium and 
it is characteristic of cells that underwent EMT. E-Cadherin is one of the 
proteins that are essential to regulate cell-cell adhesion, and its loss is 
frequently observed in invasive breast carcinomas (Lombaerts et al., 2006; 
Cano et al., 2000). Fibronectin is a glycoprotein widely expressed in connective 
tissue, where it forms fibrillar structures which are essential components of the 
extracellular matrix. Fibronectin is implicated in a plethora of cell functions, such 
as cell adhesion, growth, migration, and differentiation (Pearlstein, Gold and 
Garcia-Pardo, 1980). In Breast cancer fibronectin is often found overexpressed 
and it enhances tumorigenesis through various mechanisms, including the 
activation of EMT (Park and Schwarzbauer, 2013).  
In the following chapter I present a series of experiments aiming to elucidate the 
role of FZD6 in the regulation of signalling pathways and molecules described 
above. 
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6.2 FZD6 signalling is not involved in the regulation of 
AKT, PLC-γ and ERK 1/2 
 
Figure 6.1: EGFR receptor pathway analysis on MDA-MB-231 cells expressing 
control shRNA (Scrambled) or FZD6 shRNAs (Sh1 and Sh2). Cells were starved 
overnight and then exposed for the indicated time to serum free medium containing 100ng/mL 
EGF or medium containing 10% FBS. Antibodies against the phosphorylated form of PLC-γ, p-
AKT and p-ERK 1/2 were used to assess the EGFR pathway activation. C indicates untreated 
controls. Total PLC-γ1, total AKT and total ERK 1/2 were used as loading controls. 
144 
 
To assess whether FZD6 mediates a crosstalk between EGFR and WNT 
pathways, we assessed the activation of PLC-γ1, AKT and ERK1/2 in the 
presence of control shRNA (SCR) or FZD6 shRNA (sh1 and sh2) (fig.6.1). 
In control cells, the activation of PLC-γ1 was detectable 20 minutes following 
the exposure to EGF, but became undetectable after 1 hour. Conversely, FBS 
did not activate PLC-γ1.  We observed a mild reduction in the activation of PLC 
after the exposure with EGF in Sh1 cells compared to control cells (Figure 6.1, 
bottom panel). However, we did not observe the same effect in Sh2 cells when 
compared to the control shRNA (fig. 6.1, upper panel).  
EGF induced a marked activation of AKT when administered to cells for 20 
minutes and, to a lesser extent, for 1 hour (fig. 6.1). AKT was also activated in 
the presence of FBS but only after 1 hour of exposure. However, the 
downregulation of FZD6 did not change the activation pattern of AKT (fig.6.1).  
EGF strongly activated ERk1/2 in control cells. FBS also induced the activation 
of ERK 1/2, particularly after one hour. However in cells infected with FZD6 
shRNAs ERK 1/2 activation was unperturbed compared to cells infected with 
Scramble shRNA (fig.6.1). 
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6.3 FZD6 signalling does not regulate the expression of 
the EMT markers vimentin and E-cadherin 
 
Figure 6.2: Western blot analysis of EMT markers in MDA-MB-231 breast 
cancer cells expressing control shRNA (SCR) or FZD6 shRNAs (Sh1 and Sh2). 
Cells were starved overnight and exposed to the indicated ligands for the indicated times (A) 
Expression of E-Cadherin and Vimentin after 1 hour exposure with the indicated WNT ligands or 
FBS, or after 20 minutes exposure to EGF. (B) Expression of Vimentin after 12h exposure to 
the indicated WNTs or to FBS. β-actin was used to control on samples loading.  
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To assess whether FZD6 is involved in the regulation of EMT, we analysed the 
expression of EMT markers in in MDA-MB-231 breast cancer cells. This cell line 
expresses the mesenchymal markers vimentin and fibronectin, but does not 
express E-Cadherin (Blick et al., 2008). Moreover, we studied whether the 
administration of exogenous WNT ligands, FBS or EGF, was able to influence 
the expression of EMT markers. Cells were starved overnight and treated with 
WNT ligands, FBS or EGF for the indicated times (fig. 6.2), then subjected to 
western blot analysis. 
The addition of  WNTs ligands, FBS or EGF did not result in any significant 
changes in the expression of vimentin or E-cadherin, both in cells expressing 
FZD6 and in FZD6 depleted cells (figure 6.2 A and B). 
 
Figure 6.3: EMT markers expression in MDA-MB-231 cells expressing control 
shRNA (SCR) or FZD6 shRNAs (Sh1 and sh2) growing in presence of serum at 
different confluency levels.  Cells were lysed at about 50% and 100% confluency and 
subjected to western blot analysis for the expression of vimentin (A) or E-Cadherin (B). MCF7 
were used as a positive control for E-Cadherin. 
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To assess whether the expression of these markers is dependent on the 
number of cells and/or on cell-cell interactions, the expression of vimentin and 
E-cadherin was analysed in cells growing in complete medium and lysed at low 
confluency (approximately 50%) or at high confluency (approximately 100 %) 
(fig. 6.3). We found that Vimentin and E-Cadherin did not change in different 
conditions.  
 
6.4 FZD6 signalling regulates fibronectin matrix 
deposition, but not the secretion of soluble fibronectin 
 
Fibronectin is a well established marker of EMT and enhances adhesion and 
motility of cancer cells (Park and Schwarzbauer, 2013; Friedl and Alexander, 
2011). Therefore, we assessed fibronectin matrix deposition in MDA-MB-231 
cells in the presence or absence of FZD6, using indirect immunofluorescence. 
The depletion of FZD6 with two shRNA (sh1 and sh2) resulted in a significant 
reduction of the fibronectin immunostaining in MDA-MB-231 cells (fig. 6.4). 
In collaboration with Michele Sallese and Giorgia Fragassi at the Fondazione 
Mario Negri Sud, S.Maria Imbaro, Italy, we also analysed the structure of the 
fibronectin matrix assembly using confocal microscopy (fig.6.5). We found that 
MDA-MB-231cells expressing FZD6 have a more dispersed and homogenous 
distribution of fibronectin, whereas, in cells where FZD6 expression was 
abrogated, fibronectin was distributed more in perinuclear blobs and less 
dispersed in the cytoplasm (figure 6.5 A). Cells showing fibronectin aggregates 
were counted and plotted in figure 6.5 B. The knock down of FZD6 resulted in a 
20% increment of in the formation of perinuclear fibronectin blobs.       
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Figure 6.4: Immunofluorescence analysis of the fibronectin matrix in FZD6 
depleted MDA-MB-231 cell lines. (A) Images showing expression of fibronectin (red 
colour) in the control (scrambled) or FZD6 depleted (Sh1, Sh2) cell lines. Nuclei were stained 
using DAPI (blue colour). (B) Quantification of the experiment shown in A.  The fibronectin 
fluorescence relative to DAPI was quantified using imaging software in at least ten random 
fields per sample.  Error bars indicate standard errors and the asterisk statistical significance 
(student’s t-test, n=10). The data shown is representative of two independent experiments. 
Scale bars indicate a length of 100μm. 
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Figure 6.5: Deposition of fibronectin in dependence to FZD6 expression  
assessed by confocal microscopy. Two phenotypes were noted, dispersed in control 
cells, dots/blobs in the absence of FZD6 expression. (A) Representative photographs showing 
the organization of fibronectin in MDA-MB-231 cells expressing control shRNA or sh1 FZD6. (B) 
Percentage quantification of cells presenting blobs aggregates of fibronectin in the cells 
described in A. Data are expressed as % of total, as means ±SEM of three independent 
experiments, with at least 100 cells quantified per experiment. *** indicates p<0.001 compared 
to control cells (student’s t-test). Scale bars indicate 10μm. This experiment was carried out by 
our collaborators Michele Sallese and Giorgia Fragassi at Fondazione Mario Negri Sud, S.Maria 
Imbaro, Italy. 
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Fibronectin exists also in a soluble form that cells release in the culture media 
(Proctor, 1987). We next assessed the expression of soluble fibronectin in cell 
culture supernatants using an ELISA assay. We found that the secretion of 
fibronectin was unchanged after the knockdown of FZD6 (fig. 6.6).   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
 
 
Figure 6.6: ELISA for the detection of soluble fibronectin secreted by MDA-MB-
231 cells expressing control shRNA (Scrambled) or FZD6 shRNAs (sh1 and 
sh2). (A) Soluble fibronectin in the culture media was quantified through indirect ELISA 72 
hours following serum starvation (B). The cells used for the assay described in A were lysed in 
Laemmli buffer and subjected to western blot analysis to confirm a similar number of cells 
amongst the samples. Three wells per cell line were used and are indicated as 1 2 and 3.  The 
data is representative of one experiment carried out in triplicate. 
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6.5 FZD6 mediates a non-canonical signal in breast 
cancer cells 
 
To assess if FZD6 mediates a β-catenin dependent (canonical) signal or β-
catenin independent (non canonical) signal, we performed western blot analysis 
of MDA-MB-231 expressing control or FZD6 shRNA using an antibody 
recognising active β-catenin or anti phospho c-Jun N-terminal kinase (p-JNK) 
following the activation with WNT ligands (Fig.6.7).  
 
 
Figure 6.7: Assessment of the WNT canonical and WNT/JNK non-canonical 
pathways in MDA-MB-231 breast cancer cells in the presence (Scrambled) or 
absence (Sh1) of Fzd6 expression. Phospho-SAP/JNK or active β-catenin antibodies 
were used to monitor the non-canonical or canonical WNT pathways in the presence of the 
indicated WNT conditioned media. Cells were starved overnight and exposed to conditioned 
media produced by L-control cells or L-cells expressing WNT3a or WNT5a (diluted 1:10) for two 
hours and then subjected to western blot analysis. β-actin was used to control on proteins 
loading. Lysates of HEK 293 FT cells exposed to UV light were used as a p-JNK positive 
control. The blot shown is representative of at least three independent experiments. 
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FZD6 knock down did not influence the activation of β-catenin. With these 
experimental settings, we could not detect an activation of p-SAP/JNK.  
We next explored the activation of another non-canonical effector, the small 
GTPase Rho (Fig.6.8). The recombinant protein Rhotekin conjugated with GST 
was used as a bait protein for its capacity to bind selectively the active form 
Rho-GTP, but not the inactive form Rho-GDP. A glutathione resin was used to 
isolate the complex Rhotekin-GST-Rho-GTP. A preliminary experiment was 
carried out on cells activated with different recombinant WNTs, but since no 
differences were observed in comparison with the controls (data not shown), 
cells were analysed only in basal conditions. A substantial decrease of active 
Rho was observed in MDA-MB-231 cells in the presence of two different 
shRNAs, sh1 (52% decrease) and sh2 (32% decrease). 
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Figure 6.8: Pull down assay for the quantification of Rho-GTP in MDA-MB-231 
cells expressing control shRNA (SCR) or shRNAs targeting FZD6 (Sh1 and 
Sh2). (A) Representative western blot analysis for the quantification of active Rho-GTP in 
MDA-MB-231 cells in the presence of the indicated shRNAs. A Pull down assay was carried out 
to isolate the active form of Rho bound to GTP. One tenth of the total lysate was excluded from 
the pull down procedure and subjected to a separate western blot analysis to confirm equal 
loading. Active Rho-GTP or total Rho were detected with an anti-Rho antibody and a HRP 
conjugated secondary antibody. A FZD6 antibody was used to demonstrate the knock down of 
FZD6. (B) Densitometric quantification of active Rho-GTP normalized to total Rho and 
expressed as percentage of the control (Scrambled). The data shown is the average of three 
independent experiments. Asterisks indicate statistical significance (student t-test). 
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6.6 Discussion 
 
Activated β-catenin is usually not detectable in healthy mammary tissue, 
whereas it is in breast tumours (Howe and Brown, 2004). Our results indicate 
that constitutively active canonical WNT signalling is detectable in the MDA-MB-
231 cell line, consistent with what found by other investigators (Bilir, Kucuk and 
Moreno, 2013; Benhaj, Akcali and Ozturk, 2006). The knock down of FZD6 did 
not result in a reduction of the levels of activated β-catenin, suggesting a non-
canonical role of the receptor (fig.6.7).  
In humans there are 10 different frizzled receptors and it is possible that each 
one mediates a specific signalling, although a certain level of redundancy might 
also occur. Furthermore, 19 different WNT ligands have been found in humans, 
but their affinity for specific FZD receptors and the intracellular signals are still 
poorly characterized. WNT ligands could have different effects depending on 
the biological contest; for example it was reported that WNT5a can activate both 
canonical and non canonical pathways, depending on the expression of specific 
frizzled receptors (Mikels and Nusse, 2006). The overexpression of WNT 
ligands could have oncogenic or oncosupressing effects, depending on the 
cancer type. Even within the same tumour, WNTs overexpression can have 
different effects (Anastas and Moon, 2012). It is therefore extremely 
complicated to define the role of WNT signalling outside a very specific context.  
We found that the downregulation of FZD6 results in reduced activation of the 
small GTPase Rho (figure 6.8). Rho is a key regulator of the actin cytoskeleton, 
required for numerous biological processes during development and adult life. 
An important function of Rho is to regulate the cytoskeleton contractility that 
leads to cell movement (Hall, 1998). Moreover, Rho is activated by the 
WNT/FZD signalling to coordinate cell polarity required for the frog gastrulation 
(Habas, Kato and He, 2001). The first evidence of the involvement of Rho in 
tissue polarity derives from studies in drosophila mutants, which exhibit defects 
in the spatial orientation of omatidia in the eyes, defective organization of the 
hairs in the wings and present morphological defects of the embryos (Strutt, 
Weber and Mlodzik, 1997). Interestingly similar phenotypes are observed in 
frizzled and dishevelled mutants, suggesting that frizzled receptor and 
dishevelled could be upstream elements from Rho signal (Strutt, Weber and 
Mlodzik, 1997). FDZ6 KO mice present spatial asymmetry in the organization of 
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hair follicles and brain morphogenic abnormalities (De Marco et al., 2012; 
Stuebner et al., 2010; Wang et al., 2006a) which recall the disorganized 
orientation of drosophila omatidia and hair wings, and the embryonic defects 
observed in drosophila FZD and Rho mutants. These findings further suggest 
that FZD6 mediates a PCP signal through the activation of Rho.  
In breast cancer, the over-activation of Rho in cells overexpressing FZD6 could 
also explain the increased motility and invasion. Rho and other member of the 
small GTPases family have a fundamental role in the cytoskeleton 
rearrangements that occur during cell locomotion (Nobes and Hall, 1999) . Rho 
regulates the actin-myosin interaction that generates the contractile force 
necessary for cell protrusion (Yee Jr, Melton and Tran, 2001) and the 
generation of focal adhesions with the ECM (Chrzanowska-Wodnicka and 
Burridge, 1996). Given the role of Rho GTPase in cell motility, it is reasonable 
to think of a role in cancer invasion and metastasis. Indeed, several studies 
linked the activation of Rho in all the stages of metastasis. For example, Itoh 
and colleagues demonstrated that the expression of an active dominant mutant 
of ROCK, a downstream effector of the Rho GTPase, confers a greater invasive 
activity to hepatoma cells in vivo, whereas the expression of a dominant 
negative ROCK mutant exerted the opposite effect (Itoh et al., 1999). Studies 
on leukocytes transendothelial migration have shown that RhoA is required for 
monocytes tail retraction and efficient diapedesis, suggesting a possible role of 
Rho in cancer cells extravasation (Worthylake et al., 2001). Rho is critical also 
during tumour angiogenesis. Indeed, conditional activation of ROCK in colon 
cancer cells results in more invasive and vascularized tumours, (Croft et al., 
2004; van Nieuw Amerongen et al., 2003).  
RhoA, RhoB and RhoC are often overexpressed in breast cancer (Jiang et al., 
2003; Fritz et al., 2002; van Golen et al., 2000). Experiments in MDA-MB-231 
cell line, also used in our study, revealed that knock down of RhoA and RhoC 
reduces cell proliferation, invasion and angiogenesis in vitro and in vivo (Pillé et 
al., 2005). Liu and colleagues showed that ROCK is overexpressed in 
metastatic breast cancer cell lines and tumours compared with the non 
metastatic matched tissues, and that the ectopic expression of ROCK induces 
the onset of bone and liver metastasis in mice injected with the otherwise not 
invasive MCF7 cell line (Liu et al., 2009). Interestingly, in our experiments we 
show that the knock down of FZD6 reduces breast cancer metastasis in bones 
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and liver, the same sites of metastasis of MCF7 cells expressing conditional 
ROCK. This further suggests that FZD6-mediated activation of Rho has a role in 
the tropism of breast cells.  
TGF-β-mediated loss of E-Cadherin and expression of N-Cadherin are 
abolished by the ectopic expression of a dominant negative form of RhoA in 
mammary epithelial cells, indicating a role of RhoA in the EMT and therefore in 
tumorigenesis (Bhowmick et al., 2001). In addition, Rho could also have a 
pivotal role in breast cancer angiogenesis. Indeed, the overexpression of RhoC 
in HMEC was reported to increase the expression of VEGF and other 
angiogenetic factors (van Golen et al., 2000). Inactivation of Rho signalling 
through the antagonism of FZD6 could therefore hinder several steps of the 
metastatic process.  
The MDA-MB-231 cell line presents typical characteristics of EMT transition, i.e. 
expresses fibronectin and vimentin and does not express E-cadherin (Blick et 
al., 2008; Olmeda et al., 2007). Knock down of FZD6 did not change the 
expression of Vimentin nor restored the expression of E-cadherin in MDA-MB-
231 cells, both in basal conditions and in cells stimulated with WNT3a, WNT4, 
WNT11, WNT5a, FBS or EGF, suggesting that FZD6 signalling does not 
interact with these proteins. However, we observed reduced deposition and an 
alteration of the distribution patterns of fibronectin in FZD6 depleted cells 
compared to the controls (fig. 6.4 and 6.5). Soluble fibronectin instead, was not 
regulated by FZD6 (fig. 6.6). 
Fibronectin is a large glycoprotein that participates in numerous functions that 
require dynamic interactions of the cells with the extracellular environment, such 
as cell adhesion, growth, migration, and processes like wound healing and 
embryonic development. Fibronectin exists in humans in at least 27 different 
splicing variants that can be divided in two groups: soluble fibronectins and 
insoluble fibronectins. Fibronectins monomers contain 6 domains that allow the 
binding with other components of the extracellular matrix, such as fibrin, heparin 
sulphate, collagen, proteoglycans and other fibronectin molecules. Fibronectin 
also interacts with a class of membrane receptors called integrins. Cells secrete 
fibronectin in form of soluble dimers held together by disulphide bonds. With 
mechanisms that are not yet fully understood, cells can promote the formation 
of an insoluble network of fibrillar fibronectin, most probably through the 
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activation of the integrins receptors (Mosher, 2012; Plopper, 2012; Pankov and 
Yamada, 2002).  
Increased expression of fibronectin has been observed in breast cancer and 
associated with poor prognosis (Helleman et al., 2008; Ioachim et al., 2002), 
suggesting a potential role of fibronectin in breast cancer tumorigenesis. 
Fibronectin could promote tumorigenesis in different ways. The primary 
mechanism could be by providing to malignant cells adhesion to the ECM to 
generate mechanical forces (Ruoslahti, 1984). Stimulation of cells with 
fibronectin has been shown to increase cell spreading and motility in a variety of 
systems (McCarthy, Hagen and Furcht, 1986; Schor, Schor and Bazill, 1981). In 
the MDA-MB-231 breast cancer cell line the interaction with fibronectin coated 
plates enhances cell spreading end lamellar protrusions, with recruitment of 
myosin IIA and IIB to the marginal lamellar zone, indicating the activation of a 
motile phenotype (Betapudi, Licate and Egelhoff, 2006). Fibronectin promotes 
cell motility both in its soluble form (chemotaxis) and when is bound to the ECM 
in insoluble form (haptotaxis) (Klominek, Robert and Sundqvist, 1993; 
Aznavoorian et al., 1990). Although the culture of cells in a fibronectin substrate 
often results in enhanced motility, excessive adhesion to a fibronectin substrate 
might lead to the opposite effect. For example, the fibronectin matrix has been 
shown to inhibit dispersal and invasion of glioblastoma cells in vitro (Jia et al., 
2012; Sabari et al., 2011). Cell motility is a complex multistep process in which 
adhesion and detachment with the ECM have to be dynamically modulated. 
Different classes of integrins participate to this process and their cell-specific 
differential expression could explain the variable interaction of cancer cells with 
fibronectin (Akiyama, Olden and Yamada, 1995). The role of fibronectin in cell 
invasion was demonstrated in vivo using synthetic peptides that inhibit the 
interaction between fibronectin and integrins. Melanoma and glioblastoma cells, 
exposed to these peptides, penetrate much less trough human amniotic 
basement membranes when compared to cells exposed to control peptides 
(Gehlsen et al., 1988). Moreover, co-injection of B16-F10 murine melanoma 
cells with the pentapeptide containing the motive Gly-Arg-Gly-Asp-Ser, which 
competitively inhibits the binding of cells to fibronectin, prevents lung metastasis 
and greatly increases survival in mice (Humphries, Yamada and Olden, 1988). 
One possible mechanism through which fibronectin could promote cancer 
metastasis is by increasing the expression of matrix metalloproteinases which 
are required by cancer cells to invade through tissues. It has been shown that 
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exogenous addiction of fibronectin to cultures of breast cancer cells enhances 
the expression of metalloproteinases such as MMP-2 and MMP-9 through the 
activation of α5β1 integrin signalling (Das et al., 2008). MMP-9 expression was 
also induced in the culture of human breast cancer cell line MDA-MB-231 
growing on fibronectin-coated surface (Maity et al., 2011). Consistently with 
these findings, Saad and colleagues demonstrated that the membrane-bound 
fibronectin on MDA-MB-231 cells is required to stimulate the release of MMP-2 
by bone marrow fibroblasts (Saad et al., 2002). The fibronectin matrix could 
also be important for the arrest of circulating cancer cells to the endothelium of 
secondary organs, a necessary step before extravasation. This was 
demonstrated with blood-borne rat breast cancer cells, which require a 
membrane coating of fibronectin to metastasize to the lungs and was 
independently observed by different investigators (Huang et al., 2008; Felding-
Habermann, 2003; Cheng et al., 1998).  
Another possible mechanisms through which fibronectin could enhance 
tumorigenesis is by activating the EMT. Exposure of the non transformed 
mammary epithelial cell line MCF10A to fibronectin induces an EMT phenotype 
characterized by the increased mRNA expression levels of vimentin, N-
cadherin, Snail and MMP2. Exogenous fibronectin also upregulates its own 
expression in these cells and induces a migratory behaviour (Park and 
Schwarzbauer, 2013). When MCF10 cells are grown in a 3D culture system, 
addition of fibronectin results in the development of abnormal acini 
characterized by larger dimension and in a 50% reduction in the number of 
hollow acini when compared to the control cultures (Williams et al., 2008). Vice 
versa, inhibition of fibronectin with antibodies in the malignant breast cancer cell 
line T4-2 prevents the formation of irregular grape-like acini and results in the 
formation of normal spherical acini similar to the ones formed by the non 
transformed cell line MCF10 (Sandal et al., 2007). Interestingly, we observed a 
similar phenotype in MDA-MB-231 cells in which FZD6 was depleted (fig. 4.11), 
further suggesting a link between FZD6 and fibronectin matrix organization in 
breast cancer. Taken together, these findings suggest that fibronectin plays a 
pivotal role in breast cancer tumorigenesis through multiple mechanisms.  
A question still to be addressed is how FZD6 could modulate the assembly of 
the fibronectin matrix surrounding breast cancer cells. The knock down of FZD6 
did not perturb the amount of secreted fibronectin in breast cancer cells 
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supernatants (figure 6.6), whereas we observed a reduction of the insoluble 
fibronectin matrix formation and a perturbation of the distribution patterns. The 
perinuclear fibronectin blobs observed in FZD6 depleted cells might be deposits 
of soluble fibronectin that fail to be incorporated in the extracellular matrix. This 
suggests that FZD6 is implicated in the organization of the insoluble fibronectin 
matrix assembly but not in its expression and secretion. This would also be in 
agreement with a role of FZD6 in the PCP pathway. Indeed, the planar cell 
polarity pathway is required for the polarized surface assembly of the fibronectin 
matrix which is essential for the convergent extension movement during frog 
gastrulation. Perturbation of the expression of PCP components such as xfzd7 
(analogue of the human FZD7 receptor in Xenopus) or WNT11 leads to 
disruption of the fibronectin matrix assembly and consequent defects in the frog 
morphogenesis (Williams et al., 2008; Goto et al., 2005). Interestingly, ectopic 
expression of a constitutively active form or Rho in the embryos expressing a 
dominant negative form of WNT11, rescues the fibronectin matrix assembly. 
This suggests that the WNT pathway controls the fibronectin matrix through the 
activation of Rho (Dzamba et al., 2009). This is consistent with our observation 
in breast cancer, where the interference of the PCP pathway, through the knock 
down of FZD6, led to the reduction of Rho signalling and in a defective 
fibronectin matrix assembly. Fibronectin itself could regulate WNT non 
canonical signalling through the co-receptor Syndecan-4, indicating the 
existence of a positive feedback between fibronectin and the WNT pathway. 
Indeed, Syndecan-4 was shown to interact directly with xFzd7 and dishevelled 
to activate the PCP pathway in Xenopus Laevis, and the perturbation of 
Syndecan4 expression led to impairment of the convergent extension 
movement during Xenopus morphogenesis (Muñoz et al., 2006). 
The Fibronectin matrix assembly is a complex multistep process which is 
initiated by the interaction of soluble fibronectin with the α5β1 integrin receptor 
(Fogerty et al., 1990). Initially, integrins receptors contribute to organize 
fibronectin in short fibrils on the cellular surface (Mao and Schwarzbauer, 2005). 
Consequentially, integrins interact with the actin cytoskeleton to promote 
myosin mediated contractility. This in turn causes the integrin receptor to stretch 
the fibronectin fibres, exposing new binding sites for the interaction with other 
fibronectin molecules, resulting in the development of an insoluble matrix 
(Plopper, 2012; Wu et al., 1995; Hynes, 1990). In this process, Rho is 
necessary to couple the activation of the integrin receptor with the contraction of 
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the actin cytoskeleton (Huveneers and Danen, 2009). Indeed, interference of 
Rho activation prevents the fibronectin matrix assembly in mouse embryonic 
fibroblasts (Zhong et al., 1998).  
Given the role of Rho and fibronectin in cancer, we propose that overexpression 
of FZD6, through the activation of Rho, could lead to several process that 
enhance the malignant proprieties of breast cancer cells. The activation of Rho 
could directly increase cell motility, angiogenesis and promote the cytoskeletal 
retraction during intravasation/extravasation of breast cancer cells. Rho over 
activation could also lead to an increased production of fibronectin matrix, which 
in turn can promote haptotaxis, provide an adhesion substrate for breast cancer 
cells in the endothelium of host organs and induce the secretion of 
metalloproteinases. As previously mentioned, an analogy can be made between 
the directional migration of cells during development and the migratory process 
occurring during cancer metastasis. The non canonical PCP pathway and 
fibronectin matrix assembly are essential in both cases, and FZD6 could be a 
key regulatory element in these processes. 
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CHAPTER VII 
 
FZD6 and fibronectin in the regulation of the 
actin cytoskeleton  
 
7.1 Introduction 
 
Cell migration can be considered as a cycle of molecular events (Ridley et al., 
2003). Initially, cells respond to migratory stimuli by extending polarized 
protrusions towards their direction. These protrusions consist of actin-rich 
regions organized in actin ruffles and meshes called lamellipodia, and of 
filamentous actin-rich structures protruding radially called filipodia (Etienne‐
Manneville, 2004). The leading edge protrusions engage interactions with ECM 
elements such as fibronectin, providing both anchorage and intracellular signals 
through the interaction with the membrane receptors integrins (Friedl et al., 
1997). Tension inside the cell is provided by the strain of actin fibres through 
focal adhesions, which are macromolecular complexes that mediate the chemo-
mechanical interactions between the cell and the ECM (Pellegrin and Mellor, 
2007; Wozniak et al., 2004). The protrusive force is generated by the interaction 
between myosin II and actin fibres, resulting in the actomyosin contraction 
(Ridley et al., 2003). Cell contraction has to be accompanied by the gradual loss 
of adhesion at the rear of the cell, allowing the cell trail to slide forward (Friedl 
and Alexander, 2011). Actin rearrangements are therefore essential throughout 
all the steps of cell migration. Since we observed drastic differences in the 
migratory behaviour of breast cancer cells following the depletion of FZD6, we 
investigated whether this effect was mediated by actin rearrangements. 
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7.2 Downregulation of FZD6 results in actin 
cytoskeleton rearrangements in MDA-MB-231 cells 
 
To investigate whether FZD6 could influence the assembly of F-actin stress 
fibres, we analysed MDA-MB-231 cell expressing control vector or FZD6 
shRNA after staining with fluorescent phalloidin. We observed a striking 
rearrangement of F-actin in the absence of FZD6: actin fibres were much 
thicker compared to the ones observed in control cells (figure 7.1). Cells 
presenting thick actin fibres where scored as shown in figure 7.1 B. The 
downregulation of FZD6 resulted in a ~40% increase in the number of cells with 
thick actin fibres. 
Since we observed reduced fibronectin matrix assembly after the removal of 
FZD6 in MDA-MB-231 cells (figure 6.4), we wondered if exogenous addition of 
fibronectin could rescue the actin phenotype. We therefore analysed the 
structure of actin stress fibres after exposing FZD6 depleted cells to plasma 
fibronectin for 24 hours or 48 hours (figure 7.2). In the presence of exogenous 
fibronectin we observed a time dependent reduction of the number of cells 
presenting thick actin stress fibres. At 24 hours and at 48 hours the number of 
cells with thick actin fibres were respectively ~ 20% and ~ 40% less compared 
to control. After 48 hours exposure to exogenous fibronectin, FZD6 depleted 
cells presented an actin cytoskeleton indistinguishable from that observed in 
MDA-MB-231 control cells (fig.7.2).  
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Figure 7.1: The actin cytoskeleton is rearranged in the absence of Fzd6. (A) 
Assembly of F-actin fibres in control (scrambled) or FZD6 depleted MDA-MB-231cells (sh1 
FZD6) was detected by confocal microscopy using phalloidin staining. Two predominant 
phenotypes were observed: in the absence of FZD6 F-actin was organized in thick fibres, 
running throughout the cell. In contrast, in control cells F-actin fibres were thinner and 
concentrated in discrete areas in the proximity of the plasma membrane. Right bottom corners 
show in closer detail the actin patterns. Cells showing a “thick phenotype” were quantified and 
expressed as percentage of the total as means ±SEM of three independent experiments, with at 
least 100 cells quantified per experiment. ** indicates p<0.001 compared to control cells 
(student’s t-test). Scale bars indicate 10μm. This experiment was carried out by our 
collaborators Michele Sallese and Giorgia Fragassi at Fondazione Mario Negri Sud, S.Maria 
Imbaro, Italy. 
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7.3 Exogenous fibronectin rescues the actin phenotype 
and invasive potential of MDA-MB231 cells lacking 
FZD6 
 
 
 
 
 
Figure 7.2: Exogenous addition of Fibronectin induces depolymerisation of 
actin stress fibres in FZD6 depleted cells.  (A) Actin stress fibres were detected by 
confocal microscopy using phalloidin staining in MDA-MB-231 Sh1-FZD6 cells after the 
exposure for the indicated times to 20μg/mL fibronectin of human plasma origin. (B)  
Quantification of cells showing thick actin stress fibres, referred to the experiment described in 
A. Data is expressed as percentage of the total as means ±SEM of three independent 
experiments, with at least 100 cells quantified per experiment. * indicates p<0.05 compared to 
control cells (Student’s t-test). Scale bars indicate 10μm. This experiment was carried out by our 
collaborators Michele Sallese and Giorgia Fragassi at Fondazione Mario Negri Sud, S.Maria 
Imbaro, Italy. 
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Figure 7.3: Invasion assay on MDA-MB-231 cells expressing control shRNA 
(scrambled) or FZD6 shRNA (sh1) in the presence or absence of exogenous 
fibronectin. Cells were resuspended in serum free medium alone or containing 20μg/mL of 
human plasma fibronectin and seeded in invasion chambers. The bottom compartments of the 
invasion chambers were replenished with Serum free medium containing 100ng/mL of EGF to 
provide a chemotactic gradient. The number of invasive cells is expressed as a percentage 
relative to control cells not exposed to fibronectin. Data is shown as means of three 
independent experiments. Error bars indicate standard error. * indicates p<0.05 (student t-test). 
N.S. indicates a non significant difference.     
 
To assess whether the exposure to exogenous fibronectin had any effect on cell 
invasion, we carried out cell invasion assays using EGF as chemoattractant in 
serum free conditions. Briefly, cells expressing control shRNA or FZD6 sh1 
RNA were resuspended in serum free medium alone or containing 20μg/mL of 
fibronectin and were seeded in invasion chambers. We found that exogenous 
fibronectin did not cause any significant perturbation of the invasion of cells 
expressing scrambled shRNA. Conversely, exogenous fibronectin partially 
restored the invasive phenotype of FZD6 depleted cells, resulting in a two fold 
increase of cell invasion when compared to cells that were not stimulated with 
fibronectin (figure 7.3). 
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7.4 Discussion   
 
Actin reorganization is involved in the migration of cancer cells. In physiological 
conditions, actin is organized in helical filaments that can be modified with the 
addition or removal of subunits. The elongation, shortening, or thickening of 
these filaments, result in modifications of their mechanical proprieties. Cells 
modulate actin polymerization in a variety of conditions, including cell migration 
(Cooper, 1991). For example, actin polymerization is required at the leading 
edge of migrating cells to constitute lamellipodia and filipodia and to form 
contractile stress fibres throughout the cell. Like in a treadmill, actin monomers 
are disassembled from the rear of the fibre to become again available at the 
front for de novo polymerization, pushing the cell membrane forward (Pollard 
and Borisy, 2003). Moreover, the interaction of myosin II with actin filaments 
provides the contractility and the transmission of tension to the sites of adhesion 
(Ridley et al., 2003). A plethora of proteins modulate actin dynamics during cells 
migration, through direct or indirect mechanisms. These proteins are required 
for the control of the spatial-temporal polymerisation/depolymerisation of actin 
filaments or contractility. The Rho family of GTPases are pivotal in various 
aspects of actin dynamics. In Particular, Rac has been shown to be involved in 
the actin polymerization at the leading edge lamellipodia, where Rho is required 
for the formation of stress fibres and focal adhesions (Nobes and Hall, 1995; 
Ridley and Hall, 1992). This was demonstrated through the Injection of 
constitutive active forms of Rho or ROCK that resulted in the formation of actin 
stress fibres in cell lines (Amano et al., 1997; Ridley and Hall, 1992; Paterson et 
al., 1990). As previously mentioned, WNT/PCP signalling regulates Rho activity 
and thereby actin dynamics (Kim and Davidson, 2011; Habas, Dawid and He, 
2003; Habas, Kato and He, 2001). Our own experiments demonstrated that 
FZD6 is upstream of Rho activity. The depletion of FZD6 resulted in the 
reduced activation of Rho, however, this did not result in a reduction of actin 
stress fibres, but rather in the thickening and rearrangement of fibres. The 
antibody used recognises RhoA, RhoB and RhoC, therefore it was not possible 
to assess whether FZD6 activates specific isoforms. Interestingly, it was 
previously observed that the selective knock down of RhoA or RhoC results in 
different rearrangement of actin in MDA-MB-231 cells (Vega et al., 2011), 
suggesting different roles and functions of the two isoforms. We could therefore 
hypothesise that FZD6 controls selectively the activation of one of the Rho 
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isoforms, and that the inhibition of one isoform, rather than a pan-inhibition of 
Rho, results in the thickening of actin stress fibres. 
Two proteins downstream of Rho have been implicated in the reorganization of 
actin fibres: The Diaphanous related formin protein (mDIA) and ROCK 
(Narumiya, Tanji and Ishizaki, 2009). The work of Watanabe and colleagues 
has elegantly explained how the balance between these two Rho effectors 
controls the structure and thickness of actin stress fibres. They demonstrated 
that the relative expression of constitutively active forms of mDIA1 and ROCK 
results in different organization and thickness of actin stress fibres (Watanabe 
et al., 1999). Moreover, there are several studies suggesting that mDIA1 and 
ROCK pathways crosstalk to modulate actin dynamics. For example, ROCK 
can inhibit the mDIA1 dependent activation of RAC to inhibit the polymerization 
of actin ruffles (Tsuji et al., 2002). Unbalanced ratio between mDIA1 and ROCK 
could therefore be the cause of the striking modifications we observed in the 
actin cytoskeleton in cells lacking FZD6.  It would be interesting to investigate 
whether FZD6 dependent activation of Rho leads to specific activation of one of 
these Rho effectors. 
FZD6-dependent actin dynamics are likely to influence cell migration. Although 
this would require further investigations, we can think of a number of 
mechanisms by which actin rearrangements could impair cell invasion in FZD6 
depleted cells. A first possibility is that, although actin stress fibres are thicker 
following the depletion of FZD6, they could be less contractile. Indeed, during 
cell migration, actin polymerization alone is not sufficient to create the 
mechanical force that leads the cell forward. Actin polymerization has to be 
accompanied by the interaction of actin with myosin to generate the tension 
force indispensable for cell migration. The phosphorylation of the regulatory 
light chain of myosin (MLC) is necessary for actomyosin contractility (Ridley et 
al., 2003). Rho is essential to regulate actomyosin contractility, both directly and 
through the activation of ROCK. ROCK has a dual function: it can promote cell 
contraction by phosphorylating MLC or by inhibiting the MLC phosphatase. 
Rho-GTP can also bind directly to the MLC phosphatase preventing its function 
(Kimura et al., 1996). We observed that depletion of FZD6 results in the 
inhibition of Rho signalling and reduced cell migration. This might lead to a 
reduction of stress fibres contraction caused by the inhibition or ROCK activity 
and the increased activation of MLC phosphatase.  
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Another explanation for the increased actin polymerisation and reduced 
migration in the absence of FZD6 could be an excessive adhesion of cells to the 
extracellular matrix. Although the adhesion of cells at the leading edge is 
required for migration, the disassembly of focal adhesion at the rear of the cell 
is equally important (Ridley et al., 2003). It has been demonstrated that the 
actomyosin contractions are capable to physically break the bound between 
integrins and the actin cytoskeleton, leaving the integrins behind while the cell 
moves forward (Lauffenburger and Horwitz, 1996).This process is mediated by 
the contraction of actomyosin. Since the removal of FZD6 in breast cancer cells 
resulted in thicker actin stress fibres, we could speculate that the latter are 
strained between larger focal adhesions that engage stronger interaction with 
the ECM, hampering the detachment at the rear of the moving cell. It would be 
interesting to confirm this hypothesis assessing the phosphorylation of MLC or 
the structure of focal adhesions in FZD6 depleted cells. 
Since we observed a marked reduction in fibronectin matrix deposition following 
the knock down of FZD6, we wondered whether exogenous delivery of 
fibronectin was able to rescue the invasion and the actin phenotype of FZD6 
depleted cells. The addition of fibronectin to FZD6 depleted cells resulted in a 
twofold increase in cell invasion (figure 7.3). As previously discussed, the 
fibronectin matrix could promote cell invasion in several ways, such as 
promoting haptotactic migration, EMT, or increasing the expression of MPP2.  
We wondered whether exogenous fibronectin could also modulate the 
rearrangements of the actin cytoskeleton in MDA-MB-231 cells. It was 
previously reported that the inhibition of fibronectin matrix assembly results in 
the formation of thick actin stress fibres in rat smooth muscle cells (Shi et al., 
2014). This is similar to what we observed in breast cancer cells lacking FZD6, 
where the reduction of the fibronectin matrix is accompanied by the formation of 
thick actin stress fibres. Altogether these results suggest that the fibronectin 
matrix could modulate the organization of the actin cytoskeleton. When FZD6 
depleted cells are exposed to exogenous fibronectin, actin stress fibres become 
thinner and more similar to the ones observed in control cells (fig. 7.2 and 7.1); 
This highlights the presence of a signalling mechanism that couples the 
fibronectin matrix to the cytoskeleton. Several lines of evidence demonstrated a 
link between the extracellular matrix and the Rho family of GTPases, mainly 
through the communications via integrins and heparan sulphate proteoglycans 
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(Schwartz and Shattil, 2000; Ren, Kiosses and Schwartz, 1999). For instance, 
plating A549 human lung adenocarcinoma cells onto fibronectin coated dishes, 
activates Rho in a time dependent manner. Moreover, the interaction between 
α5β1 integrins and fibronectin stimulates RhoA activation in fibroblasts (Danen 
et al., 2002; Gu et al., 2001). Therefore, we could hypothesize that the addition 
of exogenous fibronectin to FZD6 depleted MDA-MB-231 cells could partially 
restore Rho signalling through integrin activation. This in turn could lead to a 
recovery of the actin dynamics and cell invasion. Thus, the Rho GTPase could 
be the link between WNT signalling, the extracellular matrix and the actin 
cytoskeleton. The FZD6-Actin-Fibronectin axis could therefore be pivotal in the 
regulation of breast cancer invasion and metastasis.  
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CHAPTER VIII 
 
Conclusions 
 
8.1 Overview of the findings and potential clinical 
implications  
 
Metastasis is the main cause of death in cancer patients. Thus, it is of 
paramount importance to understand the molecular basis underlying this 
process, in order to develop new therapeutic strategies. Predicting the outcome 
of a tumour at an early stage is a major challenge, but it would be a major 
advance since would allow the design of patient-specific therapies. For this 
reason, a lot of effort has been put to find novel biomarkers that predicted the 
aggressiveness of cancer (Ludwig and Weinstein, 2005).  
It is now established that many cancers contain a subpopulation of cells with 
characteristics of stem cells. These present the activation of pathways normally 
active during organogenesis, that in the context of cancer, confer a metastatic 
phenotype (Jordan, Guzman and Noble, 2006). The WNT pathway is essential 
to orchestrate different aspects of organogenesis, and signalling molecules 
belonging to this pathway are often altered in cancer. For this reason, elements 
of the WNT pathway could be used in cancer diagnosis and intervention (Barker 
and Clevers, 2006).  
Overall, our findings suggest that: 
- FZD6 is amplified and overexpressed in 19% of breast cancers 
- FZD6 expression in TNBC is associated with an increased risk of relapse 
- FZD6 expression is required for the metastatic growth of human breast cancer 
cells in vitro and in vivo 
- FZD6 regulates non-canonical WNT signalling and assembly of the fibronectin 
matrix and actin cytoskeleton 
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WNT signalling is essential for the normal development of the mammary gland. 
Studies in transgenic mice which bare a β-catenin/TCF-responsive β-
galactosidase reporter system revealed that the WNT pathway is active in early 
embryogenesis (Chu et al., 2004; van Genderen et al., 1994). WNT signalling is 
detectable in the epithelial cells of mammary placodes and developed 
mammary buds, but it is reduced during milk ducts outgrowth (Chu et al., 2004). 
During mammary development, stem cells renewal and differentiation are 
strictly controlled; WNT signalling is pivotal in this regard (Zeng and Nusse, 
2010). Zeng and colleagues demonstrated that breast stem cells can expand 
clonally remaining undifferentiated when exposed to the canonical ligand 
WNT3a (Zeng and Nusse, 2010). It is still unclear how non-canonical pathways 
participate in breast development, but there is some evidence suggesting that 
non canonical could be as important as the canonical signalling. For instance, 
WNT5a, a non canonical ligand, inhibits the extension and branching of 
mammary ducts during mammary development (Roarty and Serra, 2007). The 
PCP pathway is essential for the orientation and migration of cells during 
convergence extension movements required for vertebrates gastrulation 
(Roszko, Sawada and Solnica-Krezel, 2009) . It is likely that the polarization of 
epithelial cells during mammary gland development requires PCP signalling. It 
is tempting to speculate that the expression of FZD6 in breast cancer cells 
could activate a cell signalling normally active during breast development. Cells 
overexpressing FZD6 could therefore mimic the highly motile mesenchymal 
cells responsible for breast development, acquiring enhanced capacity to 
travers basal membranes and invade surrounding tissues, enhanced 
chemotaxis, and loss of cell polarity and cell-cell interactions. 
Abrogation of FZD6 expression in the breast cancer cell line MDA-MB-231 
resulted in the formation of more symmetrical and organized acini, similar to the 
ones formed by non transformed mammary cells (fig. 4.11). Moreover, our 
experiments in mice suggest that FZD6 is not involved in tumour growth, but 
mediates the organotropism of breast cancer cells, consistent with the 
hypothesis that FZD6 mediates PCP signalling. 
Why does the knock down of FZD6 reduce the metastasis only in bones, liver 
and heart, but not in other organs? Different factors could influence the 
metastatic niche, such as the ECM, fibroblasts, and macrophages. Our results 
suggest that fibronectin matrix assembly could have a role in the organotropism 
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of FZD6 expressing cells. Indeed, fibronectin clustering was previously reported 
to be pivotal in directing the metastatic colonization of cancer cells: an elegant 
work by Kaplan and colleagues showed that conditioned media, deriving from 
distinct tumour types with peculiar patterns of metastatic spread, can modify the 
fibronectin matrix clustering redirecting the privileged metastatic site (Kaplan et 
al., 2005). It is therefore possible that FZD6 could support increased fibronectin 
matrix assembly enhancing the adhesion of cancer cells to the endothelium of 
specific organs. The aberrant increase of the fibronectin matrix could also 
enhance the ectopic survival of breast cancer stem cells in secondary sites as 
the bones and the liver. Indeed, it was previously reported that binding to 
fibronectin could provide survival signals to stem-cells and fibroblasts (Tate et 
al., 2002; Almeida et al., 2000; Dao et al., 1998).  
The use of therapeutic antibodies targeting FZD6 might be a valuable tool to 
reduce or prevent bone and liver metastasis. Breast cancer metastases to the 
heart are very rare (Reynen, Kockeritz and Strasser, 2004). Conversely, bones 
are the most common site of distant metastasis in breast cancer patients. Pain, 
hypercalcaemia and pathological fractures are common symptoms that largely 
compromise the quality of life (Coleman and Rubens, 1987). Patients bearing 
breast cancer metastases in the liver have a very poor prognosis, with a median 
survival that is less than 6 months from diagnosis (Selzner et al., 2000). 
Therefore, reduction of metastases in the bones and liver could greatly improve 
the survival and the quality of life of breast cancer patients.  
What signalling molecules are activated downstream of FZD6? We found that 
FZD6 regulates the downstream activation of the small GTPase Rho affecting 
the actin cytoskeleton dynamics. These findings are consistent with a role of 
FZD6 in the PCP pathway. Other investigators have previously linked FZD6 to 
the PCP (De Marco et al., 2012; Cantilena et al., 2011; Stuebner et al., 2010; 
Wang, Chang and Nathans, 2010; Wang, Guo and Nathans, 2006; Guo, 
Hawkins and Nathans, 2004). The PCP pathway controls the extensive 
movements required for the gastrulation and neurulation of vertebrates. These 
developmental processes are guided by coordinated modulation of cell 
migration and polarized matrix deposition. Rho and the actin cytoskeleton are 
required for the migration of germ cell layers during these processes (Roszko, 
Sawada and Solnica-Krezel, 2009; Goto et al., 2005; Habas, Dawid and He, 
2003; Habas, Kato and He, 2001). We propose that the aberrant activation of 
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FZD6 could facilitate breast cancer cell migration through the activation of the 
PCP pathway (fig.8.1).  
 
 
 
Figure 8.1: Schematic representation of the proposed molecular pathways 
activated by FZD6 in breast cancer. The binding of WNT ligands to Fzd6 leads to the 
activation of Rho. Rho in turns, promotes the rearrangement and contractility of actin stress 
fibres and other actin structures that regulate directional motility, cell polarity and invasion. The 
interaction between actin and integrins also regulates the deposition of fibronectin matrix. A 
positive feedback between matrix deposition and Rho activation might also exist through the 
activation of integrins. Fibronectin matrix assembly contributes synergistically with actin 
rearrangements to promote cell motility and invasion. 
 
This could cause increased metastasis, higher risk of relapse and overall lower 
survival in patients, particularly those bearing the triple negative subtype.  
The regulation of Rho by FZD6 could induce the activation of EMT, increased 
migration, angiogenesis and enhanced transendothelial migration by regulating 
actin dynamics (Croft et al., 2004; van Nieuw Amerongen et al., 2003; 
Bhowmick et al., 2001; Worthylake et al., 2001; Itoh et al., 1999). Rho can also 
facilitate the polarized deposition of the fibronectin matrix assembly (Dzamba et 
al., 2009; Zhong et al., 1998). The fibronectin matrix surrounding cancer cells 
could contribute to the metastatic process in different ways, as reported by 
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several research groups (Park and Schwarzbauer, 2013; Das et al., 2008; 
Huang et al., 2008; Felding-Habermann, 2003; Ruoslahti, 1999; Friedl et al., 
1997; Klominek, Robert and Sundqvist, 1993; Aznavoorian et al., 1990; 
Gehlsen et al., 1988; Humphries, Yamada and Olden, 1988; Ruoslahti, 1984). 
For example, fibronectin provides an adhesion substrate that enhances cell 
adhesion to the endothelium of metastatic sites and promotes haptotactic 
motility (Huang et al., 2008; Klominek et al., 1993). Moreover, fibronectin could 
activate integrins and syndecan receptors to transduce intracellular signals that 
promote EMT and provide a positive feedback through the activation of Rho 
(Park and Schwarzbauer, 2014; Felding-Habermann, 2003). The coating of 
breast cancer cells with a fibronectin matrix stimulates fibroblasts to secrete 
metalloproteinases, which in turn enhance ECM degradation to promote 
invasion and colonization to metastatic sites (Maity et al., 2011; Saad et al., 
2002). Inhibitors of the α5β1 receptor, also known as the fibronectin receptor 
(Schaffner, Ray and Dontenwill, 2013), are currently tested in multiple clinical 
trials (Lahlou and Muller, 2011). For example, ATN-161, an inhibitor peptide that 
mimic the fibronectin molecular structure, was shown to have beneficial effects 
in a phase 1 clinical trial carried out in patients with various solid tumours 
(Cianfrocca et al., 2006). The same peptide was shown to be extremely efficient 
in inhibiting tumour growth and metastasis in mice injected with MDA-MB-231 
breast cancer cells (Khalili et al., 2006). These findings suggest that interfering 
with the fibronectin/integrin signalling could be a promising therapeutic strategy 
in breast cancer.   
The direct targeting of Rho could also be exploited as a potential therapeutic 
approach, since Rho GTPases are involved in many aspects of carcinogenesis 
(Sahai and Marshall, 2002). Recently, rhosin, a novel inhibitor of the RhoA 
subfamily of GTPase, was shown to inhibit the proliferation and invasion of 
breast cancer cells. Interestingly, rhosin was also able to reduce the formation 
of mammospheres, suggesting a possible implication of Rho in breast cancer 
stem cells homeostasis (Shang et al., 2012). Chen and collaborators tested a 
class of inhibitors of the enzymes farnesyltransferase and 
geranylgeranyltransferase, which are required for the farnesylation and 
geranylgeranylation of the C-terminal CAAX motif of the Rho family GTPases, 
respectively. These post-transcriptional modifications modulate the correct 
cellular localization and therefore the correct functions of Rho GTPases. The 
inhibitors caused the reduction of the 2D and 3D invasion of MDA-MB-231 
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breast cancer cells (Chen et al., 2014). Inhibition of the Rho associated kinase 
ROCK was shown to arrest the invasion of breast cancer cells in vivo and in 
vitro (Liu et al., 2009). An inhibitor of ROCK, K-115, was successfully tested in a 
phase II clinical trial for open-angle glaucoma, so its introduction in the clinic for 
breast cancer might be facilitated (Tanihara et al., 2013). It would be interesting 
to assess whether this molecule or related compounds could find applications in 
breast cancer, particularly in those subtypes still lacking efficient therapies. 
 
8.2 Future perspectives and limitations 
 
Following this study, we need to extend our findings to validate FZD6 as a novel 
oncogene and candidate target for cancer therapy. A key step would be to test 
naked or toxin-conjugated antibodies in mice models of breast cancer. The 
lentiviral transduction of shRNA targeting FZD6 in MDA-MB-231 cells does not 
cause cell death; therefore, cells might still be capable to metastasise. 
Conversely, cytotoxic antibodies would kill FZD6 positive cells, and this might 
result in a stronger reduction of the metastatic spread in mice. The in vivo 
validation of our findings should be repeated using FZD6 knock-out cell lines to 
avoid re-expression of the protein and in vivo selection of FZD6 positive 
populations. This could be achieved by deleting the FZD6 locus in breast 
cancer cells trough the CRISPR-CAS9 technology, a powerful tool commonly 
used for genome editing. 
Another limitation of our study is the limited number of triple negative breast 
cancer patients that were considered in the Kaplan Meier and multivariate 
analyses. In order to validate FZD6 as a marker of metastatic relapse in TNBC 
patients, we need to compare our data with other independent patients 
datasets. 
Another question to be addressed is whether FZD6 is a marker of cancer stem 
cell in breast cancer. Our group previously reported that this is the case in 
neuroblastoma (Cantilena et al., 2011). It is tempting to speculate that this might 
also happen in breast cancer. It is a widely held view that cancer stem cells 
might contribute to cancer metastasis, drug resistance and tumour recurrence 
(Visvader and Lindeman, 2008). If the expression of FZD6 is mainly restricted to 
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subpopulations of breast cancer stem cells, cytotoxic antibodies would be useful 
in deleting this aggressive cancer cell subtype. 
Another aspect that was not addressed in this study is the contribution of FZD6 
to angiogenesis, one of the hallmarks of cancer (Hanahan and Weinberg, 
2011). Rho is involved in multiple aspects of this process (Bryan and d’Amore, 
2007). Since FZD6 regulates Rho activity, it is reasonable to think it could be 
relevant in breast cancer angiogenesis. 
Several aspects of FZD6 signalling still remain unclear, such as which signalling 
proteins link FZD6 to the actin cytoskeleton or the fibronectin matrix assembly. 
Moreover, it remains to be determined if FZD6 interacts specifically with one of 
the Rho isoforms, RhoA, RhoB and RhoC. In this thesis, I reported that the 
knock down of FZD6 results in the thickening of actin stress fibres and their 
structural rearrangement (fig. 7.1). However, it is not known what molecules 
downstream of Rho are implicated in this process. In this respect, it would be 
interesting to assess the activation of Rho effectors such as ROCK 1/2 and 
mDIA in the absence of FZD6 expression.  
FZD6 could promote cell migration through Rho-mediated contraction of actin 
stress fibres. This could be verified by assessing the phosphorylation status of 
MLC in the absence or presence of FZD6 expression. 
In this study FZD6 signalling has been investigated predominantly in one cell 
line, MDA-MB-231. We should confirm our signalling data using more breast 
cancer cell lines and using not only loss of function approaches but also 
overexpression experiments.  
Finally, we have not investigated whether a specific WNT ligand mediates the 
pro-tumorigenic effects of FZD6 in breast cancer. Recent data gathered by 
FRAP membrane mobility analysis suggests that multiple ligands including 
WNT1, -2, 3A, -4, -5A, -7A, -9B and -10B modulate FZD6 surface mobility and 
are likely to activate or repress the receptor (Kilander, Dahlström and Schulte, 
2014). This suggests the existence of a complex network of ligands and 
pathways linked to FZD6.  
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Appendix 
 
Methods used by research collaborators 
 
A.1 Patients characteristics and immunohistochemistry  
 
The following methods were used by Rossano Lattanzio and Mauro Piantelli 
from G. D’Annunzio University, Chieti, Italy.  
The study included 352 primary infiltrating breast cancers from N0 and T1/T2 
tumours diagnosed between 1985 and 2003 at the Regina Elena National 
Cancer Institute, Rome, Italy, and presenting primary unilateral breast 
carcinomas. The study was reviewed and approved by the ethics committee of 
the ‘‘Regina Elena’’ National Cancer Institute and written informed consent was 
obtained from all patients. All patients received radiation therapy. One hundred 
and thirty-eight patients received hormonal therapy and 140 patients were 
treated with adjuvant chemotherapy (followed or not by hormonal therapy). 
Patients with HER2-positive tumours did not receive trastuzumab, as it was not 
used in breast tumour therapy in the study period. Follow-up data were obtained 
from institutional records or from referring physicians. The median follow-up 
was of 80 months (range 6-298 months). During follow-up, 32 patients (9.1%) 
developed a local recurrence and distant metastases were observed in 54 
cases (15.3%). 
Tissue microarrays (TMA) were constructed by extracting 2-mm diameter cores 
of histologically confirmed invasive breast carcinoma paraffin-embedded tissue. 
The cores were then embedded into gridded paraffin blocks, using a precision 
instrument (MTA, Beecher Instruments). After antigen retrieval (microwave 
treatment at 750 W for 10 min in 10 mM sodium citrate buffer, pH 6.0), five-
micrometres sections were incubated overnight at 4°C with the anti-Fzd6 
antibody (Novus Biological, Littleton, CO) at  1:100 dilution. The anti-rabbit 
EnVision kit (K4003, Dako, Glostrup, Denmark) was used for signal 
amplification. In control sections the specific primary antibody was replaced with 
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non-immune serum. The percentage of tumour cells with positive membrane 
staining for FZD6 ranged from 6 to 85%, with a mean ± SE of 23.8% ± 2.2. The 
following antibodies were used for the identification of tumour subtypes:  anti-
ER-α MoAb 6F11 (Novocastra, Leica Biosystems, Newcastle, UK), the anti-
PGR MoAb 1A6 (Novocastra), the anti-Ki-67 MoAb MIB-1 (Dako) and the anti-
HER2 (Herceptest, Dako). Immunohistochemical analysis was done by two 
pathologists (MP, RL) by consensus without knowledge of the 
clinicophatological information. 
Ki-67 expression was dichotomized according to the St Gallen criteria: Ki-67 
was considered high when the percentage of cells expressing the marker was ≥ 
20% (Goldhirsch et al., 2013). HER2 membranous staining was assessed with 
Herceptest (Dako) and classified as positive if the intensity was scored 3+ (30% 
of cells showing complete membrane staining), or, if scored 2+ (between 10% 
and 30% of positive cells), was considered positive in the presence of an 
amplification of the HER-2 gene as assessed by fluorescent in situ 
hybridization. Tumours were classified positive for PR or ER if ≥10% of cells 
were positive to the staining. Tumour size and tumour grade were dichotomized 
according to the Saint Gallen criteria for the definition of risk categories (T ≤ 
2cm vs. T > 2 cm; grade 1 vs. grade 2-3).  The relation between Fzd6 
expression and the clinicophatological parameters were assessed by Pearson’s 
χ2 or Fisher’s exact test, as appropriate. Fzd6 expression was studied in 
different breast cancer molecular subtypes: Luminal A-like (n = 128), Luminal B-
like, HER2 negative (n = 123), Luminal B-like, HER2 positive (n = 33), HER2 
positive, non-luminal (n = 21) and Triple negative breast cancers (TNBC, n = 
47). DFS was defined as the time from surgery to the first of the following 
events: tumour recurrence at local site or at distant sites. LRFS and DRFS were 
defined as the times from surgery to the occurrence of relapse at local and 
distant sites, respectively. Kaplan–Meier plots were used to illustrate the 
survival in specified cohorts and the log-rank test to test for equality of survival 
curves. The association of Fzd6 expression with outcome, adjusted for other 
prognostic factors, was tested by multivariate analysis (Cox’s proportional 
hazards model). The following covariates were included in the multivariate DFS 
models: tumour size and grade, ER, PGR, Ki-67, HER2 and FZD6 status. 
Appropriateness of the proportional hazard assumption was assessed by 
plotting the log cumulative hazard functions over time and checking for 
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parallelism. SPSS Version 15.0 (SPSS, Chicago, IL) was used throughout and 
P<0.05 was considered statistically significant. 
 
A.2 Threedimensional cultures  
 
The methods described in this section were performed by Sibylle Ermler and 
Elisabete Silva from the Institute for the Environment, Department of Life 
Sciences, Brunel University London. 
Wells in an eight-chamber slide (Millipore) were coated with 60 µl/well of growth 
factor reduced (GFR) matrigel and allowed to settle for 15 minutes. Cells were 
resuspended in complete medium containing 2% GFR matrigel (assay medium) 
and seeded in duplicate wells. Cells were incubated for 20 days and the 
medium replaced every 3–4 days with fresh assay medium. At the end of the 
incubation, the assay medium was discarded and the acini were fixed with 2% 
PFA (in PBS, pH 7.4) for 20 min at room temperature. Next, cells were 
permeabilized with 0.5% Triton-X in PBS for 10 min at 4° C and washed thrice 
with 100 mM glycine in PBS at room temperature. Acini were then blocked with 
immunofluorescence blocking buffer (IF buffer; 130 mM NaCl, 7.7 mM NaN3, 
0.1% BSA, 0.2% Triton X-100, 0.05% Tween-20) containing 10% of goat serum 
for 1.5 hours at room temperature. A secondary blocking step was performed 
incubating cells with Immunofluorescence blocking buffer containing 10% goat 
serum and 20 mg/ml of goat anti-mouse F(ab’)2 fragment for 30 minutes. 
Primary antibodies were diluted 1:200 in the secondary blocking solution, 
incubated overnight at 4° C and rinsed thrice with IF buffer. The primary 
antibodies used were: Mouse anti-laminin V (ABcam; 1:200 in IF buffer) or anti-
fibronectin (BD; 1:200 in IF buffer). Incubation with secondary antibody (Alexa 
Fluor 555 goat anti-mouse, Molecular Probes, Invitrogen) was in IF buffer 
containing 10% goat serum for 50 minutes (Dilution of 1:200), followed by three 
washes at room temperature. Cell nuclei were counterstained with a 300 nM 
solution of DAPI in PBS for 5 minutes and mounted with Vectashield HardSet 
mounting medium (Vector Laboratories, Peterborough, UK). Photographs of the 
acini were taken with an Olympus BX41 fluorescence microscope with IMSTAR 
Pathfinder™ software. 
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A.3 Orthotopic transplantations in immunodeficient 
mice 
 
The in vivo transplantation and the analysis of tumour tissue sections were 
carried out by our collaborators Dr Manuela Iezzi and Dr Alessia Lamolinara at 
the Aging Research Centre, G. D’Annunzio University, Chieti, Italy. 
NOD scid gamma (NSG) mice were purchased from the Jackson Laboratory 
and bred in the animal facility of the Aging Research Centre, G. D’Annunzio 
University, Chieti. Animal care and experimental procedures were approved by 
the Ethics Committee for Animal Experimentation of the institute, according to 
the Italian law. Eight weeks old female mice (10 mice per group) were injected 
unilaterally with 3.5×106 cells into the fourth mammary fat pad. Tumour growth 
was monitored biweekly using callipers up to 96 days or when tumours reached 
0.3 cm3 of volume. Tumour volume was calculated as 0.5 X d12 X d2, where d1 
and d2 are the smaller and larger diameters, respectively. Primary tumours and 
organs were fixed in 10% neutral buffered formalin, paraffin embedded, 
sectioned and stained with haematoxylin and eosin. Slides were independently 
evaluated by two pathologists. To quantify microscopic metastases, lungs and 
livers were cut transversally into 2.0 mm thick parallel slabs starting from a 
random position, resulting in 5-8 slabs for lungs and 8-10 slabs for livers. A 
semiquantitative evaluation was performed attributing to each sample a value 
from 0 to 4, based on the number and size of metastases; 0 was attributed to 
organs with no detectable metastases; 4 to organs with numerous large 
metastases. Fisher’s exact test was utilised to compare differences in 
metastatic spread. 
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A.4 Confocal microscopy 
 
Confocal microscopy experiments were carried out by Michele Sallese and 
Giorgia Fragassi at Fondazione Mario Negri Sud, S.Maria Imbaro, Italy. 
70000 cells were plated in 1 mL of complete medium in coverslips placed into 
24 well plates. Cells were then washed with PBS and fixed with 4% PFA in PBS 
for 15 minutes. Cells were then washed 4 times with PBS and incubated in 
blocking solution (0.1 % saponin, 0.5 % BSA, 50 mM NH4Cl pH 7.4, 0.02 % 
NaN3) for 1 hour. 
Cells were then incubated either with Phalloidin Alexafluor546-conjugated 
(Invitrogen) diluted 1:400 in blocking buffer for 30 minutes or with mouse anti-
Fibronectin (BD) diluted 1:100 in blocking buffer for 2 hours. In the case of the 
Fibronectin staining, cells were then washed 4 times with PBS and stained with 
anti-mouse texas red (Invitrogen) diluted 1:400 in blocking buffer for 1 hour. The 
following steps were analogous for the phalloidin and fibronectin staining: Cells 
were washed in PBS and stained with DRAQ5 (Cell Signaling) diluted 1:1000 in 
PBS for 15 minutes. The coverslips were then washed 4 times with PBS and 
mounted with Mowiol (Sigma) into microscope glass slides. 
Confocal images were acquired using a Zeiss LSM510 inverted confocal 
microscope system (Carl Zeiss, Gottingen, Germany). Cells were analysed 
using a 63x oil-immersion objective, maintaining the pinhole of the objective at 1 
Airy unit. Images were acquired under non-saturating conditions and using the 
same settings for all samples.  
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